
<html lang="en"     class="pb-page"  data-request-id="59892857-c04f-4eba-86bb-24abf0022e79"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2011.54.issue-22;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm200900q"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)" /></meta><meta name="dc.Creator" content="Carl R.  Illig" /></meta><meta name="dc.Creator" content="Carl L.  Manthey" /></meta><meta name="dc.Creator" content="Mark J.  Wall" /></meta><meta name="dc.Creator" content="Sanath K.  Meegalla" /></meta><meta name="dc.Creator" content="Jinsheng  Chen" /></meta><meta name="dc.Creator" content="Kenneth J.  Wilson" /></meta><meta name="dc.Creator" content="Shelley K.  Ballentine" /></meta><meta name="dc.Creator" content="Renee L.  DesJarlais" /></meta><meta name="dc.Creator" content="Carsten  Schubert" /></meta><meta name="dc.Creator" content="Carl S.  Crysler" /></meta><meta name="dc.Creator" content="Yanmin  Chen" /></meta><meta name="dc.Creator" content="Christopher J.  Molloy" /></meta><meta name="dc.Creator" content="Margery A.  Chaikin" /></meta><meta name="dc.Creator" content="Robert R.  Donatelli" /></meta><meta name="dc.Creator" content="Edward  Yurkow" /></meta><meta name="dc.Creator" content="Zhao  Zhou" /></meta><meta name="dc.Creator" content="Mark R.  Player" /></meta><meta name="dc.Creator" content="Bruce E.  Tomczuk" /></meta><meta name="dc.Description" content="A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS), as exemplified by 8 and 21, was optimized to improve pharmacokinetic and pharmacodynamic properties and potenti..." /></meta><meta name="Description" content="A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS), as exemplified by 8 and 21, was optimized to improve pharmacokinetic and pharmacodynamic properties and potenti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 31, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm200900q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm200900q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm200900q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm200900q" /></link>
        
    
    

<title>Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm200900q" /></meta><meta property="og:title" content="Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0006.jpeg" /></meta><meta property="og:description" content="A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS), as exemplified by 8 and 21, was optimized to improve pharmacokinetic and pharmacodynamic properties and potential toxicological liabilities. Early stage absorption, distribution, metabolism, and excretion assays were employed to ensure the incorporation of druglike properties resulting in the selection of several compounds with good activity in a pharmacodynamic screening assay in mice. Further investigation, utilizing the type II collagen-induced arthritis model in mice, culminated in the selection of anti-inflammatory development candidate JNJ-28312141 (23, FMS IC50 = 0.69 nM, cell assay IC50 = 2.6 nM). Compound 23 also demonstrated efficacy in rat adjuvant and streptococcal cell wall-induced models of arthritis and has entered phase I clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm200900q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm200900q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm200900q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm200900q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm200900q&amp;href=/doi/10.1021/jm200900q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 7860-7883</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200894e" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2009343" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-<i>N</i>-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1<i>H</i>-imidazole-2-carboxamide (JNJ-28312141)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carl+R.++Illig">Carl R. Illig</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carl+L.++Manthey">Carl L. Manthey</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Wall">Mark J. Wall</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sanath+K.++Meegalla">Sanath K. Meegalla</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinsheng++Chen">Jinsheng Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+J.++Wilson">Kenneth J. Wilson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shelley+K.++Ballentine">Shelley K. Ballentine</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Renee+L.++DesJarlais">Renee L. DesJarlais</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carsten++Schubert">Carsten Schubert</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carl+S.++Crysler">Carl S. Crysler</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanmin++Chen">Yanmin Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Molloy">Christopher J. Molloy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Margery+A.++Chaikin">Margery A. Chaikin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+R.++Donatelli">Robert R. Donatelli</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Yurkow">Edward Yurkow</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhao++Zhou">Zhao Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+R.++Player">Mark R. Player</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+E.++Tomczuk">Bruce E. Tomczuk</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Johnson & Johnson Pharmaceutical Research & Development, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States</span></div><div class="corresp-info">E-mail: <a href="/cdn-cgi/l/email-protection#e88b818484818fa8819c9bc6828682c68b8785"><span class="__cf_email__" data-cfemail="76151f1a1a1f11361f0205581c181c5815191b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm200900q&amp;href=/doi/10.1021%2Fjm200900q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 7860–7883</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 31, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 July 2011</li><li><span class="item_label"><b>Published</b> online</span>31 October 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 November 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm200900q" title="DOI URL">https://doi.org/10.1021/jm200900q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7860%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DCarl%2BR.%2BIllig%252C%2BCarl%2BL.%2BManthey%252C%2BMark%2BJ.%2BWall%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D22%26contentID%3Djm200900q%26title%3DOptimization%2Bof%2Ba%2BPotent%2BClass%2Bof%2BArylamide%2BColony-Stimulating%2BFactor-1%2BReceptor%2BInhibitors%2BLeading%2Bto%2BAnti-inflammatory%2BClinical%2BCandidate%2B4-Cyano-N-%255B2-%25281-cyclohexen-1-yl%2529-4-%255B1-%255B%2528dimethylamino%2529acetyl%255D-4-piperidinyl%255Dphenyl%255D-1H-imidazole-2-carboxamide%2B%2528JNJ-28312141%2529%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7883%26publicationDate%3DNovember%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm200900q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3069</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm200900q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;R. Illig&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;L. Manthey&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Wall&quot;},{&quot;first_name&quot;:&quot;Sanath&quot;,&quot;last_name&quot;:&quot;K. Meegalla&quot;},{&quot;first_name&quot;:&quot;Jinsheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;J. Wilson&quot;},{&quot;first_name&quot;:&quot;Shelley&quot;,&quot;last_name&quot;:&quot;K. Ballentine&quot;},{&quot;first_name&quot;:&quot;Renee&quot;,&quot;last_name&quot;:&quot;L. DesJarlais&quot;},{&quot;first_name&quot;:&quot;Carsten&quot;,&quot;last_name&quot;:&quot;Schubert&quot;},{&quot;first_name&quot;:&quot;Carl&quot;,&quot;last_name&quot;:&quot;S. Crysler&quot;},{&quot;first_name&quot;:&quot;Yanmin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Molloy&quot;},{&quot;first_name&quot;:&quot;Margery&quot;,&quot;last_name&quot;:&quot;A. Chaikin&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;R. Donatelli&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Yurkow&quot;},{&quot;first_name&quot;:&quot;Zhao&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;R. Player&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;E. Tomczuk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;7860-7883&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm200900q&quot;},&quot;abstract&quot;:&quot;A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS), as exemplified by 8 and 21, was optimized to improve pharmacokinetic and pharmacodynamic properties and potential toxicological liabilities. Early stage absorption, distribution, metabolism, and excretion assays were employed to ensure the incorporation of druglike properties resulting in the selection of several compounds with good activity in a pharmacodynamic screening assay in mice. Further investigation, utilizing the type II collagen-induced arthritis model in mice, culminated in the selection of anti-inflammatory development candidate JNJ-28312141 (23, FMS IC50 = 0.69 nM, cell assay IC50 = 2.6 nM). Compound 23 also demonstrated efficacy in rat adjuvant and streptococcal cell wall-induced models of arthritis and has entered phase I clinical trials.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200900q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200900q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200900q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200900q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200900q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200900q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm200900q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200900q&amp;href=/doi/10.1021/jm200900q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm200900q" /></input><a href="/doi/pdf/10.1021/jm200900q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm200900q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm200900q%26sid%3Dliteratum%253Aachs%26pmid%3D22039836%26genre%3Darticle%26aulast%3DIllig%26date%3D2011%26atitle%3DOptimization%2Bof%2Ba%2BPotent%2BClass%2Bof%2BArylamide%2BColony-Stimulating%2BFactor-1%2BReceptor%2BInhibitors%2BLeading%2Bto%2BAnti-inflammatory%2BClinical%2BCandidate%2B4-Cyano-N-%255B2-%25281-cyclohexen-1-yl%2529-4-%255B1-%255B%2528dimethylamino%2529acetyl%255D-4-piperidinyl%255Dphenyl%255D-1H-imidazole-2-carboxamide%2B%2528JNJ-28312141%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D22%26spage%3D7860%26epage%3D7883%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jmcmar.2011.54.issue-22/production/jmcmar.2011.54.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A class of potent inhibitors of colony-stimulating factor-1 receptor (CSF-1R or FMS), as exemplified by <b>8</b> and <b>21</b>, was optimized to improve pharmacokinetic and pharmacodynamic properties and potential toxicological liabilities. Early stage absorption, distribution, metabolism, and excretion assays were employed to ensure the incorporation of druglike properties resulting in the selection of several compounds with good activity in a pharmacodynamic screening assay in mice. Further investigation, utilizing the type II collagen-induced arthritis model in mice, culminated in the selection of anti-inflammatory development candidate JNJ-28312141 (<b>23</b>, FMS IC<sub>50</sub> = 0.69 nM, cell assay IC<sub>50</sub> = 2.6 nM). Compound <b>23</b> also demonstrated efficacy in rat adjuvant and streptococcal cell wall-induced models of arthritis and has entered phase I clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span></span> Accession Codes</h4><p class="last">PDB IDs are as follows: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL">3KRL</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ">3KRJ</a>.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inflammation comprises a complex series of biochemical events that can be initiated by a number of stimuli including noxious chemical agents, pathogens, and autoimmune responses and, in pathological situations, may lead to the destruction of cells, tissues, and organs. Among autoimmune diseases, rheumatoid arthritis (RA) represents an area of significant unmet medical need and affects about 1% of the population. The annual economic burden caused by this disease in 2006 was estimated to be $58 billion in Europe and $54 billion in the United States,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> while the global market for arthritis drugs was estimated to be as high as $35 billion for 2008.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Low-dose methotrexate is the first-line therapy in RA. Although methotrexate has a very low associated cost, patients must be monitored several times a year for the development of hepatitis. Additional monitoring is also necessary to guard against the development of renal, pulmonary, or bone marrow disease. Many patients on this regimen experience side effects such as fatigue and nausea, and approximately half of all patients do not respond sufficiently to methotrexate monotherapy.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In these patients, methotrexate may then be combined with a biologic therapy, which includes anti-tumor necrosis factor (TNF) agents<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> such as infliximab or etanercept. Biologics, despite their effectiveness in reducing symptoms and structural damage, are of significantly higher cost and must be given parenterally. Thus, there is a continuing need for an oral agent that effectively relieves the symptoms of RA, prevents structural damage, and is better tolerated than methotrexate.</div><div class="NLM_p">Of the many cellular components of the inflammatory process, macrophages are known to play a critical role<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> where they contribute to antigen presentation and immunomodulation via the production of growth factors and activating cytokines such as TNF, IL-1, and IL-6. Of cell types present in rheumatoid synovium, macrophage numbers present in synovial biopsies provide the strongest correlation with clinical symptoms, including scores for knee pain.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The change in the number of these macrophages also correlates significantly with changes in the 28-joint count Disease Activity Score (DAS28) associated with disease therapy.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Synovial inflammation in RA is chronic and eventually organizes to form granulation tissue known as pannus, which is a highly invasive tissue that progressively erodes cartilage, bone, tendons, and ligaments and is associated with structural damage and irreversible loss of joint function. Moreover, pannus macrophages can differentiate to osteoclasts required for bone invasion. Therefore, the modulation of proliferation and activity of macrophages and osteoclasts is a potentially attractive approach for the treatment of RA, and as such, we became interested in one of the key signaling pathways for the macrophage lineage.</div><div class="NLM_p">The colony-stimulating factor-1 receptor (CSF-1R) is alternatively known as FMS, that is, the product of the cellular proto-oncogene homologue of the feline McDonough sarcoma virus oncogene (v-fms). FMS is a member of the class III receptor tyrosine kinases that include FMS-like tyrosine kinase-3 (FLT-3), stem cell factor receptor (KIT), and platelet-derived growth factor receptors (PDGFR) α and β. FMS is the exclusive cell-surface protein receptor for colony-stimulating factor-1 (CSF-1, or macrophage colony-stimulating factor, M-CSF),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> which, upon binding to the extracellular domain of FMS, induces dimerization and trans-autophosphorylation of the intracellular FMS kinase domain on Tyr723 and other tyrosine residues. These phosphorylated sites subsequently act as binding sites for several cytoplasmic Src homology-2 (SH2) domain-containing signaling molecules, which promote de novo gene expression, proliferation, and differentiation. High expression of FMS is restricted to monocytes, tissue macrophages, oocytes, trophoblasts, and osteoclasts, and CSF-1 is the predominant growth factor for macrophages and macrophage-lineage cells including osteoclasts.</div><div class="NLM_p last">There is evidence that CSF-1 may drive the macrophage population in RA.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Although CSF-1 is expressed constitutively, expression is strongly induced in fibroblasts, endothelial cells, and chondrocytes by TNF and IL-1.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Endothelial cells from rheumatoid synovium express more CSF-1 than endothelial cells purified from other anatomical sites,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and CSF-1 levels are significantly elevated in rheumatoid plasma, synovium, and synovial fluid.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a> Furthermore, it has been shown that administered CSF-1 will exacerbate arthritis in rodents,<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> and CSF-1 deficient (op/op) mice were highly resistant to arthritis in a collagen-induced model.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Thus, it is expected that FMS inhibitors could intervene advantageously in diseases where osteoclasts and macrophages are pathogenic, particularly RA. In fact, in collagen-induced arthritis (CIA) models in rodents, researchers have demonstrated decreases in overall progression of clinical scores, destruction of bone and cartilage, and macrophage numbers using specific oral FMS inhibitors,<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a> as well as other nonspecific kinase inhibitors possessing known FMS inhibitory activity such as imatinab mesylate,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> and also with CSF-1-specific antibodies.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> FMS inhibitors may also find therapeutic applications for other immune-modulated inflammatory or remodeling diseases with high macrophage or osteoclast involvement, such as metastatic bone disease.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The methodology for constructing the core structure of the compounds is outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The synthesis commences with a Suzuki–Miyaura coupling<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> between the anilinoboronic ester <b>1</b> and the enol triflate ester derivative of <i>N</i>-Boc-protected piperidinone <b>2</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> After hydrogenation of the olefin, the resulting aniline <b>3</b> was brominated with <i>N</i>-bromosuccinimide (NBS) to give <b>4</b>. This set up the next Suzuki–Miyaura coupling with 1-cyclohexeneboronic acid to afford the tricyclic aniline <b>5</b>. The potassium salt of the trimethylsilylethoxymethyl (SEM)-protected imidazole-2-carboxylate <b>6</b> previously reported in these laboratories<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> is coupled to <b>5</b> using <i>N</i>-(3-dimethylaminopropyl)-<i>N′-</i>ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt), and <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA) to provide amide <b>7</b>. Simultaneous removal of both the Boc and the SEM groups with trifluoroacetic acid (TFA) afforded a common intermediate <b>8</b> that was widely employed for derivatizations of the piperidine ring.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, LiCl, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, 2 h. (b) H<sub>2</sub>, 10% Pd/C, MeOH, 20 psi, 1 h. (c) NBS, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 10 h. (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, toluene, EtOH, 80 °C, 3 h. (e) EDCI, HOBt, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 10 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 1 h.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> outlines the chemistry used to introduce the various <i>N</i>-alkyl and <i>N</i>-aryl substitutions on the piperidine nitrogen. Reaction of <b>8</b> with 2-fluoropyridine at 120 °C afforded the aminopyridine <b>9</b>. Conjugate addition of <b>8</b> to acrylonitrile led to the cyanoethyl derivative <b>10</b>. Reductive amination of the appropriate aldehyde or ketone with <b>8</b> in the presence of sodium triacetoxyborohydride was useful for the addition of a 2-pyridylmethyl group as on <b>11</b>, a hydroxyethyl group as on <b>12</b>, and, after deprotection of <b>13</b>, a 1,3-dihydroxy-2-propyl group as on <b>14</b>. Direct alkylation chemistry was also employed to produce a number of piperidines appended with a methylsulfonylethyl group as in <b>15</b>, a carbamylmethyl group as in <b>16</b>, and a carboxymethyl group, along with its corresponding <i>t</i>-butyl ester, as in compounds <b>18</b> and <b>17</b>, respectively. In some instances, protection of the imidazole was beneficial during reactions with the piperidine; thus, selective deprotection of the Boc group was effected by careful treatment of the doubly protected <b>7</b> with TFA in the presence of ethanol to afford <b>19</b>. Alkylation of <b>19</b> with 4-(2-chloroethyl)-morpholine in DMA at 80 °C followed by final acidic removal of the SEM group afforded the morpholinoethyl analogue <b>20</b>.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-Fluoropyridine, DMA, 120 °C. (b) Acrylonitrile, Et<sub>3</sub>N, MeOH, DCE, 80 °C. (c) Aldehyde or ketone, NaBH(OAc)<sub>3</sub>, DIEA, 1,2-dichloroethane, room temperature. (d) DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (e) TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temperature. (f) 4-(2-Chloroethyl)morpholine HCl, NaI, DMA, 80 °C.</p></p></figure><div class="NLM_p">The numerous <i>N</i>-acyl analogues of the core structure were synthesized as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Reaction of <b>8</b> with acetic anhydride afforded <i>N</i>-acetylpiperidine <b>21</b>. Acylation of <b>8</b> with the acid chlorides of nicotinic acid and <i>N</i>,<i>N</i>-dimethylglycine produced compounds <b>22</b> and <b>23</b>, respectively. The remainder of the analogues was synthesized by means of amide coupling chemistry with the corresponding carboxylic acids. Thus, various derivatives, including <i>N</i>-acetyl derivatives substituted α to the carbonyl with amino, methylsulfonyl, various pyridyl <i>N</i>-oxides, imidazoyls, and pyridyls, were all made by reaction of the appropriate carboxylic acids and EDCI resulting in compounds <b>24</b>, <b>26</b>, and <b>30</b>–<b>38</b>. Hydrolysis of the ketal of <b>24</b> with aqueous HCl afforded 2,3-dihydroxypropionyl compound <b>25</b>. Deprotection of <i>N</i>-Boc-protected <b>26</b> with TFA followed by sodium triacetoxyborohydride and glyoxal gave <i>N</i>-hydroxyethylglycinyl derivative <b>28</b>. Further treatment of <b>28</b> with sodium triacetoxyborohydride and formalin then gave the <i>N</i>-methyl analogue of <b>28</b>, compound <b>29</b>. Similarly, bromotripyrrolidinophosphonium hexafluorophosphate (PyBrop) was used as the coupling agent in the production of the morpholinoacetyl analogue <b>39</b>, the <i>N</i>-Boc-protected amine <b>40</b>, as well as compound <b>42</b>, where SEM-protected compound <b>19</b> was the precursor. Removal of the Boc group in <b>40</b> and simultaneous removal of both the Boc and the SEM groups in <b>42</b> with TFA yielded the final compounds <b>41</b> and <b>43</b>, respectively. When intermediate <b>19</b> was treated with triphosgene followed by 2-aminoethanol and then deprotected as before, <i>N</i>-(2-hydroxyethyl)urea <b>44</b> was produced. Finally, the unsubstituted urea <b>45</b> was derived by treatment of <b>8</b> with trimethylsilylisocyanate followed by hydrolysis during aqueous purification by reverse HPLC.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (b) DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (c) EDCI, HOBt, DIEA or Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (d) EDCI, HOBt, DIEA, DMF, room temperature. (e) PyBrop, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (f) Triphosgene, DIEA, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>OH, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, then TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (g) TMS-NCO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (h) 2 M HCl, MeOH–H<sub>2</sub>O, room temperature. (i) TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (j) Na(OAc)<sub>3</sub>BH, glyoxal, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (k) Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>O, MeOH, room temperature.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We embarked on this discovery program with a focused screening effort within our chemical library collection. This endeavor resulted in three promising chemical classes: a series of quinolones<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and pyrimidinopyridones,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> both of which have been reported previously, and, the subject of this article, a series of arylamides as represented by <b>46</b> in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. It seemed evident from the initial collection of screening hits that an <i>ortho</i>-aminophenyl heteroarylcarboxamide comprised the basic pharmacophore of this series. Subsequent hit-to-lead efforts<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> resulted in significant improvements in binding affinity as in, for example, <b>47</b>, and eventually resulted in an initial lead compound <b>48</b>. This compound, in addition to improved druglike properties, also stabilized the crystal packing of an engineered chimeric form of the FMS kinase domain, thereby providing our first crystallographic information on the binding mode of this interesting new series<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and supplying us with an avenue to rapid structure-based optimization.</div><figure id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further optimization studies and investigation of the structure–activity relationship (SAR) produced proof-of-concept compounds, for example, furans and pyrroles <b>49</b>–<b>52</b>, of excellent potency (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> which permitted confirmation of in vivo efficacy for this class of compounds. Compound <b>52</b>, for example, in addition to possessing subnanomolar potency, displayed a very favorable pharmacokinetic profile and demonstrated significant efficacy in a collagen-induced model of arthritis in mice at doses as low as 5 mg/kg po BID. Histological evaluation of the tissues was consistent with the reductions in arthritis clinical scores, revealing that this agent reduced pannus invasion as well as destruction of both bone and cartilage, competitive in degree to that seen with biological anti-TNF agents in similar models. Moreover, the significant reductions in the number of macrophages in the joints of <b>52</b>-treated mice were consistent with both the observed macroscopic results and the hypothesized mechanism of action for these agents, viz., FMS inhibition.</div><div class="NLM_p">Despite these promising data, it was important to remain mindful of the latent liability of a 1,2,4-phenylenetriamine core structure, possessed by these proof-of-concept compounds, to undergo possible in vivo oxidation to form reactive quinonediimine metabolites. Such reactive species could potentially haptenize proteins as well as deplete glutathione concentrations, culminating in tissue damage via an idiosyncratic drug reaction (IDR).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this respect, in vitro glutathione conjugation assays<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> partly corroborated this prospective risk.</div><div class="NLM_p">Hoping to circumvent this anticipated liability and armed with the knowledge of the binding mode of this class from X-ray studies, a focused structure-based design effort was initiated to replace two of the three nitrogen substituents on the benzene core to derive the 2- and 4-substituted carbon-based analogues.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Although the challenge of instituting such major structural changes was recognized with regard to maintaining potency and good pharmacological properties, it was deemed necessary to ensure the long-term safety characteristics for a drug candidate.</div><div class="NLM_p">The SAR at the 4-position proved tolerant to replacement of the piperazine with a range of lipophilic rings and substituents (data not shown) where the direct replacement of a piperazine with a 4-piperidine resulted in derivatives, such as <b>53</b>, with no loss in potency. This was consistent with structural evidence indicating that substituents at the 4-position have close contact with a lipophilic region of the protein proximal to the attachment point at the benzene ring. The region more distal to the attachment point is largely directed out into solvent and is therefore open for more variation.</div><div class="NLM_p">Unlike the 4-position, the SAR surrounding the 2-position revealed that a piperidine group was very specific in its steric and conformational requirements. Hence, the best carbocyclic analogue that could be obtained for the piperidine, a 1-cyclohexenyl group, resulted in an unavoidable 20–30-fold erosion of the potency as illustrated by <b>54</b>. Ultimately, this significant loss of potency was mitigated by further optimization of the terminal acyl heterocycle.</div><div class="NLM_p">It was hypothesized through modeling that the equipotent nature of cyanofurans and cyanopyrroles in this acyl heterocyclic location was a result of two different hydrogen-bonding scenarios. An intramolecular hydrogen bond was thought to form between the amide NH and the furan oxygen, which assisted in holding the inhibitor in the conformation required for binding. This hydrogen bond was confirmed in the now-available X-ray cocrystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL">3KRL</a>) of <b>49</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> in FMS as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A. In the contrasting case of the pyrrole <b>50</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> modeled into FMS (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), the internal hydrogen bond cannot form. However, the anticipated reduction in binding affinity from the loss of this interaction was not observed. This appears to have been the result of an alternate intermolecular hydrogen bond that can form between the pyrrole NH and the carbonyl of Glu664, which, from modeling, would exist where the dashed line in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B is placed. Using this information, it was possible to combine the individually advantageous hydrogen-bonding characteristics of the two heterocycles. The result was the corresponding class of cyanoimidazoles, for example, <b>8</b> and <b>21</b>, which show approximately 10-fold improvement in affinity over either the furan or the pyrrole analogues compensating for the loss induced by replacement of the piperidine in the 2-position with the suboptimally potent 1-cyclohexenyl group. A cocrystal structure of <b>8</b> in FMS (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ">3KRJ</a>), also reported here for the first time and shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C, confirmed the hypothesis for increased potency where the two complementary internal and external hydrogen bonds were unmistakably present.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of FMS, cyan carbons, with furan-containing compound <b>49</b>, brown carbons (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL">3KRL</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (B) Model of FMS, cyan carbons, with pyrrole-containing compound <b>50</b>, salmon carbons. (C) Crystal structure of FMS, cyan carbons, with imidazole-containing compound <b>8</b>, orange carbons (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ">3KRJ</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(37)</a> Hydrogen bonds between the inhibitor and FMS and the inhibitor intramolecular hydrogen bonds are shown as green dashed lines. The figures were prepared with PyMol.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, these molecules also demonstrated low nanomolar potency in a cellular assay that measured the ability of compounds to inhibit the proliferation of murine bone marrow-derived macrophages (BMDM).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> More importantly, these compounds did not show the potential for reactive metabolite formation as gauged by the glutathione conjugation assay previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. FMS and Cell Potency and Potential for Reactive Metabolite Formation of Early Leads <b>8</b> and <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mean IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">FMS</th><th class="colsep0 rowsep0" align="center" char=".">BMDM assay</th><th class="colsep0 rowsep0" align="center">glutathione conjugation<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.1 (<i>n</i> = 31)</td><td class="colsep0 rowsep0" align="char" char=".">7.2 (<i>n</i> = 5)</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="left">Ac</td><td class="colsep0 rowsep0" align="char" char=".">2.4 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="char" char=".">5.6 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">no</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The test compound at 20 or 40 μM was incubated with NADPH (1 mM), GSH (5 mM) in PBS (0.1 mM), and 1 mg/mL of mouse liver microsomes at 37 °C for 1 h. The products were then analyzed by LC/MS for the glutathione conjugate of the parent (P + GSH), the amide bond cleavage product (ACP + GSH), and their fragments.</p></div></div></div><div class="NLM_p">Secure in the knowledge that these were potent inhibitors, which were less likely to present an IDR liability, we investigated the pharmacokinetic (PK) and pharmacodynamic (PD) properties of <b>8</b> and <b>21</b>. A PD assay in mice<a onclick="showRef(event, 'ref20 ref24'); return false;" href="javascript:void(0);" class="ref ref20 ref24">(20, 24)</a> was developed based on the ability of CSF-1 to induce the expression of c-fos mRNA in macrophages.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(39)</a> Tail-vein injection of CSF-1 caused an increase in c-fos mRNA concentrations of more than 10-fold in the spleen within 15 min but returned toward baseline by 30 min. The CSF-1-induced expression of c-fos was dose-dependent and specific as it was blocked completely in mice predosed with a neutralizing antibody to CSF-1.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> shows the PD effect of compounds <b>8</b>, <b>21</b>, and the earlier proof-of-concept compound <b>51</b>, at a time of 8 h following an oral dose of 50 mg/kg. This PD assay was used routinely throughout the program. With initial assessment at relatively high doses, compounds were often triaged on the basis of the presence or absence of robust (80–100%) inhibition of c-fos induction. Thus, the 70% inhibition of compound <b>8</b> and the 24% inhibition of compound <b>21</b> fell short of this criterion, while compound <b>51</b>, by comparison, which had excellent oral efficacy in a mouse CIA model,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> had strong inhibition (96%) even at a dose that is significantly lower (20 mg/kg) than for either of the two candidates <b>8</b> and <b>21</b>. Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> also presents some of the PK properties of <b>8</b> and <b>21</b>. In mice, the oral exposures of <b>51</b> at 4 and 8 h postdose were robust as compared to <b>8</b> and <b>21</b> and provided the apparent explanation of the superior PD activity. The superior exposures were largely a consequence of the good oral bioavailability of <b>51</b> vs the poor oral bioavailability of <b>8</b> and <b>21</b>. All three compounds exhibited moderate to high clearance relative to liver blood flow, together with moderate to high volumes of distribution. It seemed apparent from these results, in particular the failure of both <b>8</b> and <b>21</b> to attain adequate bioavailability, that the early evaluation of the in vivo properties of subsequent candidates would be essential for the rapid progression of this program.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PK and PD Data for Compounds <b>8</b>, <b>21</b>, and <b>51</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" align="center">PD (po)</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">PK (iv)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">PK (po)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">c-fos assay (% inhib at 8 h<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Vz (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>(ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub>(min ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">concn at 4 h (ng/mL)</th><th class="colsep0 rowsep0" align="center">concn at 8 h (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">70 (50 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">5715</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">BLQ<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="left">24 (50 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">209</td><td class="colsep0 rowsep0" align="char" char=".">27218</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>51</b><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">96 (20 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">12.3</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">0.5–4.0</td><td class="colsep0 rowsep0" align="char" char=".">285</td><td class="colsep0 rowsep0" align="char" char=".">69711</td><td class="colsep0 rowsep0" align="char" char=".">183</td><td class="colsep0 rowsep0" align="left">64</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">See the text for details of PD assay.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compounds <b>8</b> and <b>51</b> administered in 20% HPβCD (pH 2 by HCl) at 0.5 mg/kg iv and 5 mg/kg po.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Compound <b>21</b> administered in 20% DMSO/80% PEG400 at 0.5 mg/kg iv and in 1% Tween 80/0.5% hydroxypropylmethylcellulose at 5 mg/kg po.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Below the limit of quantitation.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">PK values for <b>51</b> are the mean of multiple studies (<i>n</i> = 4).</p></div></div></div><div class="NLM_p">To investigate the potential for side effects, <b>8</b> and <b>21</b> at 10 μM were examined in a battery of 50 counterscreen assays<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(40)</a> for activity against a wide variety of receptors, transporters, and ion channels. Compound <b>8</b> hit nine targets with greater than 50% inhibition of specific control ligand binding, whereas <b>21</b> gave greater than 50% inhibition at only three targets. It is not uncommon to see significant levels of off-target binding with relatively basic compounds such as piperidine <b>8</b> (calculated p<i>K</i><sub>a</sub> = 10.2 ± 0.1).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(41)</a> Many groups have investigated the target promiscuity of compounds as a function of their basicity and, in general, it seems clear that increased basicity as well as the potential for a positive charge at physiological pH are strong contributors to off-target activity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(42)</a></div><div class="NLM_p">Of particular concern was that higher levels of binding at ion channels, in particular sodium<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(43)</a> and calcium ion channels,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(44)</a> for basic compounds may lead to an increased risk of adverse cardiovascular effects. Indeed, it was demonstrated<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(45)</a> that the highly basic compound <b>8</b> inhibited Ca<sup>2+</sup> channel, L, reference compound binding by 91% and Na<sup>+</sup> channel, site 2 reference compound binding by 96% at 10 μM, and had somewhat greater undesirable effects in a guinea pig right atrium assay than the less basic amide derivative <b>21</b>, which inhibited Ca<sup>2+</sup> channel and Na<sup>+</sup> channel binding by 46 and 27%, respectively. The strategy of reducing the basicity of compounds to mitigate off-target ion channel effects has been used for calcium and sodium channels<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(46)</a> and for potassium channels such as human ether-a-go-go-related gene potassium channel (hERG).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(47)</a> Thus, we hypothesized that moderating the basicity of future analogues would be beneficial and, so, the majority of analogues in this paper were selected with that concept in mind.</div><div class="NLM_p">Leads also were optimized against a battery of in vitro tests for ADMET properties including the in vitro metabolic stability in human and rodent liver microsomes as a means to separate out compounds that may not withstand first-pass metabolism. A compound stability of at least 70% remaining after a 10 min exposure to the microsomal mixture was preferred. In addition, in vitro assays for inhibition of recombinant cytochrome P450 (CYP) enzymes provided a means to predict future problems with drug–drug interactions,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(48)</a> and we routinely monitored four of the CYP enzyme subtypes (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) responsible for metabolism of a majority of drugs.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(49)</a> IC<sub>50</sub> values below 3 μM were considered suspect requiring follow-up in secondary assays, and values below 1 μM can often prove problematic.</div><div class="NLM_p">As mentioned above, many of the derivatives for this optimization process were selected to modulate the basicity of the piperidine nitrogen. The predictable effects on basicity of various electron-withdrawing groups, electronegative heteroatoms, and heteroaryl rings placed two to three bonds away from an amine nitrogen are well-documented,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a> and selections based on these principles resulted in a group of <i>N</i>-alkyl and <i>N</i>-aryl piperidines (compounds <b>9</b>–<b>20</b>). The data for these analogues are displayed in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> where the unsubstituted piperidine lead <b>8</b> is included as a reference.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. FMS and Cell Potency and Early ADMET Properties of <i>N</i>-Alkyl/<i>N</i>-Aryl Piperidines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0004.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">For comparative purposes, data in the table are formatted in bold when they met desired subjective criteria (FMS IC<sub>50</sub> < 10 nM (bolded but not used as a selection criterion), BMDM IC<sub>50</sub> < 15 nM, liver microsomal stability 70–100%, CYP450 IC<sub>50</sub> > 3 μM, and hERG IC<sub>50</sub> > 3.2 μM).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">na, not assayed.</p></div></div><div></div></div><div class="NLM_p">As a first screening criterion, we sought compounds with an IC<sub>50</sub> potency better than 15 nM in the cellular BMDM proliferation assay based on experience that compounds with higher values often did not exhibit PD activity at reasonable (<50 mg/kg) doses. In general, the data in the tables are formatted in bold when they met the criteria as discussed above for a particular assay. Thus, bolded values for all assay results within a given row indicate compounds of greater interest for secondary studies.</div><div class="NLM_p">It is immediately apparent that this entire group of compounds displayed good in vitro stability in the presence of both human and mouse liver microsomal preparations. It is possible that the additional functionality present on the various <i>N</i>-alkyl groups prevents metabolism commonly observed with simpler <i>N</i>-alkyl groups. In vitro potency in the FMS enzyme assay was also excellent with the only exception being the 2-pyridylpiperidine <b>9</b> (IC<sub>50</sub> = 22 nM), which was further compromised by significant inhibition of CYP3A4 (IC<sub>50</sub> = 1.7 μM). Of the remaining candidates, the highest IC<sub>50</sub> values in the group did not exceed 2.4 nM.</div><div class="NLM_p">In the cellular BMDM assay, only two compounds (<b>14</b> and <b>18</b>) failed to give IC<sub>50</sub> values below 15 nM. In the case of the carboxymethyl derivative <b>18</b>, the low p<i>K</i><sub>a</sub> expected for an aminoacid of this type likely resulted in insufficient concentration of the free acid at physiological pH to provide adequate cell membrane penetration.</div><div class="NLM_p">The values for inhibition of the four cytochrome P450 enzymes assayed also did not strongly rule out any additional compounds. A number of the compounds were also tested for inhibition of [<sup>3</sup>H]-astemizole binding at the hERG potassium channel as a predictor for compounds that may prolong cardiac action potential duration, potentially resulting in long QT syndrome.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(51)</a> None of the compounds tested gave results that merited concern. Thus, the six compounds from the <i>N</i>-alkylpiperidine analogues with the greatest cell potency (<b>10</b>–<b>12</b>, <b>15</b>, <b>16</b>, and <b>20</b>) were selected for further evaluation.</div><div class="NLM_p">Data for the corresponding collection of <i>N</i>-acylpiperidine derivatives (compounds <b>22</b>–<b>45</b>) are displayed in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Because acylation of the piperidine to give nonbasic amides could potentially impact the solubility, some acyl groups were selected that still contained amines to retain a solubilizing feature. As discussed above, however, the proximity of the added amine to the acyl carbonyl or other heteroatoms was maintained to modulate the p<i>K</i><sub>a</sub> and limit ion-channel and other off-target activity. As before, one of the early leads, <i>N</i>-acetyl piperidine <b>21</b>, is included as an <i>N</i>-acyl reference for this group.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. FMS and Cell Potency and Early ADMET Properties of <i>N</i>-Acyl Piperidines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0005.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">For comparative purposes, data in the table are formatted in bold when they met desired subjective criteria (FMS IC<sub>50</sub> < 10 nM (bolded but not used as a selection criterion), BMDM IC<sub>50</sub> < 15 nM, liver microsomal stability 70–100%, CYP450 IC<sub>50</sub> > 3 μM, and hERG IC<sub>50</sub> > 3.2 μM).</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">na, not assayed.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Insufficient solubility in PBS to determine.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">On different occasions, hERG assays were run with a maximum concentration that limited the determination of IC<sub>50</sub> values to either 3.2 or 10 μM.</p></div></div><div></div></div><div class="NLM_p">All compounds in this series also exhibited excellent in vitro potency in the FMS enzyme assay with no IC<sub>50</sub> values exceeding 3.8 nM. Five compounds were discarded based on relatively modest cellular potency, viz., the isonicotinic amide <i>N</i>-oxide <b>32</b>, the 4-imidazoyl amides <b>33</b> and <b>34</b>, the aminoalkylamide <b>41</b>, and the primary urea <b>45</b>. Additionally, the 4-imidazoyl amides, <b>33</b> and <b>34</b>, showed greater CYP inhibition with <b>33</b> being a particularly potent inhibitor of CYP2C9 and CYP2C19. With regard to the relatively weak cellular potency of <b>41</b>, one may postulate that the more strongly basic nature of the α-branched amine results in a more charged species at physiological pH that does not pass easily through cell membranes, whereas, by comparison, the closer proximity of the amino group to the carbonyl in <b>43</b> attenuates the p<i>K</i><sub>a</sub> such that <b>43</b> does not suffer the same fate and retains good cellular activity.</div><div class="NLM_p">When the remaining 14 candidates were subsequently incubated in the presence of liver microsomes, a significant number demonstrated less-than-desirable stability. All of the pyridylmethyl amides, <b>35</b>–<b>37</b>, were very unstable in both species. In addition, nicotinic amide <b>22</b>, the two hydroxyethylaminomethyl amides <b>28</b> and <b>29</b>, both morpholinoalkyl amides <b>38</b> and <b>39</b>, as well as the hydroxyethylurea <b>44</b> all suffered varying degrees of reduced stability in the presence of one or both species of microsomes, which did meet our threshold for desired stability. Nicotinic amide <b>22</b> also displayed submicromolar inhibition of CYP2C9.</div><div class="NLM_p">Finally, of the remaining five most potent and stable derivatives within this group, nicotinic amide <i>N</i>-oxide <b>31</b> and aminoalkylamide <b>43</b> showed low micromolar CYP inhibition. More importantly, the <i>N</i>-oxide <b>31</b>, despite its apparent in vitro microsomal stability, also carried the liability that any in vivo metabolic loss of the <i>N</i>-oxide would result in the formation of the potent CYP2C9 inhibitor <b>22</b>, a concern that also removed it from further consideration. Again, of the compounds tested for inhibition of binding of astemizole to hERG, none appeared to have a hERG liability. The remaining compounds appeared quite promising in their profile. Unfortunately, the attrition of compounds from this group of <i>N</i>-acyl derivatives shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> was significantly greater than from the <i>N</i>-alkyl and <i>N</i>-aryl compounds shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, resulting in only three analogues (<b>23</b>, <b>25</b>, and <b>30</b>) for advancement to further studies.</div><div class="NLM_p">At this stage, there remained a collection of nine promising candidates from Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, and it was clear from the shortcomings of <b>8</b> and <b>21</b> that an early assessment of in vivo efficacy would be useful for the most efficient selection of improved candidates. Because the activity in the PD model was presumably an integrated function of potency and tissue exposure, the performance in the PD model was deemed the most efficient way to prioritize compounds for further advancement. However, the resource-intensive nature of this assay at multiple doses and time points required an abbreviated approach be used to screen this collection. Therefore, the top candidates were investigated in this model initially at a single dose of 50 mg/kg and at a time of 8 h after oral administration.</div><div class="NLM_p">The results of these PD screening studies are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Of the nine compounds, two (<b>11</b> and <b>25</b>) were not tested. After Cerep counterscreening for other activities, compound <b>11</b> demonstrated greater than 50% inhibition against 12 targets at 10 μM, and compound <b>25</b>, as a chiral compound, was also excluded. Lead compounds <b>8</b> and <b>21</b> are included again in this table for reference. To ensure that the in vitro screens based on cellular activity and microsomal stability were not excluding potentially useful compounds, a selection of compounds that did not meet the cutoff criteria were also added as controls. These included <b>35</b>–<b>37</b> and <b>44</b>, which had excellent cellular potency for inhibition of BMDM proliferation but which had marginal to poor stability in mouse liver microsomes. Also added as a control was <b>34</b>, which, by contrast, had good mouse microsomal stability but poor cellular BMDM activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PD, PK, and Solubility Properties of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">PK parameters<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">iv</th><th class="rowsep1 colsep0" colspan="4" align="center">po</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">PD assay % inhibition at 8 h<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (50 mpk po)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">Vz (L/kg)</th><th class="colsep0 rowsep0" align="center">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>(ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>last</sub>(min ng/mL)</th><th class="colsep0 rowsep0" align="center">% <i>F</i></th><th class="colsep0 rowsep0" align="center" char=".">solubility in PBS (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">7.16</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">51.7</td><td class="colsep0 rowsep0" align="left">2.00</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">5715</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="char" char=".">38.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">1.21<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.84<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">27.0<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.88<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">209<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">27218</td><td class="colsep0 rowsep0" align="left">15<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">26.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="left"><b>88</b>–<b>93</b></td><td class="colsep0 rowsep0" align="left">1.44</td><td class="colsep0 rowsep0" align="left">3.84</td><td class="colsep0 rowsep0" align="left">30.7</td><td class="colsep0 rowsep0" align="left">1.55</td><td class="colsep0 rowsep0" align="left"><b>866</b></td><td class="colsep0 rowsep0" align="left">127845</td><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="left"><51</td><td class="colsep0 rowsep0" align="left">1.39</td><td class="colsep0 rowsep0" align="left">6.43</td><td class="colsep0 rowsep0" align="left">53.3</td><td class="colsep0 rowsep0" align="left">0.88</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">8445</td><td class="colsep0 rowsep0" align="left">9.8</td><td class="colsep0 rowsep0" align="char" char=".">28.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>20</b></td><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">8.99</td><td class="colsep0 rowsep0" align="left">46.6</td><td class="colsep0 rowsep0" align="left">2.37</td><td class="colsep0 rowsep0" align="left"><b>461</b></td><td class="colsep0 rowsep0" align="left">93173</td><td class="colsep0 rowsep0" align="left"><b>101</b></td><td class="colsep0 rowsep0" align="char" char=".">25.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>23</b></td><td class="colsep0 rowsep0" align="left"><b>88</b>–<b>100</b></td><td class="colsep0 rowsep0" align="left">1.36</td><td class="colsep0 rowsep0" align="left">7.11</td><td class="colsep0 rowsep0" align="left">60.6</td><td class="colsep0 rowsep0" align="left">2.33</td><td class="colsep0 rowsep0" align="left"><b>296</b></td><td class="colsep0 rowsep0" align="left">61365</td><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="char" char=".">37.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>30</b></td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">1.20<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.58<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">23.9<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.55<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">24<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">7500</td><td class="colsep0 rowsep0" align="left">2.3<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">0.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">3.85</td><td class="colsep0 rowsep0" align="left">81.8</td><td class="colsep0 rowsep0" align="left">0.40</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">6075</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="char" char=".">36.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>35</b></td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>36</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">10.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">7.27</td><td class="colsep0 rowsep0" align="left">205</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">4080</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>44</b></td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">2.41</td><td class="colsep0 rowsep0" align="left">10.3</td><td class="colsep0 rowsep0" align="left">49.2</td><td class="colsep0 rowsep0" align="left">1.63</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">7740</td><td class="colsep0 rowsep0" align="left">9.3</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">PD model in B6C3F1 mice with all compounds administered po in 20% HPβCD (see the details in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">PK studies in 30–40 g male CD-1 mice. All compounds administered in 20% HPβCD (pH 2 by HCl) at 0.5 mg/kg iv and 5 mg/kg po except where indicated otherwise.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Compounds administered in 20% DMSO/80% PEG400 at 0.5 mg/kg iv and in 1% Tween 80/0.5% hydroxypropyl- methylcellulose at 5 mg/kg po.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">na, not assayed.</p></div></div></div><div class="NLM_p">The negative control compounds <b>34</b>–<b>37</b> and <b>44</b> gave little or no PD response, as expected. Also, the seven top primary screen candidates did not all perform equally well in this screen. Ultimately, three candidates, <b>15</b>, <b>20</b>, and <b>23</b>, gave good to excellent results.</div><div class="NLM_p">In an effort to understand some of the factors that contributed to the ineffectiveness of some compounds in this assay, PK parameters and solubility values in PBS are included in this table for selected compounds. In general, it seems clear that nearly all of the compounds within this series suffer from moderate to high clearance rates, ranging from values of 24 up to as high as 82 mL/min/kg. Nevertheless, in some cases, correspondingly high volumes of distribution result in compounds that still retain iv half-lives of reasonable length. Control compound <b>44</b>, which was below the desired threshold for stability in the mouse microsomal assay, had low bioavailability and low <i>C</i><sub>max</sub> values in plasma, consistent with the poor PD activity seen, and although poor microsomal stability may often be a predictor of high clearance, compounds with good microsomal stability may still suffer from high clearance for other reasons (such as phase II metabolism), as shown by control compound <b>34</b>, which possessed one of the highest clearance values of those tested. Among the remaining compounds, the poor <i>C</i><sub>max</sub> and bioavailability of compounds <b>16</b> and <b>30</b> appear to explain the low PD inhibition effects observed. The three compounds that demonstrated the most promising PD activities, <b>15</b>, <b>20</b>, and <b>23</b>, all possessed good PK. Moderate to high clearance values of each compound were compensated for by excellent bioavailabilities (all greater than 80%) and by high volumes of distribution resulting in good oral half-lives (1.6–2.4 h).</div><div class="NLM_p">Solubility may play a role in the PK behavior observed. It can be seen that the solubility in phosphate buffered saline (PBS) of the control compounds <b>35</b>–<b>37</b> and <b>44</b> and for test compounds <b>10</b> and <b>30</b> was lower than for the reference compounds <b>8</b> and <b>21</b> and may have been an additional contributing factor in the poor PK observed for compounds <b>30</b> and <b>44</b>. However, good solubility is only one helpful characteristic and, clearly, somewhat lower solubility did not impact the good PK seen for test compound <b>15</b>.</div><div class="NLM_p">To assess kinase selectivity, compounds <b>15</b>, <b>20</b>, and <b>23</b> were screened against a large number of tyrosine, serine-threonine, or mixed kinases. Differences in the profiles of the three compounds were not pronounced (data not shown). For example, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, compound <b>23</b> was assessed at 1 μM for activity vs 39 tyrosine kinases and 79 serine-threonine or mixed kinases. Seventy-eight of the serine-threonine or mixed kinases were inhibited less than 50%; one serine-threonine kinase, ALK, was inhibited by 51%. Sixteen of the 39 tyrosine kinases were inhibited by more than 50% by 1 μM <b>23</b>. Of these, six were inhibited by more than 50% at 0.1 μM, and the IC<sub>50</sub> values of <b>23</b> vs these six kinases were determined and are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>. IC<sub>50</sub> values are also reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a> for <b>15</b> and <b>20</b>. All three compounds were found to be relatively potent inhibitors of FLT3, AXL, KIT, and TRKA with modest selectivities for FMS ranging from 7- to 43-fold. The inhibition of FLT3 and KIT can suppress functions in dendritic cells and mast cells, suggesting that the presence of these activities may have beneficial effects toward inflammation. However, there is also evidence that potent inhibition of KIT can produce myelosuppression and anemia.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> We also tested these compounds in cell-based assays designed to exhibit dependence on these kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). While the selectivity for FMS vs FLT3 and KIT was modest for compound <b>23</b> and the selectivity for FMS vs FLT3 was minimal for compound <b>20</b>, compound <b>15</b> exhibited the highest selectivity for FMS among the three compounds with FMS selectivity in cells ranging from ca. 32- to 161-fold. Although compound <b>23</b> was a potent inhibitor of AXL and LCK enzyme assays, only high (>2 μM) concentrations inhibited these targets in cellular assays.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Inhibition by <b>23</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinases inhibited more than 50% by 0.1 μM <b>23</b></th><th class="colsep0 rowsep0" align="center">kinases not inhibited 50% by 0.1 μM <b>23</b> but more than 50% by 1 μM <b>23</b></th><th class="colsep0 rowsep0" align="center">kinases not inhibited 50% by 1 μM <b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS, FLT3, KIT, AXL, TRKA, and LCK</td><td class="colsep0 rowsep0" align="left">ALK, BLK, BMX, FES, FGR, FYN, PDGFRA, PDGFRB, TRKB, and YES</td><td class="colsep0 rowsep0" align="left">Abl1, Akt1, Akt2, Akt3, Arg, Brk, BTKC, aMKII-α, CHK1, CHK2, CK2-α1, MET, Csk, EGFR, EphA3, EphB4, ERK1, ERK2, FGFR1, FGFR2, FGFR3, FGFR4, GSK3-α, GSK3-β, Hck, Hyl, IGF1R, IRAK4, Lyn A, Lyn B, MAPKAP-K2, MAPKAP-K3, MAPKAP-K5, NEK2, PHKG2, PKA, PKC (α, β I, β II, δ, ϵ, η, γ, ι, θ, ζ), RSK2, Src, AMPK, Aurora-A, CaMKIV, CDK/cyclinB, CDK2/cyclinA, CDK2/cyclinE, CDK3/cyclinE, CDK5/p35, CDK6/cyclinD3, CDK7/cyclinH, CK1, CK1d, c-RAF, CSK, EphB2, IKKα, IKKβ, IR, JNK1α1, JNKα2, JNK3, MAPK1, MAPK2, MEK1, MKK4, MKK6, MKK7b, MSK1, MST2, NEK2, p70S6K, PAK2, PAR-1Ba, PDK1, PKBα, PKBβ, PKBγ, PRAK, PRK2, ROCK-II, Ros, Rsk1, Rsk3, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, Syk, Tie, and ZAP-70</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Kinase Selectivities of <b>15</b>, <b>20</b> and <b>23</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="."><b>15</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20</b></th><th class="colsep0 rowsep0" align="center" char="."><b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKA</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="char" char=".">860</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">88</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cell-Based Kinase Selectivities of <b>15</b>, <b>20</b>, and <b>23</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">cells/cell line</th><th class="colsep0 rowsep0" align="center">stimulus</th><th class="colsep0 rowsep0" align="center">end point</th><th class="colsep0 rowsep0" align="center"><b>15</b></th><th class="colsep0 rowsep0" align="center"><b>20</b></th><th class="colsep0 rowsep0" align="center" char="."><b>23</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS</td><td class="colsep0 rowsep0" align="left">BMDM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">CSF-1</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITD-FLT 3</td><td class="colsep0 rowsep0" align="left">MV-4–11<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="left">Mo7e<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">SCF</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">210</td><td class="colsep0 rowsep0" align="left">na<a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKA</td><td class="colsep0 rowsep0" align="left">TF-1<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NGF</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">500</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="left">Jurkat<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">anti-CD3, PMA</td><td class="colsep0 rowsep0" align="left">IL-2</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">3900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL</td><td class="colsep0 rowsep0" align="left">AXL/HEK<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">GAS6</td><td class="colsep0 rowsep0" align="left">phospho-AXL</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="left">na</td><td class="colsep0 rowsep0" align="char" char=".">2600</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Assays were performed as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> or as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Mouse BMDMs.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Leukemia cell lines.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">T-cell lymphoma cell line.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">HEK cells were transfected to overexpress AXL.</p></div><div class="footnote" id="t8fn6"><sup>f</sup><p class="last">na, not assayed.</p></div></div></div><div class="NLM_p">Compounds <b>15</b>, <b>20</b>, and <b>23</b> had properties from the abbreviated in vivo screening studies that more than qualified each to advance to more extensive efficacy studies. Therefore, to better characterize and compare them, a more detailed dose–response PD study was performed. Each compound was dosed at high and medium doses of 50 and 20 mg/kg, respectively, and at a lower dose of either 10 mg/kg for compounds <b>20</b> and <b>23</b> or at 8 mg/kg for compound <b>15</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. PD Dose–Response Studies of <b>15</b>, <b>20</b>, and <b>23</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">PD assay</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">% inhibition at 8 h (po)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">mg/kg</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center" char=".">50</th><th class="colsep0 rowsep0" align="center" char=".">20</th><th class="colsep0 rowsep0" align="center">10</th><th class="colsep0 rowsep0" align="center">8</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">na<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>20</b></td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">na</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">88–100</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">na</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">PD model in B6C3F1 mice with all compounds administered in 20% HPβCD (see the details in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">na, not assayed.</p></div></div></div><div class="NLM_p">Differences in the in vivo activity of the three compounds became apparent in the dose–response comparison. By the mid-dose of 20 mg/kg, the performance of <b>15</b> had fallen off sharply, while the responses of <b>20</b> and <b>23</b> remained robust (77–79% inhibition). At the lowest dose, <b>20</b> and <b>23</b> still showed substantial responses with <b>20</b> (51% inhibition) appearing somewhat superior to <b>23</b> (32% inhibition).</div><div class="NLM_p">The three candidates, compounds <b>15</b>, <b>20</b>, and <b>23</b>, were subsequently evaluated in a type II CIA model in mice.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(53, 54)</a> This model has been particularly useful in evaluating the beneficial effects of soluble TNF receptors and other cytokine inhibitors.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(55)</a> Although <b>15</b> had demonstrated a reduced response relative to the other two candidates in the previous PD assay, it was still included in the CIA study at a high dose.</div><div class="NLM_p">Male B10RII mice were administered Freund's complete adjuvant containing bovine type II collagen and supplemental <i>Mycobacterium tuberculosis</i> H37 RA at the base of the tail on day 0 and again on day 15. Groups of 15 mice received twice daily oral administration of either the vehicle (20% HPβCD) in a disease control group or the test compound on days 12–26. Compounds <b>20</b> and <b>23</b> were tested at doses of 60 and 20 mg/kg po BID and <b>15</b> at a single dose of 60 mg/kg po BID. One untreated naive group was used as a normal (nondisease) control. Efficacy was based on four individual histopathological parameters, that is, inflammation, pannus formation, cartilage damage, and bone erosion. Histopathology scores were recorded for each category in a range of 0 (normal) to 5 (severe), and the mean value was calculated for the four paws. Statistical significance (<i>p</i> < 0.05, Student's <i>t</i> test) was based, in each group, relative to the vehicle-treated disease control group and, when achieved, is indicated in the charts with an asterisk. A separate, overall, four-paw, animal score based on the sum of the four histological scores was also calculated to provide a more generalized indication of efficacy.</div><div class="NLM_p">The vehicle-treated disease control animals developed arthritis symptoms with histological changes in most paws with scores ranging from minimal (1) to severe (5). As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, the vehicle-treated disease control group displayed a greatly elevated four-paw summary score (mean = 5.45) relative to the disease-free naive group. Compound <b>15</b> at 60 mg/kg produced a significant 61% reduction in the four-paw score relative to the vehicle-treated disease control. This was the result of significant inhibition, ranging from 57 to 63%, in all four of the measured individual histological parameters as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. Compound <b>20</b> proved the most efficacious of the three candidates in this model. However, the 60 mg/kg dose of <b>20</b> caused acute weight loss in a subset of mice and resulted in the deaths of two animals by day 17. As a result of this toxicity and the subsequent deaths, the dose of compound <b>20</b> was reduced to 40 mg/kg beginning day 18 and maintained at the lower dose through day 26. Even so, compound <b>20</b> produced a significant overall reduction of 82% in the summary score. This is a result of marked reductions in inflammation, pannus, cartilage damage, and bone damage, all in the range of 77–88%. When the dose of <b>20</b> was reduced to 20 mg/kg, the toxicity seen at the higher dose was not seen, but the overall efficacy was still impressive with a summary score of 74% inhibition. The inhibition of the individual histological parameters for <b>20</b> at this lower dose displayed a range of 69–77% reduction relative to the disease controls. Compound <b>23</b> at 60 mg/kg produced a significant 73% reduction of the four-paw score (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). The inhibition of individual histological parameters ranged from 65 to 79% (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) with the reductions in the scores for both pannus formation (79%) and bone erosion (79%) of particular note. When administered at the lower dose of 20 mg/kg, compound <b>23</b> was less effective overall, providing a nonsignificant 20% reduction in the summary score. This reflected nonsignificant reductions in inflammation and cartilage damage of 16 and 18%, respectively, and significant 25% reductions in pannus formation and bone erosions (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). With the exception of the 60 mg/kg dose of <b>20</b>, the candidates had no deleterious effects on body weight or any clinical signs of toxicity.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>15</b>, <b>20</b>, and <b>23</b> reduced four-paw histopathology summary scores in mouse CIA. CIA was induced in mice as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Group mean values (SEM) are plotted, and percent inhibition values relative to the vehicle-treated disease control are indicated in text within the bars (mpk = mg/kg); *<i>p</i> < 0.01 vs disease control (vehicle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>15</b>, <b>20</b>, and <b>23</b> reduced the histopathology evidence of inflammation, pannus, cartilage, and bone damage. CIA was induced in mice, and scores for each histopathology parameters were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Group mean values (SEM) are plotted. *<i>p</i> < 0.01 vs disease control (vehicle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although compound <b>20</b> showed a clear advantage in terms of efficacy over <b>15</b> and <b>23</b>, the toxicity observed at the high dose was worrisome. In further studies, <b>20</b> and <b>23</b> were examined in a battery of 50 counterscreen assays<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(40)</a> for activity against a wide variety of receptors, transporters, and ion channels. While <b>23</b> hit four targets with greater than 50% inhibition of specific control ligand binding, <b>20</b> gave greater than 50% inhibition at seven targets. The apparent increased off-target activity of <b>20</b> was also reflected in unambiguous conductance effects in guinea pig acute cardiovascular (CV) safety<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(56)</a> and guinea pig right atrium studies.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(57)</a> Consequently, despite the lack of overt toxicity at the lower dose of 20 mg/kg in the arthritis study, the potential for safety issues was of significant concern, and the decision was made to eliminate <b>20</b> as a candidate. Thus, compound <b>23</b>, which was superior to <b>15</b> at a comparable dose for every histological parameter and in its summary score, was chosen as the best candidate in the group for further evaluation. To better characterize the potential of compound <b>23</b> as a potential treatment for RA, it was subsequently characterized in additional models of this disease.</div><div class="NLM_p">Rat adjuvant arthritis is an experimental model of polyarthritis that has been widely employed for preclinical testing of antiarthritic agents.<a onclick="showRef(event, 'ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62 ref63">(58-61)</a> Two characteristics of this model are the reliable onset and progression of robust, easily measurable, periarticular inflammation, and marked bone resorption. Cartilage destruction also occurs but is disproportionally mild in comparison to the inflammation and bone destruction that takes place. This is a fairly aggressive model especially when used, as in this case, in a therapeutic mode for evaluation of compounds administered after the symptoms of the disease have emerged.</div><div class="NLM_p">Arthritis was induced in male Lewis rats by injection of Freund's complete adjuvant containing lipoidal amine [<i>N</i>,<i>N</i>-dioctyldecyl-<i>N′</i>,<i>N</i>-bis(2-hydroxyethyl)propanediamine] at the base of the tail on day 0. Clinical signs of disease began to emerge on day 8 postinjection. Beginning on day 8, randomized groups of rats received twice daily oral administration of either the vehicle (0.5% hydroxypropylmethylcellulose/0.5% Tween 80) or compound <b>23</b> at 5, 20, and 60 mg/kg. All adjuvant-injected control rats developed clinical signs of arthritis as evidenced by increased ankle joint diameter. Mean body weights were similar in all groups at the start of the study, and none of the treatment groups with established arthritis had significant mean body weight changes as compared to the established arthritis vehicle controls (data not shown).</div><div class="NLM_p">After euthanization on day 14, the hind paws were removed, weighed, processed, and scored for histopathology assessment. Paw weights were increased nearly 2-fold in rats with adjuvant arthritis (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A). The increase in paw weights was reduced by <b>23</b> in a dose-dependent fashion with 60 mg/kg reducing the gain in paw weight by 49%. Suppression of paw weight increase by <b>23</b> correlated with suppression in the histological scores of inflammation (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). The abundance of periarticular macrophages was assessed in sections following immunohistochemical detection of ED-1 antigen (CD68), a marker of macrophage lineage cells. ED-1<sup>+</sup> macrophages were reduced by <b>23</b> in a dose-dependent fashion with significant reductions at all doses (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C). Splenomegally, an additional manifestation of the immune inflammatory response to adjuvant, was reduced by <b>23</b> in a similar dose-dependent fashion (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>D).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>23</b> reduced disease activity in rats with adjuvant arthritis. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Commencing on day 8, adjuvant-induced rats (Adj) received twice daily oral doses of vehicle (veh) or 5, 20, or 60 mg/kg of <b>23</b> until study termination on day 14. An additional group of rats was not adjuvant induced and served as the disease-free (normal) control. All end points were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. (A) Hind paws were severed at the level of the medial and lateral malleolus and weighed. (B) H&E-stained sections of formalin-fixed hind paws were scored for inflammation by histopathology assessment using a five-point scale. (C) Soft tissue regions of sections stained for ED-1 antigen (CD68) positive macrophages were assessed for the number of areas (hot spots) with marked numbers of positive cells. (D) Spleens were weighed at necropsy. (E) H&E-stained sections of formalin-fixed hind paws were scored for bone erosions using a five-point scale. All values represent group means (<i>n</i> = 16 hind limbs or 8 spleens). Error bars represent standard errors of the means. Percent inhibition values relative to adjuvant-induced, vehicle-treated rats were provided as white text within bars. *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Paws were examined further for histopathological evidence of bone erosion (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>E). By day 14, all 16 evaluated tibio-tarsal joints of the vehicle-treated group exhibited signs of bone erosion ranging from minimal to severe. Loss of medulary trabecular bone was readily observed at low power in most paws from vehicle-treated diseased rats. Osteoclast numbers per 400× field were averaged from examining the five fields of greatest bone resorption. In vehicle-treated rats, areas of bone erosion were characterized by numerous osteoclasts (average of 12.6 osteoclasts per 400× field). The occurrence of erosions and erosion-associated osteoclasts was completely prevented in rats dosed with 60 or 20 mg/kg <b>23</b>. Even in rats receiving 5 mg/kg <b>23</b>, 11 of 16 evaluated joints were characterized by an absence of bone erosion, and the remaining five joints had mild erosions. At all three doses of <b>23</b>, osteoclast numbers were similar to disease-free joints. Adjuvant arthritis was additionally associated with periosteal new bone formation. The formation of new bone was proportional to inflammation scores and was reduced 67% by a dose of 60 mg/kg <b>23</b> but was not reduced by lower doses.</div><div class="NLM_p">In a third model, polyarthritis was induced in female Lewis rats following intraperitoneal (ip) administration of streptococcal cell wall (SCW) proteoglycan-polysaccharides (PG-PS). This model has an acute nonerosive phase (days 3–7) that is complement- and neutrophil-dependent and that resolves. A chronic erosive phase then begins at about day 10 and is dependent on macrophages and on the development of specific T-cell immunity to SCW.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(62, 63)</a> In an initial study, dosing of <b>23</b> was commenced on day 8 when the acute phase was resolving and transitioning to the chronic phase. Rats treated with vehicle progressively developed a severe arthritis until study termination (day 19). Administration of <b>23</b> at 20 mg/kg (po, BID) blocked the emergence of the chronic arthritic phase with a significant effects on ankle thickness (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A) and clinical scores (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B) observed as early as day 12, 4 days after dose initiation. Histological assessment of the ankles of vehicle-treated rats revealed recruitment of numerous ED-1 positive macrophages into the periarticular tissues together with fibroplasia (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C). Also notable were the greatly increased numbers osteoclasts (also ED-1 positive) eroding many large areas of trabecular bone in all vehicle-treated rats (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C). Compound <b>23</b> reduced the recruitment of macrophages into the periarticular tissues (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>D). Furthermore, osteoclast counts and distribution were normal, and the large areas of trabecular bone loss observed in all vehicle-treated rats were not observed in rats treated with <b>23</b>. The bone protective effects of 23 were corroborated when imaged by microradiography (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). When compared to disease-free controls (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A), the ankle bones of vehicle-treated rats appeared pitted and deformed (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>B). Consistent with the observed histological effects, joints of rats dosed from day 8 to day 19 with 20 mg/kg <b>23</b> appeared normal (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>C) with the exception of one rat that exhibited minimal signs of pitting. On the basis of a four-point severity scale, the mean (SD) bone deformation score in vehicle-treated rats was 2.83 ± 0.41 vs 0.17 ± 0.41 for rats dosed with <b>23</b>.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>23</b> prevented the chronic phase of SCW arthritis and the recruitment of macrophages and osteoclasts and bone erosion. Arthritis was induced in rats following a single ip injection of SCW as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Following partial resolution of the acute phase, twice daily oral dosing was commenced on day 8 with vehicle or with 20 mg/kg compound <b>23</b>. Ankle thickness was determined using calipers (A), and clinical scores were assigned as described in the <a class="ref internalNav" href="#sec5" aria-label="Experiment Section">Experiment Section</a> (B). Immunohistochemistry was used to assess formalin-fixed sections of hind-limb ankles for ED-1 antigen positive cells. Representative low power (20×) fields of rats treated with vehicle (C) or with 20 mg/kg compound <b>23</b> (D) are provided. The arrow head indicates periarticular tissue with intense infiltration of macrophages. Arrows indicated erosions in trabecular bone associated with large numbers of osteoclasts. All values represent group means (<i>n</i> = 6). Error bars represent standard errors of the means. *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>23</b> prevented the development of bone deformation. Following necropsy on day 19, microradiographic images were prepared of tibial tarsal joints. Representative images are shown obtained from a disease-free rat (A), a rat with adjuvant arthritis treated with vehicle (B), and a rat with adjuvant arthritis treated with 20 mg/kg <b>23</b> (C). Bones in vehicle-treated rats with adjuvant arthritis appeared pitted and lacked fine definition, while bones from rats treated with <b>23</b> appeared normal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a second study, dosing was commenced on day 18 when chronic arthritis was well-established (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Treatment with <b>23</b> induced a dose-dependent decrease in arthritis scores with significant effects observed by day 21 for the 6 and 20 mg/kg dose groups and for all dose groups by day 26. Both ankle swelling and arthritic scores continued to decrease in the 6 and 20 mg/kg dose groups 1 day prior to study termination (day 39). On day 39, the ankle thickness measurements for the SCW vehicle group rats were 13.78 ± 0.57 mm, and the ankle thickness measurements of 2 mg/kg <b>23</b> group rats were 11.56 ± 1.54; the ankle thickness measurements of 6 mg/kg <b>23</b> group rats were 9.91 ± 0.41 mm; the ankle thickness measurements of 20 mg/kg <b>23</b> group rats were 9.30 ± 0.39 and 7.58 ± 0.03 mm for naïve disease-free rats.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0015.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SCW model of arthritis. Dosing commenced after the establishment of chronic arthritis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Collectively, <b>23</b> was shown to prevent osteoclastogenesis and to reduce synovial and periarticular macrophages in three models of RA together with reductions in histopathology scores or joint swelling and erosion. These data sugget the potential for substantial disease modification with <b>23</b> in RA as a single agent. Furthermore, because the antirheumatic effects of low-dose methotrexate (MTX) are currently ascribed to the capacity of the drug to suppress the development of a fully activated T-cell phenotype, <b>23</b> and MTX might be expected to have complementary effects in suppressing autoimmune disease, macrophage-derived inflammation, and bone erosion. Because of the overall promising preclinical profile of <b>23</b> and the potential to provide benefit to RA patients, <b>23</b> was selected as a candidate for clinical studies in humans pending the results of safety testing.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Two previous lead FMS inhibitors, <b>8</b> and <b>21</b>, which possessed excellent in vitro potency against FMS and cells, were found to have poor PK characteristics resulting in less than ideal in vivo PD activity. A sequence of analogues of the piperidine group was prepared to optimize both the ADME and the PK/PD properties of this series, resulting in three potent and efficacious compounds, <b>15</b>, <b>20</b>, and <b>23</b>, with relatively good selectivity against a number of kinases. In vivo PD dose–response behavior, CIA efficacy, and toxicity observations were used to ultimately select <b>23</b> as the most promising clinical candidate. Compound <b>23</b> was shown to effectively reduce inflammation and bone erosion in mouse CIA as well as in rat adjuvant and SCW models of arthritis, indicating that this agent may be beneficial in the treatment of RA.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div class="NLM_p last">Reagents and solvents were obtained from commercial suppliers and used without further purification. <sup>1</sup>H NMR spectra were measured in the indicated solvent with tetramethylsilane (TMS) or the residual solvent peak as the internal standard on a Bruker B-ACS-120 (400 MHz) spectrophotometer at room temperature. Chemical shifts are given in ppm (δ) relative to the internal standard, and coupling constants (<i>J</i>) are in Hertz (Hz). Abbreviations for the multiplicities of the signals are as follows: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sep (septet), m (multiplet), br s (broad singlet), and combinations thereof. All reactions were monitored by thin-layer chromatography (TLC) carried out on EMD silica gel plates (2.5 cm × 7.5 cm, 250 μm thick, 60 F<sub>254</sub>), visualized by using UV (254 nm) or stains such as KMnO<sub>4</sub>, <i>p</i>-anisaldehyde, and ceric ammonium molybdate (CAM). All organic solutions were dried over anhydrous MgSO<sub>4</sub> or Na<sub>2</sub>SO<sub>4</sub> and concentrated on a rotary evaporator. Hydrogenation was performed at atmospheric pressures under a balloon of hydrogen and at higher pressures on a shaker type hydrogenation apparatus (Parr Instrument Co.). Flash chromatography was performed using Fisher Chemical Silica Gel Sorbent (230–400 mesh, grade 60) or on prepacked silica solid-phase extraction (SPE) columns (Biotage IST Isolute or Waters Sep-Pak columns). Preparative TLC was performed on Analtech Silica Gel GF plates (1000 or 2000 μm, 20 cm × 20 cm). Preparative high-performance liquid chromatography (HPLC) was carried out on a Varian Prep Star system equipped with a Varian model 325 UV detector (monitoring at 254 nm) and a Varian Pro Star fraction collector and using a ThermoElectron Betasil C<sub>18</sub> (150 mm × 21.2 mm, 10 μm particle size,) reverse phase column. The solvents, both acetonitrile (MeCN) and water, contained 0.05% of trifluoroacetic acid (TFA, v/v). LC-MS was performed on a system consisting of an electrospray ionization (ESI) source on a Finnigan LCQ Classics ion trap mass spectrometer, an Agilent 1100 DAD UV detector (214 nm wavelength), an Agilent 1100-LC binary gradient pumping system, a Gilson 215 configured as an autosampler, and a PrincetonSPHER HTS 60A (Princeton Chromatography Inc.) C<sub>12</sub> HPLC column (5 μm, 50 mm × 3.0 mm). The purities of the key target compounds were determined on the Finnigan LCQ instrument, which gave both the MS and LC trace of the compound in a 5 min run. The HPLC method used was as follows: column, PrincetonSPHER HTS 60A C<sub>12</sub> HPLC column (5 μm, 50 mm × 3.0 mm); column temperature, ambient; flow rate, 1.5 mL/min; and gradient, 10% acetonitrile in water to 100% acetonitrile in water in 5 min, both MeCN and water contained 0.05% of TFA, v/v. All compounds used for biological assays were at least of 95% purity based on HPLC analytical results, unless otherwise noted.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide Trifluoroacetic Acid Salt (<b>8</b>)</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-(4-Amino-phenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylic Acid <i>tert</i>-Butyl Ester</h4><div class="NLM_p last">A solution of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine <b>1</b> (4.0 g, 18 mmol), 4-trifluoromethanesulfonyloxy-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylic acid <i>tert</i>-butyl ester<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(64)</a><b>2</b> (7.4 g, 22 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (80 mL) in toluene (160 mL) and EtOH (80 mL) was placed under Ar and heated to 80 °C for 3 h. The mixture was washed with 1 M aqueous NaOH, and the organic layer was removed, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with 20% EtOAc/hexanes to afford 3.2 g (63%) of the title compound as a yellow foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.18–7.23 (m, 2H, <i>J</i> = 8.4 Hz), 6.64–6.69 (m, 2H, <i>J</i> = 8.6 Hz), 5.90 (br s, 1H), 4.02–4.08 (m, 2H), 3.68 (s, 2H), 3.62 (t, 2H, <i>J</i> = 5.6 Hz), 2.48 (br s, 2H), 1.49 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>16</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>, 275.2 (M + H); found, 275.1.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-(4-Amino-phenyl)-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>3</b>)</h4><div class="NLM_p last">A solution of 4-(4-amino-phenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylic acid <i>tert</i>-butyl ester (0.350 g, 1.28 mmol) (as prepared in the previous step) in methanol was hydrogenated over 10% Pd/C at 20 psi for 1 h. The solution was filtered through diatomaceous earth, and the filtrate was concentrated to give 0.35 g (100%) of the title compound <b>3</b> as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 6.96–7.01 (d, 2H, <i>J</i> = 8.4 Hz), 6.62–6.67 (d, 2H, <i>J</i> = 8.4 Hz), 4.21 (br s, 2H), 3.58 (br s, 2H), 2.77 (t, 2H, <i>J</i> = 12.6 Hz), 2.53 (tt, 1H, <i>J</i> = 12.1, 3.5 Hz), 1.77 (d, 2H, <i>J</i> = 12.3 Hz), 1.52–1.59 (m, 2H), 1.48 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, 277.2 (M + H); found, 277.1.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-(4-Amino-3-bromo-phenyl)-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>4</b>)</h4><div class="NLM_p last">To a solution of 4-(4-amino-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester (0.20 g, 0.71 mmol) (as prepared in the previous step) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added <i>N</i>-bromosuccinimide (NBS) (0.13 g, 0.71 mmol), and the reaction was stirred at room temperature for 10 h. The reaction was diluted with EtOAc (10 mL) and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 10 mL) and brine (10 mL). Concentration of the organic layer gave 0.26 g (100%) of the title compound <b>4</b> as a yellow foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.27 (d, 1H, <i>J</i> = 2.1 Hz), 6.96 (dd, 1H, <i>J</i> = 8.1, 1.9 Hz), 6.73 (d, 1H, <i>J</i> = 8.1 Hz), 4.24 (br s, 2H), 4.01 (br s, 2H), 2.78 (t, 2H, <i>J</i> = 12.2 Hz), 2.53 (tt, 1H, <i>J</i> = 12.2, 3.3 Hz), 1.79 (d, 2H, <i>J</i> = 12.6 Hz), 1.52–1.59 (m, 2H), 1.50 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>16</sub>H<sub>23</sub>BrN<sub>2</sub>O<sub>2</sub>, 355.1 (M + H); found, 355.1.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-(4-Amino-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5</b>)</h4><div class="NLM_p last">4-(4-Amino-3-bromo-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester (0.13 g, 0.36 mmol) (as prepared in the previous step), cyclohex-1-enyl boronic acid <b>4</b> (0.060 g, 0.48 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.04 g, 10 mol %), aqueous 2 M Na<sub>2</sub>CO<sub>3</sub> (1.5 mL), ethanol (1.5 mL), and toluene (3 mL) were heated at 80 °C for 3 h. The reaction was diluted with EtOAc (10 mL) and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 10 mL) and brine (10 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated. The residue was purified on a 20 g SPE cartridge (silica) with 30% EtOAc/hexane to give 0.10 g (85%) of the title compound <b>5</b> as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 6.90 (dd, 1H, <i>J</i> = 8.1, 2.1 Hz), 6.85 (d, 1H, <i>J</i> = 1.9 Hz), 6.67 (d, 1H, <i>J</i> = 8.1 Hz), 5.76 (dq, 1H, <i>J</i> = 3.5, 1.8 Hz), 4.23 (br s, 2H), 3.71 (s, 2H), 2.79 (t, 2H, <i>J</i> = 12.7 Hz), 2.54 (tt, 1H, <i>J</i> = 12.3, 3.4 Hz), 2.22–2.29 (m, 2H), 2.16–2.22 (m, 2H), 1.62–1.85 (m, 8H), 1.50 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>, 357.2 (M + H); found, 357.1.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (4-{[4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbo-nyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>7</b>)</h4><div class="NLM_p last">To a solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylate potassium salt<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><b>6</b> (3.34 g, 10.9 mmol) in 20 mL of CH<sub>2</sub>Cl<sub>2</sub> were added DIEA (3.80 mL, 21.8 mmol) and PyBroP (5.59 g, 12.0 mmol), and the reaction was stirred at 25 °C for 15 min. A solution of 4-(4-amino-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester (3.92 g, 11.0 mmol) (as prepared in the previous step) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added, and the reaction was stirred for 8 h at 25 °C. The reaction was diluted with EtOAc (60 mL) and washed with saturated aqueous NaHCO<sub>3</sub> (2 × 60 mL) and brine (100 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated. The residue was purified by flash chromatography (silica gel, 2% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to give 5.5 g (85%) of the title compound <b>7</b> as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.68 (s, 1H), 8.25 (d, 1H, <i>J</i> = 8.4 Hz), 7.78 (s, 1H), 7.12 (dd, 1H, <i>J</i> = 8.6, 2.1 Hz), 7.02 (d, 1H, <i>J</i> = 2.1 Hz), 5.96 (s, 2H), 5.83 (dt, 1H, <i>J</i> = 3.6, 1.9 Hz), 4.25 (br s, 2H), 3.63–3.69 (m, 2H), 2.80 (t, 2H, <i>J</i> = 11.7 Hz), 2.63 (tt, 1H, <i>J</i> = 12.2, 3.5 Hz), 2.27–2.33 (m, 2H), 2.20–2.27 (m, 2H), 1.77–1.87 (m, 6H), 1.56–1.68 (m, 2H), 1.49 (s, 9H), 0.95–1.00 (m, 2H), 0.01 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>33</sub>H<sub>47</sub>N<sub>5</sub>O<sub>4</sub>Si, 606.2 (M + H); found, 606.2.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide Trifluoroacetic Acid Salt (<b>8</b>)</h4><div class="NLM_p last">To a solution of 4-(4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>7</b> (1.50 g, 2.48 mmol) (as prepared in the previous step) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> and 0.3 mL of EtOH was added 3 mL of TFA, and the solution was stirred for 3 h at 25 °C. The reaction was diluted with 5 mL of EtOH and then concentrated. The residue was crystallized from methanol and ethyl ether to give 0.85 g (70%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.18 (d, 1H, <i>J</i> = 8.4 Hz), 8.04 (s, 1H), 7.22 (dd, 1H, <i>J</i> = 8.6, 2.1 Hz), 7.12 (d, 1H, <i>J</i> = 2.3 Hz), 5.76 (m, 1H), 3.54 (m, 2H), 3.16 (m, 2H), 2.92 (m, 1H), 2.30 (m, 4H), 2.10 (m, 2H), 1.87 (m, 6H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>N<sub>5</sub>O, 376.2 (M + H); found, 376.2.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid [2-Cyclohex-1-enyl-4-(3,4,5,6-tetrahydro-2<i>H</i>-[1,2′]bipyridinyl-4-yl)-phenyl]-amide Trifluoroacetic Acid Salt (<b>9</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (75.0 mg, 0.153 mmol), K<sub>2</sub>CO<sub>3</sub> (84.7 mg, 0.613 mmol), 2-fluoropyridine (26.4 μL, 0.306 mmol), and 0.3 mL of <i>N</i>,<i>N-</i>dimethylacetamide were stirred for 8 h at 120 °C. The reaction was diluted with 3 mL of H<sub>2</sub>O, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 9 min to give 50 mg (75%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.18 (d, 1H, <i>J</i> = 8.4 Hz), 8.06 (m, 1H), 8.02 (s, 1H), 7.94 (dd, 1H, <i>J</i> = 6.3, 1.6 Hz), 7.48 (d, 1H, 9.5 Hz), 7.22 (dd, 1H, <i>J</i> = 8.5, 2.2 Hz), 7.12 (d, 1H, <i>J</i> = 2.1 Hz), 6.98 (t, 1H, <i>J</i> = 7.1 Hz), 5.82 (m, 1H), 4.32 (m, 2H), 3.46 (m, 2H), 3.00 (m, 1H), 2.30 (m, 4H), 2.18 (m, 2H), 1.96–1.74 (m, 6H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>28</sub>N<sub>6</sub>O, 453.2 (M + H); found, 453.2.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {4-[1-(2-Cyano-ethyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide Trifluoroacetic Acid Salt (<b>10</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (77.0 mg, 0.157 mmol), Et<sub>3</sub>N (21.9 μL, 0.157 mmol), acrylonitrile (12.4 μL, 0.188 mmol), 0.1 mL of MeOH, and 1.0 mL of 1,2-dichloroethane were stirred for 1 h at 80 °C. The reaction was concentrated, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 12 min to give 83 mg (95%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.18 (d, 1H, <i>J</i> = 8.6 Hz), 8.06 (m, 1H), 7.22 (dd, 1H, <i>J</i> = 8.4, 1.9 Hz), 7.12 (d, 1H, <i>J</i> = 1.9 Hz), 5.82 (m, 1H), 3.76 (m, 2H), 3.60 (m, 2H), 3.28 (t, 2H, <i>J</i> = 12.6 Hz), 3.12 (t, 2H, <i>J</i> = 7.2), 2.92 (m, 1H), 2.30 (m, 4H), 2.18–1.98 (m, 4H), 1.92–1.74 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>28</sub>N<sub>6</sub>O, 429.2 (M + H); found, 429.2.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid [2-Cyclohex-1-enyl-4-(1-pyridin-2-ylmethyl-piperidin-4-yl)-phenyl]-amide Trifluoroacetic Acid Salt (<b>11</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (88.0 mg, 0.180 mmol), pyridine-2-carbaldehyde (20.5 μL, 0.216 mmol), Et<sub>3</sub>N (30.1 μL, 0.216 mmol), sodium triacetoxyborohydride (53.4 mg, 0.252 mmol), and 0.8 mL of 1,2-dichloroethane were stirred for 10 h at 25 °C. The solvent was evaporated, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 20 min to give 81 mg (78%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.62 (s, 1H), 8.62 (ddd, 1H, <i>J</i> = 4.9, 1.7, 0.8 Hz), 8.25 (d, 1H, <i>J</i> = 8.4 Hz), 7.72–7.77 (m, 2H), 7.57 (d, 1H, <i>J</i> = 7.7 Hz), 7.26–7.31 (m, 1H), 7.17 (dd, 1H, <i>J</i> = 8.5, 2.0 Hz), 7.05 (d, 1H, <i>J</i> = 1.9 Hz), 5.84 (dt, 1H, <i>J</i> = 3.5, 1.8 Hz), 3.99 (s, 2H), 3.51 (s, 1H), 3.28 (d, 2H, <i>J</i> = 11.6 Hz), 2.59 (tt, 1H, <i>J</i> = 11.8, 4.0 Hz), 2.44–2.54 (m, 2H), 2.27–2.34 (m, 2H), 2.21–2.27 (m, 2H), 1.75–2.05 (m, 8H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>30</sub>N<sub>6</sub>O, 467.2 (M + H); found, 467.2.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-hydroxy-ethyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>12</b>)</h3><div class="NLM_p last">The title compound was prepared in 85% yield from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> and hydroxyacetaldehyde according to the procedure in the preparation of <b>11</b>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.18 (d, 1H, <i>J</i> = 8.6 Hz), 8.02 (s, 1H), 7.22 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.14 (d, 2H, <i>J</i> = 2.1 Hz), 5.82 (m, 1H), 3.94 (m, 2H), 3.74 (m, 2H), 3.30 (m, 2H), 3.18 (t, 2H), 2.92 (m, 1H), 2.30 (m, 4H), 2.20–1.98 (m, 4H), 1.96–1.74 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>, 420.2 (M + H); found, 420.2.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-hydroxy-1-hydroxymethyl-ethyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>14</b>)</h3><div class="NLM_p">To a slurry of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (81 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added Et<sub>3</sub>N (33 μL, 0.24 mmol). The solution was then treated with 2,2-dimethyl-[1,3]dioxan-5-one (31 mg, 0.24 mmol), and the reaction was allowed to stir for 3 h. At this time, NaBH(OAc)<sub>3</sub> (51 mg, 0.24 mmol) was added in one portion, and the reaction was allowed to stir for an additional 4 h. The reaction was diluted with H<sub>2</sub>O (10 mL) and extracted with EtOAc (2 × 25 mL). The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. Purification by silica gel preparative TLC (10% MeOH–CHCl<sub>3</sub>) afforded 22 mg (28%) of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2,2-dimethyl-[1,3]dioxan-5-yl)-piperidin-4-yl]-phenyl}-amide (<b>13</b>) as an off-white semisolid. Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>35</sub>N<sub>5</sub>O<sub>3</sub>, 490.2 (M + H); found, 490.6.</div><div class="NLM_p last">To a solution of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2,2-dimethyl-[1,3]dioxan-5-yl)-piperidin-4-yl]-phenyl}-amide <b>13</b> (22 mg, 0.045 mmol, as prepared above) in THF–H<sub>2</sub>O (1 mL, 4:1 v/v) was added TFA (0.4 mL), and the reaction was allowed to stir for 1 h. Removal of the solvent under vacuum afforded 14 mg (60%) of the title compound as an amber foam. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.17 (d, 1H, <i>J</i> = 8.4 Hz), 8.03 (s, 1H), 7.22 (dd, 1H, <i>J</i> = 8.4, 2.0 Hz), 7.13 (d, 1H, <i>J</i> = 2.0 Hz), 5.83 (s, 1H), 3.98 (d, 4H, <i>J</i> = 4.9 H), 3.74–3.78 (m, 2H), 3.46–3.53 (m, 2H), 3.37–3.40 (m, 1H), 2.88–2.96 (m, 1H), 2.29 (br s, 4H), 2.03–2.16 (m, 4H), 1.78–1.90 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>31</sub>N<sub>5</sub>O<sub>3</sub>, 450.2 (M + H); found, 450.2.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-methanesulfonyl-ethyl)-piperidin-4-yl]-phenyl}-amide (<b>15</b>)</h3><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Methanesulfonic Acid 2-Methanesulfonyl-ethyl Ester</h4><div class="NLM_p last">To a solution of methanesulfonyl chloride (484 mg, 4.23 mmol) in 15 mL of CH<sub>2</sub>Cl<sub>2</sub> at 0 °C was added 2-methanesulfonyl-ethanol (500 mg, 4.03 mmol) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> followed by DIEA (1.05 mL, 6.05 mmol) under Ar. The mixture was warmed to room temperature and stirred for 20 h under Ar. The mixture was treated with 100 mL of EtOAc and washed with H<sub>2</sub>O (3 × 20 mL) and brine (20 mL) and was dried (Na<sub>2</sub>SO<sub>4</sub>). Removal of the solvent in vacuo gave 534 mg (66%) of the title compound as a brown oil, which was used directly in the following step without purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 4.67 (d, 2H, <i>J</i> = 5.5 Hz), 3.46 (d, 2H, <i>J</i> = 5.5 Hz), 3.11 (s, 3H), 3.04 (s, 3H).</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-methanesulfonyl-ethyl)-piperidin-4-yl]-phenyl}-amide (<b>15</b>)</h4><div class="NLM_p last">To a solution of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (85 mg, 0.17 mmol) and DIEA (91 μL, 0.52 mmol) in 3 mL of CH<sub>2</sub>Cl<sub>2</sub> at room temperature was added 2-methanesulfonic acid 2-methanesulfonyl-ethyl ester (as prepared in the previous step, 42 mg, 0.21 mmol). The resulting mixture was stirred at room temperature for 3 h. Treated with 50 mL of EtOAc, the mixture was washed with H<sub>2</sub>O (2 × 20 mL) and brine (10 mL) and was dried (Na<sub>2</sub>SO<sub>4</sub>). Removal of the solvent in vacuo followed by flash chromatography of the residue on silica gel (1–3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave 54 mg (65%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.54 (s, 1H), 8.25 (d, 1H, <i>J</i> = 8.4 Hz), 7.72 (s, 1H), 7.15 (dd, 1H, <i>J</i> = 8.4, 2.0 Hz), 7.04 (d, 1H, <i>J</i> = 2.0 Hz), 5.85 (m, 1H), 3.21 (t, 2H, <i>J</i> = 6.5 Hz), 3.09 (s, 3H), 3.02–3.11 (m, 2H), 2.92 (t, 2H, <i>J</i> = 6.5 Hz), 2.52 (dddd, 1H, <i>J</i> = 12.1, 12.1, 3.3, 3.3 Hz), 2.18–2.34 (m, 4H), 2.18 (t, 2H, <i>J</i> = 10.8 Hz), 1.64–1.94 (m, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>31</sub>N<sub>5</sub>O<sub>3</sub>S, 482.2 (M + H); found, 482.2.</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid [4-(1-Carbamoylmethyl-piperidin-4-yl)-2-cyclohex-1-enyl-phenyl]-amide Trifluoroacetic Acid Salt (<b>16</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (50.0 mg, 0.102 mmol), Et<sub>3</sub>N (32.7 μL, 0.235 mmol), 2-bromoacetamide (16.9 mg, 0.123 mmol), and 0.5 mL of CH<sub>2</sub>Cl<sub>2</sub> were stirred for 4 h at 25 °C. The reaction was concentrated, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 12 min to give 42 mg (75%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.14 (d, 1 H, <i>J</i> = 8.6 Hz), 8.00 (s, 1H), 7.19 (d, 1H, <i>J</i> = 8.4 Hz), 7.11 (s, 1H), 5.75–5.83 (m, 1H), 3.99 (s, 2H), 3.73 (d, 2H, <i>J</i> = 11.4 Hz), 3.14–3.29 (m, 2H), 2.78–2.97 (m, 1H), 2.19–2.32 (m, 4H), 2.01–2.16 (m, 4H), 1.71–1.90 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>, 433.2 (M + H); found, 433.2.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-acetic Acid Trifluoroacetic Acid Salt (<b>18</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (33 mg, 0.067 mmol), <i>t</i>-butyl bromoacetate (9.90 μL, 0.0675 mmol), Et<sub>3</sub>N (18.8 μL, 0.135 mmol), and 0.25 mL of CH<sub>2</sub>Cl<sub>2</sub> were stirred for 10 h at 25 °C. The reaction mixture was loaded on a 5 g SPE cartridge (silica), and 23 mg (70%) of (4-{4-[(4-cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-acetic acid <i>tert</i>-butyl ester <b>17</b> was eluted with 25% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>. This compound was dissolved in 1 mL of CH<sub>2</sub>Cl<sub>2</sub>, 20 μL of EtOH and 1 mL of TFA were added, and the reaction was stirred for 3 h at 25 °C. The residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 12 min to give 10 mg (40%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.16 (d, 1H, <i>J</i> = 8.4 Hz), 8.02 (s, 1H), 7.22 (dd, 1H, <i>J</i> = 8.5, 2.0 Hz), 7.10 (d, 1H, <i>J</i> = 1.9 Hz), 5.72 (m, 1H), 4.04. (s, 2H), 3.76 (m, 2H), 3.22 (m, 2H), 2.90 (m, 1H), 2.29 (m, 4H), 2.10 (m, 4H), 1.82 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>, 434.2 (M + H); found, 434.2.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide Trifluoroacetic Acid Salt (<b>19</b>)</h3><div class="NLM_p last">To a solution of 4-(4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>7</b> (81 mg, 0.12 mmol) in 18 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 1 mL of EtOH followed by 5 mL of TFA at 0 °C. The resulting solution was stirred at room temperature for only 0.5 h and treated with 20 mL of EtOH followed by 20 mL of <i>n</i>-PrOH and 5 mL of H<sub>2</sub>O. The mixture was then concentrated under reduced pressure to give a slightly yellow solid. Flash chromatography of the compound on silica gel (2–4% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave 0.87 g (85%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.70 (s, 1H), 9.66 (br s, 1H), 9.15 (m, 1H), 8.29 (d, 1H, <i>J</i> = 8.3 Hz), 7.78 (s, 1H), 7.13 (dd, 1H, <i>J</i> = 8.3, 2.2 Hz), 7.03 (d, 1H, <i>J</i> = 2.2 Hz), 5.95 (s, 2H), 5.83 (m, 1H), 3.66 (t, 2H, <i>J</i> = 8.4 Hz), 3.55 (d, 2H, <i>J</i> = 12.3 Hz), 2.95–3.11 (m, 2H), 2.76 (m, 1H), 2.18–2.33 (m, 4H), 1.99–2.15 (m, 4H), 1.82 (m, 4H), 0.97 (t, 2H, <i>J</i> = 8.3 Hz), 0.00 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>39</sub>N<sub>5</sub>O<sub>2</sub>Si, 506.3 (M + H); found, 506.1.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide Bis-trifluoroacetic Acid Salt (<b>20</b>)</h3><div id="sec5_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide</h4><div class="NLM_p last">4-Cyano-1-(2-trimethyl-silanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>19</b> (830 mg, 1.34 mmol), K<sub>2</sub>CO<sub>3</sub> (600 mg, 4.34 mmol), sodium iodide (40.2 mg, 0.268 mmol), 4-(2-chloro-ethyl)-morpholine hydrochloride (260 mg, 1.40 mmol), and 5.0 mL of <i>N</i>,<i>N</i>-dimethylacetamide were stirred for 8 h at 80 °C. The reaction was diluted with EtOAc (50 mL), washed with saturated aqueous NaHCO<sub>3</sub> (2 × 50 mL) and brine (50 mL), and concentrated. The residue was purified by flash chromatography (silica gel, 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give 650 mg (78%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.67 (s, 1H), 8.23 (d, 1H, <i>J</i> = 8.6 Hz), 7.78 (s, 1H), 7.14 (dd, 1H, <i>J</i> = 8.5, 2.0 Hz), 7.04 (d, 1H, <i>J</i> = 1.9 Hz), 5.95 (s, 2H), 5.78–5.85 (m, 1H), 3.70–3.74 (m, 4H), 3.62–3.68 (m, 2H), 2.58–2.67 (m, 4H), 2.46–2.57 (m, 4H), 2.24–2.40 (m, 4H), 2.10–2.20 (m, 4H), 1.73–1.92 (m, 7H), 1.60–1.68 (m, 2H), 0.92–1.00 (m, 2H), 0.00 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>34</sub>H<sub>50</sub>N<sub>6</sub>O<sub>3</sub> Si, 619.4 (M + H); found, 619.3.</div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>20</b>)</h4><div class="NLM_p last">To a solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide <b>19</b> (650 mg, 1.05 mmol) (as prepared in the previous step) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> were added 0.3 mL of EtOH and 3.0 mL of TFA, and the reaction was allowed to proceed for 2 h at 25 °C. The reaction was diluted with 10 mL of EtOH and concentrated. The residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 9 min to give 600 mg (80%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.18 (d, 1H, <i>J</i> = 8.4 Hz), 8.04 (s, 1H), 7.24 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.14 (d, 1H, <i>J</i> = 2.1 Hz), 5.84 (m, 1H), 3.84 (m, 4H), 3.76 (m, 2H), 3.50 (m, 2H), 3.30–3.10 (m, 4H), 2.92 (m, 5H), 2.30 (m, 4H), 2.20–2.00 (m, 4H), 1.90–1.74 (m, 4H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub>, 489.2; found, 489.2.</div></div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid [4-(1-Acetyl-piperidin-4-yl)-2-cyclohex-1-enyl-phenyl]-amide (<b>21</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (22.3 mg, 0.0456 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was treated with Et<sub>3</sub>N (22.2 μL, 0.159 mmol) and acetic anhydride (6.03 μL, 0.0638 mmol) at room temperature for 30 min using a procedure similar to that used in the preparation of <b>23</b>. Purification of the mixture on a 10 g silica gel SPE cartridge with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> afforded the title compound (20 mg, 95%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 13.12 (br s, 1H), 9.58 (s, 1H), 8.34 (d, 1H, <i>J</i> = 8.4 Hz), 7.76 (s, 1H), 7.21 (dd, 1H, <i>J</i> = 8.6, 2.1 Hz), 7.05 (d, 1H, <i>J</i> = 2.1 Hz), 5.86 (s, 1H), 4.84 (m, 1H), 4.00 (m, 1H), 3.22 (m, 1H), 2.72 (m, 2H), 2.30 (m, 4H), 2.21 (s, 3H), 1.80 (m, 8H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>, 418.2 (M + H); found, 418.1.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(pyridine-3-carbonyl)-piperidin-4-yl]-phenyl}-amide (<b>22</b>)</h3><div class="NLM_p last">A solution of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (75.0 mg, 0.152 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was treated with Et<sub>3</sub>N (64.1 μL, 0.460 mmol) and cooled to 0 °C. The mixture was treated with nicotinoyl chloride hydrochloride (30.0 mg, 0.169 mmol) and stirred at 0 °C for 15 min and then at room temperature for 17 h. The reaction mixture was adsorbed directly onto silica gel. Silica gel chromatography (10% MeOH in EtOAc) afforded the title compound (61.0 mg, 83%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.51 (br s, 1H), 8.77 (s, 1H), 8.70–8.66 (m, 1H), 8.32 (d, 1H, <i>J</i> = 8.4 Hz), 7.86–7.81 (m, 1H), 7.70 (s, 1H), 7.42–7.37 (m, 1H), 7.17 (d, 1H, <i>J</i> = 8.4 Hz), 7.06–7.04 (m, 1H), 5.87–5.82 (m, 1H), 4.98–4.87 (m, 1H), 3.94–3.84 (m, 1H), 3.29–3.18 (m, 1H), 2.98–2.86 (m, 1H), 2.86–2.76 (m, 1H), 2.34–2.20 (m, 4H), 1.94–1.72 (m, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>, 481.2 (M + H); found, 481.3.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide (<b>23</b>)</h3><div class="NLM_p last">A suspension of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (655 mg, 1.34 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was cooled to 0 °C, and DIEA (0.932 mL, 5.35 mmol) was added. Dimethylaminoacetyl chloride hydrochloride (211 mg, 1.34 mmol) was then added portion wise over 10 min. The reaction mixture was stirred at 0 °C for 30 min and allowed to warm to room temperature and stir for 2 h. The solvent was removed in vacuo, and the resulting residue was partitioned between brine and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue obtained was purified on silica (5% MeOH:CH<sub>2</sub>Cl<sub>2</sub>) to obtain 432 mg (70%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.49 (s, 1H), 8.24 (d, 1H, <i>J</i> = 8.3 Hz), 7.70 (s, 1H), 7.12 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.01 (d, 1H, <i>J</i> = 2.1 Hz), 5.82 (m, 1H), 4.75 (d, 1H, <i>J</i> = 13.4 Hz), 4.13 (d, 1H, <i>J</i> = 13.4 Hz), 3.57 (d, 1H, <i>J</i> = 14.2 Hz), 3.18 (d, 1H, <i>J</i> = 14.2 Hz), 3.12 (td, 1H, <i>J</i> = 13.3, 2.4 Hz), 2.73 (dddd, 1H, <i>J</i> = 11.9, 11.9, 3.8, 3.8 Hz), 2.65 (ddd, 1H, <i>J</i> = 13.3, 13.3, 2.4 Hz), 2.40 (s, 6H), 2.18–2.32 (m, 4H), 1.60–1.98 (m, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 461.3 (M + H); found, 461.2.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 5-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(<i>R</i>)-(+)-(2,3-dihydroxy-propionyl)-piperidin-4-yl]-phenyl}-amide (<b>25</b>)</h3><div id="sec5_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(<i>R</i>)-(+)-(2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-piperidin-4-yl]-phenyl}-amide (<b>24</b>)</h4><div class="NLM_p">To a solution of methyl (<i>R</i>)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (0.16 mL, 1.0 mmol) in MeOH (2 mL), 2 N KOH (0.50 mL, 1.0 mmol) was added. The resulting solution was stirred at room temperature for 20 min and concentrated in vacuo. The residue obtained was suspended in ether (10 mL) and sonicated for 5 min. The ether was then removed, and the resulting residue was placed under high vacuum for 4 h to obtain (<i>R</i>)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid potassium salt (173 mg, 94%), which was directly used in the next step without purification.</div><div class="NLM_p last">To a solution of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (40 mg, 0.082 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added a mixture of (<i>R</i>)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid potassium salt (as prepared above, 18 mg, 0.090 mmol), EDCI (19 mg, 0.090 mmol), HOBt (13 mg, 0.090 mmol), and DIEA (42 μL, 0.24 mmol). The resulting mixture was stirred at room temperature for 6 h. Water (10 mL) was added, and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue obtained was chromatographed on silica (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to obtain the title compound (47 mg, 97%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.57 (d, 1H, <i>J</i> = 7.9 Hz), 8.31 (dd, 1H, <i>J</i> = 8.4, 6.0 Hz), 7.76 (s, 1H), 7.18 (dd, 1H, <i>J</i> = 8.6, 1.9 Hz), 7.05 (s, 1H), 5.84–5.88 (m, 1H), 4.76–4.82 (m, 2H), 4.45 (dt, 1H, <i>J</i> = 8.4, 5.7 Hz), 4.30 (d, 1H, <i>J</i> = 13.3 Hz), 4.06–4.21 (m, 2H), 3.08–3.29 (m, 1H), 2.67–2.85 (m, 2H), 2.31 (br s, 2H), 2.25 (br s, 2H), 1.90–2.02 (m, 2H), 1.73–1.90 (m, 6H), 1.43 (d, 6H, <i>J</i> = 4.4 Hz). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>, 504.2 (M + H); found, 503.9.</div></div><div id="sec5_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(<i>R</i>)-(+)-(2,3-dihydroxy-propionyl)-piperidin-4-yl]-phenyl}-amide(<b>25</b>)</h4><div class="NLM_p last">To a solution of 5-cyano-1<i>H</i>-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(<i>R</i>)-(+)-(2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-piperidin-4-yl]-phenyl}-amide <b>24</b> (as prepared in the previous step, 45 mg, 0.090 mmol) in MeOH (1 mL) was added aqueous 2 N HCl (2 mL). The resulting mixture was stirred at room temperature for 12 h. Solvents were removed in vacuo, and the resulting residue was placed under vacuum for 4 h. Ether (10 mL) was added, and the mixture was sonicated for 5 min. The ether was removed in vacuo, and the residue was placed under vacuum for 12 h to obtain the title compound (21.3 mg, 52%). <sup>1</sup>H NMR (DMSO, 400 MHz): δ 14.1 (br s, 1H), 9.85 (s, 1H), 8.32 (s, 1H), 7.92 (d, 1H, <i>J</i> = 8.4 Hz), 7.18 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.13 (d, 1H, <i>J</i> = 2.1 Hz), 5.72 (br s, 1H), 4.51 (m, 1H), 4.33 (m, 1H), 4.15 (m, 1H), 3.55 (m, 1H), 3.43 (m, 1H), 3.08 (m, 1H), 2.81 (m, 1H), 2.63 (m, 1H), 2.12–2.24 (m, 4H), 1.31–1.38 (m, 10 H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>, 464.2 (M + H); found, 464.1.</div></div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethylamino)-acetyl]-piperidin-4-yl}-phenyl)-amide Trifluoroacetic Acid Salt (<b>28</b>)</h3><div id="sec5_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> [2-(4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-2-oxo-ethyl]-carbamic Acid <i>tert</i>-Butyl Ester (<b>26</b>)</h4><div class="NLM_p last">A solution of <i>N</i>-Boc-glycine (286 mg, 1.63 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was treated with DIEA (854 μL, 4.90 mmol), HOBt (265 mg, 1.96 mmol), and EDCI (376 mg, 1.96 mmol). The mixture was stirred at room temperature for 10 min and added to a suspension of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (800 mg, 1.63 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The solution was stirred at room temperature for 17 h. Solvents were evaporated in vacuo. Silica gel chromatography (50% EtOAc in hexanes) afforded the title compound (0.41 g, 47%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.53 (s, 1H), 8.26 (d, 1H, <i>J</i> = 8.4 Hz), 7.80–7.78 (m, 1H), 7.71 (s, 1H), 7.45–7.43 (m, 1H), 7.06 (d, 1H, <i>J</i> = 8.4 Hz), 7.00 (s, 1H), 5.83 (br s, 1H), 5.76 (br s, 1H), 4.78–4.68 (m, 1H), 3.96–3.85 (m, 2H), 3.17–3.03 (m, 1H), 2.78–2.63 (m, 2H), 2.29 (br s, 2H), 2.22 (br s, 2H), 1.95–1.87 (m, 2H), 1.86–1.72 (m, 4H), 1.70–1.55 (m, 2H), 1.44 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>29</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub> 533.3 (M + H); found, 532.9.</div></div><div id="sec5_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethylamino)-acetyl]-piperidin-4-yl}-phenyl)-amide Trifluoroacetic Acid Salt (<b>28</b>)</h4><div class="NLM_p">A solution of [2-(4-{4-[(4-cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid <i>tert</i>-butyl ester <b>26</b> (as prepared in the previous step, 0.410 g, 0.770 mmol) in CH<sub>2</sub>Cl<sub>2</sub>(20 mL) was treated with EtOH (0.2 mL) and TFA (6 mL). The mixture stirred at room temperature for 45 min, and the solvents were evaporated in vacuo to afford 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid {4-[1-(2-amino-acetyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl]-amide trifluoroacetic acid salt <b>27</b>, which was used directly in the next step. Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>, 433.2 (M + H); found, 433.2.</div><div class="NLM_p last">A suspension of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid {4-[1-(2-amino-acetyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl]-amide trifluoroacetic acid salt <b>27</b> (0.420 g, 0.769 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was treated with Na(OAc)<sub>3</sub>BH (0.326 g, 1.54 mmol) and solid glyoxal (44.6 mg, 0.769 mmol). The mixture was stirred at room temperature for 1 h, and the solvent was evaporated in vacuo. The residue was taken up in MeOH, the solids were filtered off, and the filtrate was concentrated in vacuo. Reverse phase HPLC (C-18 column) (20–60% acetonitrile in water with 0.1% TFA over 30 min) afforded the title compound (83 mg, 19% over two steps) as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.06 - 8.16 (m, 1H), 7.99–8.05 (m, 1H), 7.18 (m, 1H), 7.07 (m, 1H), 5.81 (m, 1H), 4.64 (m, 1H), 3.74–4.24 (m, 4H), 3.18–3.29 (m, 2H), 2.77–2.93 (m, 2H), 2.27 (m, 4H), 1.52–2.00 (m, 10H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>, 477.2 (M + H); found, 477.2.</div></div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethyl)-methyl-amino-acetyl]-piperidin-4-yl}-phenyl)-amide Trifluoroacetic Acid Salt (<b>29</b>)</h3><div class="NLM_p last">A solution of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethylamino)-acetyl]-piperidin-4-yl}-phenyl)-amide trifluoroacetic acid salt <b>28</b> (50 mg, 0.085 mmol) in MeOH (3 mL) was treated with Na(OAc)<sub>3</sub>BH (40 mg, 0.19 mmol) and 37% aqueous formaldehyde (8.2 μL, 0.10 mmol). The mixture was stirred at room temperature for 5.5 h, and the solvents were removed in vacuo. Reverse phase HPLC (C-18 column) (10–50% acetonitrile in water with 0.1% TFA over 30 min) afforded the title compound (19.5 mg, 47%) as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.12 (d, 1H, <i>J</i> = 8.4 Hz), 8.02 (s, 1H), 7.19 (dd, 1H, <i>J</i> = 8.4, 2.0 Hz), 7.09 (d, 1H, <i>J</i> = 2.0 Hz), 5.84–5.79 (m, 1H), 4.72–4.64 (m, 1H), 4.39–4.23 (m, 2H), 3.84–3.79 (m, 1H), 3.31–3.21 (m, 1H), 3.03–2.94 (m, 6H), 2.92–2.80 (m, 2H), 2.32–2.24 (m, 4H), 2.00–1.90 (m, 2H), 1.90–1.76 (m, 5H), 1.78–1.59 (m, 2H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub>, 491.3 (M + H); found, 491.2.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-methanesulfonyl-acetyl)-piperidin-4-yl]-phenyl}-amide (<b>30</b>)</h3><div class="NLM_p last">Methanesulfonyl-acetic acid (14 mg, 0.10 mmol), EDCI (30 mg, 0.15 mmol), HOBt (14 mg, 0.10 mmol), DIEA (36 μL, 0.20 mmol), and 0.5 mL of CH<sub>2</sub>Cl<sub>2</sub> were stirred at 25 °C. After 10 min, a solution containing 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> (40 mg, 0.082 mmol) and Et<sub>3</sub>N (14 μL, 0.10 mmol) in 0.5 mL of CH<sub>2</sub>Cl<sub>2</sub> was added, and the reaction was allowed to proceed for 10 h at 25 °C. The reaction mixture was loaded on a 5 g SPE cartridge (silica) and eluted with 10% EtOH/EtOAc to give 10 mg (25%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 11.60 (br s, 1H), 9.52 (s, 1H), 8.30 (dd, 1H, <i>J</i> = 8.4, 1.6 Hz), 7.74 (d, 1H, <i>J</i> = 2.0 Hz), 7.15 (dd, 1H, <i>J</i> = 8.6, 1.9 Hz), 7.03 (d, 1H, <i>J</i> = 2.0 Hz), 5.86 (m, 1H), 4.84 (m, 1H), 4.18 (s, 2H), 4.12 (m, 1H), 3.32 (m, 1H), 3.20 (s, 3H), 2.82 (m, 2H), 2.30 (m, 4H), 1.98 (m, 2H), 1.84 (m, 5H), 1.72 (m, 1H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>S, 496.2 (M + H); found, 496.2.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid [2-Cyclohex-1-enyl-4-[1-(1-oxy-pyridine-3-carbonyl)-piperidin-4-yl]-phenyl}-amide (<b>31</b>)</h3><div class="NLM_p last">The title compound was prepared in 32% yield from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> and nicotinic acid-N oxide according to the procedure for the preparation of <b>35</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 13.95 (br. s., 1H), 9.44 (s, 1H), 8.52 (s, 1H), 8.32 (d, <i>J</i> = 6.1 Hz, 1H), 8.07 (d, <i>J</i> = 8.1 Hz, 1H), 7.74 (s, 1H), 7.51–7.56 (m, 1H), 7.41–7.50 (m, 1H), 6.95 (s, 1H), 6.86–6.93 (m, 1H), 5.79 (br. s., 1H), 4.80 (br. s., 1H), 3.88 (d, <i>J</i> = 12.6 Hz, 1H), 3.17 (br. s., 1H), 2.86 (br. s., 1H), 2.66 (t, <i>J</i> = 11.6 Hz, 1H), 2.12–2.33 (m, 4H), 2.00 (br. s., 1H), 1.47–1.88 (m, 7H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub>, 497.2 (M + H); found, 497.2.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(1-oxy-pyridine-4-carbonyl)-piperidin-4-yl]-phenyl}-amide (<b>32</b>)</h3><div class="NLM_p last">The title compound was prepared in 42% yield from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> and 1-oxy-isonicotinic acid in 42% yield according to the procedure for the preparation of <b>35</b>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 13.64 (br s, 1H), 11.17 (br s, 1H), 9.50 (s, 1H), 8.53 (d, 2H, <i>J</i> = 7.0 Hz), 8.30 (d, 1H, <i>J</i> = 8.6 Hz), 7.73 (s, 1H), 7.46 (d, 2H, <i>J</i> = 7.0 Hz), 7.28 (m, 1H), 7.09–7.18 (m, 1H), 7.03 (d, 1H, <i>J</i> = 1.9 Hz), 5.80–5.88 (m, 1H), 3.62–3.76 (m, 2H), 3.11 (qd, 2H, <i>J</i> = 7.3, 4.9 Hz), 2.81 (t, 1H, <i>J</i> = 12.8 Hz), 2.29 (br s, 2H), 2.23 (br s, 2H), 1.75–1.89 (m, 6H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub>, 497.2 (M + H); found, 497.2.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-1<i>H</i>-imidazol-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>33</b>)</h3><div class="NLM_p last">The title compound was prepared from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> in 60% yield according to the procedure for the preparation of <b>35</b> using (1<i>H</i>-imidazol-4-yl)-acetic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.88 (s, 1H), 8.12 (d, 1H, <i>J</i> = 1.6 Hz), 8.02 (s, 1H), 7.44 (s, 1H), 7.20 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.10 (d, 1H, <i>J</i> = 2.1 Hz), 5.82 (m, 1H), 4.70 (m, 1H), 4.18 (m, 1H), 4.06 (m, 2H), 3.36 (m, 1H), 2.84 (m, 2H), 2.30 (m, 4H), 2.00–1.70 (m, 7H), 1.64 (m, 1H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>, 484.2 (M + H); found, 484.2.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid (2-Cyclohex-1-enyl-4-{1-[2-(1-methyl-1<i>H</i>-imidazol-4-yl)-acetyl]-piperidin-4-yl}-phenyl)-amide Trifluoroacetic Acid Salt (<b>34</b>)</h3><div class="NLM_p last">The title compound was prepared from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> in 66% yield according to the procedure for the preparation of <b>35</b> using (1-methyl-1<i>H</i>-imidazol-4-yl)-acetic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.82 (s, 1H), 8.10 (d, 1H, <i>J</i> = 8.4 Hz), 8.00 (s, 1H), 7.42 (s, 1H), 7.16 (dd, 1H, <i>J</i> = 8.6, 2.1 Hz), 7.06 (d, 1H, <i>J</i> = 2.1 Hz), 5.80 (m, 1H), 4.66 (m, 1H), 4.12 (m, 1H), 4.04 (m, 2H), 3.92 (s, 3H), 3.28 (m, 1H), 2.82 (m, 2H), 2.26 (m, 4H), 2.00–1.70 (m, 7H), 1.64 (m, 1H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>31</sub>N<sub>7</sub>O<sub>2</sub>, 498.2 (M + H); found, 498.2.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-pyridin-2-yl-acetyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>35</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt (25.0 mg, 0.0511 mmol) <b>8</b>, pyridin-2-yl-acetic acid hydrochloride (9.75 mg, 0.0562 mmol), EDCI (11.7 mg, 0.0613 mmol), HOBt (8.28 mg, 0.0613 mmol), DIEA (26.7 μL, 0.153 mmol), and 0.2 mL of DMF were stirred at 25 °C for 10 h. The reaction was diluted with 2 mL of H<sub>2</sub>O, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 30–50% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 9 min to give 22 mg (70%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.82 (d, 1H, <i>J</i> = 5.6 Hz), 8.52 (td, 1H, <i>J</i> = 7.8, 1.7 Hz), 8.14 (d, 1H, <i>J</i> = 8.4 Hz), 8.04 (s, 1H), 7.96 (m, 2H), 7.20 (dd, 1H, <i>J</i> = 8.4, 2.1 Hz), 7.10 (d, 1H, <i>J</i> = 2.1), 5.82 (m, 1H), 4.68 (m, 1H), 4.32 (m, 2H), 4.18 (m, 1H), 3.40 (m, 1H), 2.88 (m, 2H), 2.30 (m, 4H), 2.06–1.60 (m, 8H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>, 495.2 (M + H); found, 495.2.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-pyridin-3-yl-acetyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>36</b>)</h3><div class="NLM_p last">The title compound was prepared from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> in 68% yield according to the procedure for the preparation of <b>35</b> using pyridin-3-yl-acetic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.80 (s, 1H), 8.77 (d, 1H, <i>J</i> = 5.7 Hz), 8.54 (d, 1H, <i>J</i> = 8.0 Hz), 8.10 (d, 1H, <i>J</i> = 8.4 Hz), 8.06 (dd, 1H, <i>J</i> = 7.8, 6.1 Hz), 7.98 (s, 1H), 7.18 (dd, 1H, <i>J</i> = 8.4, 2.0 Hz), 7.08 (d, 1H, <i>J</i> = 2.0 Hz), 5.78 (m, 1H), 4.68 (m, 1H), 4.20 (m, 1H), 4.18 (s, 2H), 3.36 (m, 1H), 2.84 (m, 2H), 2.28 (m, 4H), 2.06–1.70 (m, 7H), 1.62 (m, 1H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>, 495.2 (M + H); found, 495.2.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-pyridin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide Trifluoroacetic Acid Salt (<b>37</b>)</h3><div class="NLM_p last">The title compound was prepared from 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt <b>8</b> in 58% yield according to the procedure for the preparation of <b>35</b> using pyridin-4-yl-acetic acid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.78 (d, 2H, <i>J</i> = 5.1 Hz), 8.12 (d, 1H, <i>J</i> = 8.4 Hz), 8.03 (s, 1H), 7.99 (d, 2H, <i>J</i> = 6.1 Hz), 7.18 (dd, 1H, <i>J</i> = 8.4, 1.9 Hz), 7.08 (d, 1H, <i>J</i> = 1.9 Hz), 5.80 (m, 1H), 4.66 (m, 1H), 4.22 (s, 2H), 4.18 (m, 1H), 3.34 (m, 1H), 2.84 (m, 2H), 2.24 (m, 4H), 2.00–1.70 (m, 7H), 1.64 (m, 1H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>, 495.2 (M + H); found, 495.2.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(3-morpholin-4-yl-propionyl)-piperidin-4-yl]-phenyl}-amide (<b>38</b>)</h3><div class="NLM_p last">3-Morpholin-4-yl-propionic acid potassium salt (93.8 mg, 0.475 mmol, prepared from 3-morpholin-4-yl-propionic acid ethyl ester and 6 N KOH as described in the preparation of <b>39</b>), 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (179 mg, 0.366 mmol), EDCI (83.7 mg, 0.439 mmol), and HOBT (69.2 mg, 0.512 mmol) were taken up in DMF (4 mL). To the stirred slurry was added DIEA (157 μL, 0.901 mmol), and the reaction was allowed to stir overnight. The reaction was diluted with H<sub>2</sub>O (10 mL) and extracted with EtOAc (2 × 25 mL). The combined organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo, and the crude product was purified by silica gel preparative TLC (6% of 7 M NH<sub>3</sub> in MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 10.4 mg (6%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.51 (s, 1H), 8.26 (d, 1H, <i>J</i> = 8.2 Hz), 7.70 (s, 1H), 7.09–7.13 (m, 1H), 6.99–7.00 (m, 1H), 6.81–6.82 (m, 1H), 5.81–5.82 (m, 1H), 4.76–4.81 (m, 2H), 3.97–4.02 (m, 2H), 3.72 (br s, 4H), 3.10–3.17 (m, 2H), 2.74–2.76 (m, 4H), 2,58–2.63 (m, 3H), 2.52 (br s, 4H), 2.22–2.31 (m, 3H), 1.49–1.93 (m, 5H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>29</sub>H<sub>36</sub>N<sub>6</sub>O<sub>3</sub>, 517.3 (M + H); found, 517.3.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide (<b>39</b>)</h3><div class="NLM_p last">To a solution of morpholin-4-yl-acetic acid ethyl ester (117 mg, 0.675 mmol) in ethanol (4 mL) was added 6 N KOH (110 μL, 0.660 mmol) via syringe, and stirring was continued for 3 h. Concentration in vacuo afforded 122 mg (100%) of morpholin-4-yl-acetic acid potassium salt. To a mixture of morpholin-4-yl-acetic acid potassium salt (29.2 mg, 0.160 mmol), 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid <b>8</b> (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt (65.1 mg, 0.133 mmol), and bromotri(pyrrolidino)phosphonium hexafluorophosphate (PyBroP) (93.0 mg, 0.199 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added DIEA (51.0 μL, 0.293 mmol), and the reaction was allowed to stir overnight. The reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL), washed with H<sub>2</sub>O (2 × 25 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. Purification of the crude product by silica gel preparative TLC (6% of 7 M NH<sub>3</sub> in MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded 8.1 mg (12%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.48 (s, 1H), 8.27 (d, 1H, <i>J</i> = 8.1 Hz), 7.73 (s, 1H), 7.12 (dd, 1H, <i>J</i> = 0.6, 8.0 Hz), 7.00 (s, 1H), 5.82 (s, 1H), 4.73–4.77 (m, 1H), 4.16–4.22 (m, 1H), 3.72 (br s, 4H), 3.35–3.40 (m, 1H), 3.09–3.23 (m, 6H), 2.53–2.78 (m, 5H), 2.20–2.29 (m, 4H), 1.68–2.04 (m, 5H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>34</sub>N<sub>6</sub>O<sub>3</sub>, 503.3 (M + H); found, 503.1.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {4-[1-(3-Amino-3-methyl-butyryl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide Trifluoroacetic Acid Salt (<b>41</b>)</h3><div id="sec5_29_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> [3-(4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-1,1-dimethyl-3-oxo-propyl]-carbamic Acid <i>tert</i>-Butyl Ester (<b>40</b>)</h4><div class="NLM_p last">To a mixture of 4-cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>8</b> (40.0 mg, 0.0818 mmol), 3-<i>tert</i>-butoxycarbonylamino-3-methyl-butyric acid (21.4 mg, 0.0981 mmol), and PyBroP (55.0 mg, 0.0981 mmol) in 1,2-dichloroethane (2 mL) was added DIEA (42.7 μL, 0.245 mmol), and the resulting mixture was stirred at room temperature for 24 h under Ar. The mixture was diluted with EtOAc (30 mL), washed with H<sub>2</sub>O (2 × 10 mL) and brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 10–40% EtOAc/hexane) to give 33.0 mg (70%) of the title compound as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.93 (br s, 1H), 9.55 (s, 1H), 8.28 (d, 1H, <i>J</i> = 8.4 Hz), 7.74 (d, 1H, <i>J</i> = 2.5 Hz), 7.15 (dd, 1H, <i>J</i> = 8.5, 2.1 Hz), 7.02 (d, 1H, <i>J</i> = 2.1 Hz), 5.84 (dt, 1H, <i>J</i> = 3.5, 2.0 Hz), 5.60 (br s, 1H), 4.85 (d, 1H, <i>J</i> = 13.5 Hz), 4.17 (d, 1H, <i>J</i> = 13.9 Hz), 3.16 (t, 1H, <i>J</i> = 12.1 Hz), 2.56–2.84 (m, 4H), 2.29 (d, 2H, <i>J</i> = 3.4 Hz), 2.23 (br s, 2H), 1.67–1.94 (m, 8H), 1.45 (d, 6H, <i>J</i> = 1.7 Hz), 1.41 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>32</sub>H<sub>42</sub>N<sub>6</sub>O<sub>4</sub>, 575.3 (M + H); found, 574.8.</div></div><div id="sec5_29_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {4-[1-(3-Amino-3-methyl-butyryl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide Trifluoroacetic Acid Salt (<b>41</b>)</h4><div class="NLM_p last">To a solution of [3-(4-{4-[(4-cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidin-1-yl)-1,1-dimethyl-3-oxo-propyl]-carbamic acid <i>tert</i>-butyl ester (33.0 mg, 0.0574 mmol) (as prepared in the previous step) in 3 mL of CH<sub>2</sub>Cl<sub>2</sub> and 0.10 mL of EtOH at 0 °C was added 1.0 mL of TFA, and the mixture was warmed to room temperature and stirred for 3 h. The reaction was diluted with 3 mL of <i>n</i>-PrOH and then concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 3–8% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give 33.5 mg (99%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 13.3 (s, 1H), 9.52 (s, 1H), 8.57 (br s, 2H), 8.26 (d, 1H, <i>J</i> = 8.6 Hz), 7.69 (s, 1H), 7.02 (dd, 1H, <i>J</i> = 8.6, 1.7 Hz), 6.98 (d, 1H, <i>J</i> = 1.7 Hz), 5.78 (m, 1H), 4.67 (br d, 1H, <i>J</i> = 13.4 Hz), 3.88 (br d, 1H, <i>J</i> = 13.4 Hz), 3.10 (m, 1H), 2.55–2.85 (m, 4H), 2.23 (m, 4H), 1.72–2.01 (m, 8H), 1.50 (s, 6H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>34</sub>N<sub>6</sub>O<sub>2</sub>, 475.3 (M + H); found, 475.1.</div></div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 5-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {4-[1-(2-Amino-2-methyl-propionyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide Trifluoroacetic Acid Salt (<b>43</b>)</h3><div id="sec5_30_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> {2-[4-(4-{[4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-carbamic Acid <i>tert</i>-Butyl Ester (<b>42</b>)</h4><div class="NLM_p last">To a solution of 4-(4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>7</b> (231 mg, 0.380 mmol) in 2.5 mL of CH<sub>2</sub>Cl<sub>2</sub> and 0.4 mL of EtOH was added 700 μL of TFA, and the solution stirred for 3 h at 25 °C. The reaction was diluted with 4 mL of EtOH and then concentrated to give ca. a 2:1 mixture of 5-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>19</b> and starting material by <sup>1</sup>H NMR and LC/MS, which was used in the following step without further purification. The mixture in 3 mL of CH<sub>2</sub>Cl<sub>2</sub> was added to a solution of 2-<i>tert</i>-butoxycarbonylamino-2-methyl-propionic acid (53.0 mg, 0.261 mmol), DIEA (122 μL, 0.700 mmol), and PyBroP (144 mg, 0.309 mmol) in 3 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the reaction was stirred at 25 °C overnight. The reaction was diluted with EtOAc (25 mL) and washed with saturated aqueous NaHCO<sub>3</sub>(1 × 25 mL) and brine (25 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated. Purification of the residue by preparative TLC (50% EtOAc–hexanes) afforded 40.0 mg (15%) of the title compound as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.67 (s, 1H), 8.24 (d, 1H, <i>J</i> = 8.4 Hz), 7.78 (s, 1H), 7.68–7.76 (m, 1H), 7.48–7.59 (m, 1H), 7.10 (dd, 1H, <i>J</i> = 8.5, 1.9 Hz), 7.00 (d, 1H, <i>J</i> = 2.1 Hz), 5.96 (s, 2H), 5.78–5.85 (m, 1H), 4.24–4.38 (m, 1H), 3.62–3.76 (m, 3H), 2.66–2.77 (m, 1H), 2.28 (br s, 2H), 2.22 (br s, 2H), 1.42–1.57 (s, 18H), 0.94–1.01 (m, 2H), 0.81–0.92 (m, 6H), 0.01 (s, 9H). Mass Spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>37</sub>H<sub>54</sub>N<sub>6</sub>O<sub>5</sub>Si, 691.3 (M + H); found, 691.1.</div></div><div id="sec5_30_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-Cyano-1<i>H</i>-imidazole-2-carboxylic Acid {4-[1-(2-Amino-2-methyl-propionyl)-piperidin-4-yl]-2-cyclohex-1-enyl-phenyl}-amide Trifluoroacetic Acid Salt (<b>43</b>)</h4><div class="NLM_p last">To a solution of {2-[4-(4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 42 (40.0 mg, 0.0579 mmol, as prepared in the previous step) in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> and 20 μL of EtOH was added 1.5 mL of TFA. The solution was stirred for 3 h at 25 °C, diluted with 2 mL of EtOH, and concentrated in vacuo. Trituration of the residue with ether afforded 8.4 mg (29%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.10 (d, 1H, <i>J</i> = 8.4 Hz), 8.00 (s, 1H), 7.16 (d, 1H, <i>J</i> = 8.4 Hz), 7.07 (s, 1H), 5.79 (s, 1H), 4.55–4.48 (m, 1H), 3.30 (s, 6H), 2.89–2.87 (m, 2H), 2.40–2.25 (m, 4H), 1.96–1.93 (m, 2H), 1.86–1.83 (m, 6H), 1.64–1.61 (m, 2H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>, 461.3 (M + H); found, 461.3.</div></div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidine-1-carboxylic Acid (2-Hydroxy-ethyl)-amide (<b>44</b>)</h3><div id="sec5_31_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-(4-{[4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic Acid (2-Hydroxy-ethyl)-amide</h4><div class="NLM_p last">A solution of 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide trifluoroacetic acid salt <b>19</b> (116 mg, 0.192 mmol) and DIEA (134 μL, 0.770 mmol) in 4 mL of CH<sub>2</sub>Cl<sub>2</sub> was added slowly to solution of triphosgene (22.8 mg, 0.0770 mmol) in 4 mL of CH<sub>2</sub>Cl<sub>2</sub> at −78 °C under Ar. The mixture was stirred at −78 °C for 15 min, warmed to room temperature, stirred for 15 min, and cooled to −78 °C again. A suspension of 2-amino-ethanol (350 μL, 5.77 mmol) in 4 mL of THF was added, and the resulting mixture was warmed to room temperature and stirred for 20 h under Ar. Treated with 100 mL of EtOAc, the mixture was washed with H<sub>2</sub>O (3 × 20 mL) and brine (20 mL) and was dried (Na<sub>2</sub>SO<sub>4</sub>). Removal of the solvent in vacuo followed by flash chromatography of the residue on silica gel (10% EtOAc/CH<sub>2</sub>Cl<sub>2</sub> then 5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave 95 mg (83%) of the title compound as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 9.68 (s, 1H), 8.25 (d, 1H, <i>J</i> = 8.4 Hz), 7.77 (s, 1H), 7.12 (dd, 1H, <i>J</i> = 8.4, 2.2 Hz), 7.01 (d, 1H, <i>J</i> = 2.2 Hz), 5.94 (s, 2H), 5.83 (m, 1H), 4.96 (t, 1H, <i>J</i> = 5.6 Hz), 4.11 (d, 2H, <i>J</i> = 13.3 Hz), 3.75 (ddd, 2H, <i>J</i> = 4.4 Hz), 3.66 (t, 2H, <i>J</i> = 8.3 Hz), 3.44 (ddd, 2H, <i>J</i> = 5.0 Hz), 3.36 (t, 1H, <i>J</i> = 4.6 Hz), 2.91 (ddd, 2H, <i>J</i> = 13.0, 2.2 Hz), 2.66 (dddd, 1H, <i>J</i> = 12.2, 12.2, 3.3, 3.3 Hz), 2.18–2.33 (m, 4H), 1.75–1.91 (m, 6H), 1.67 (dddd, 2H, <i>J</i> = 12.9, 12.9, 12.9, 4.0 Hz), 0.97 (t, 2H, <i>J</i> = 8.3 Hz), 0.00 (s, 9H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>31</sub>H<sub>44</sub>N<sub>6</sub>O<sub>4</sub>Si, 593.3 (M + H); found, 593.1.</div></div><div id="sec5_31_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidine-1-carboxylic Acid (2-Hydroxy-ethyl)-amide (<b>44</b>)</h4><div class="NLM_p last">To a solution of 4-(4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1<i>H</i>-imidazole-2-carbonyl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid (2-hydroxy-ethyl)-amide (as prepared in the previous step, 95 mg, 0.16 mmol) in 3 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 0.10 mL of EtOH followed by 1.0 mL of TFA. The resulting solution was stirred at room temperature for 6 h. Removal of the solvent under reduced pressure followed by flash chromatography of the residue on silica gel (2–8% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) gave 68 mg (92%) of the title compound as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.09 (d, 1H, <i>J</i> = 8.4 Hz), 8.00 (s, 1H), 7.15 (dd, 1H, <i>J</i> = 8.4, 2.2 Hz), 7.06 (d, 1H, <i>J</i> = 2.2 Hz), 5.79 (m, 1H), 4.15 (dd, 2H, <i>J</i> = 13.3, 1.1 Hz), 3.61 (t, 2H, <i>J</i> = 5.9 Hz), 3.27–3.32 (m, 2H), 2.90 (ddd, 2H, <i>J</i> = 13.0, 13.0, 2.5 Hz), 2.73 (dddd, 1H, <i>J</i> = 12.1, 12.1, 2.6, 2.6 Hz), 2.26 (m, 4H), 1.73–1.88 (m, 6H), 1.62 (dddd, 2H, <i>J</i> = 12.6, 12.6, 12.6, 4.0 Hz). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>, 463.2 (M + H); found, 463.2.</div></div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 4-{4-[(4-Cyano-1<i>H</i>-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidine-1-carboxylic Acid Amide (<b>45</b>)</h3><div class="NLM_p last">4-Cyano-1<i>H</i>-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide TFA salt (51.0 mg, 0.104 mmol) <b>8</b>, Et<sub>3</sub>N (21.7 μL, 0.156 mmol), trimethylsilyl isocyanate (15.5 μL, 0.114 mmol), and 1.0 mL of CH<sub>2</sub>Cl<sub>2</sub> were stirred for 10 h at 25 °C. The solvent was evaporated, and the residue was purified by RP-HPLC (C<sub>18</sub>), eluting with 35–60% CH<sub>3</sub>CN in 0.1% TFA/H<sub>2</sub>O over 11 min to give 30 mg (70%) of the title compound as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 14.28 (br s, 1H), 9.76 (s, 1H), 8.34 (d, 1H, <i>J</i> = 2.56 Hz), 7.84 (d, 1H. <i>J</i> = 8.1 Hz), 7.18 (dd, 1H, <i>J</i> = 8.5, 2.2 Hz), 7.08 (d, 1H, <i>J</i> = 1.9 Hz), 6.00 (br s, 2H), 5.72 (m, 1H), 4.18 (m, 2H), 2.80–2.60 (m, 3H), 2.24–2.10 (m, 4H), 1.80–1.60 (m, 6H), 1.50 (m, 2H). Mass spectrum (ESI, <i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>26</sub>N<sub>6</sub>O, 419.2 (M + H); found, 419.0.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Biology</h3><div id="sec5_33_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Kinase Assays</h4><div class="NLM_p last">Assays for FMS and the other kinases listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> were carried out using a fluorescence polarization competition immunoassay format and have been described elsewhere in detail.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The full cytoplasmic regions of FMS (538–972) encompassing the tyrosine kinase domain were expressed and purified from a baculovirus system.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The FMS kinase assay measured FMS-mediated phosphorylation of tyrosine residues present on a synthetic FMS<sub>555–568</sub> peptide (SYEGNSYTFIDPTQ). To each well of a black 96-well microplate (catalog no. 42-000-0117, Molecular Devices, Sunnyvale, CA), 5 μL of compound solution (in 4% DMSO in assay buffer) was mixed with 2 μL of 3.5 nM FMS, 25 mM MgCl<sub>2</sub> in assay buffer (100 mM HEPES, pH 7.5, 1 mM DTT, and 0.01% Tween-20), and 2 μL of 1540 μM peptide in assay buffer. The kinase reaction was initiated by adding 1 μL of 10 mM ATP in assay buffer. The final concentrations in the 10 μL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 μM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl<sub>2</sub>, and 0.7 nM FMS. The plates were incubated at room temperature for 80 min. Reactions were stopped by the addition of 1.2 μL of 50 mM EDTA. Each well then received 10 μL of a 1:1:3 mixture of 10× antiphosphotyrosine antibody, 10× PTK green tracer, and fluorescence polarization dilution buffer (catalog no. P2837, Invitrogen, Carlsbad, CA). The plates were incubated for 30 min at room temperature, and the fluorescence polarization was read (485 nm excitation, 530 nm emission) on an Analyst plate reader (Molecular Devices). Fluorescence polarization values for positive (EDTA) and negative (DMSO) controls were used to define 100 and 0% inhibition of the FMS reaction.</div></div><div id="sec5_33_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Cellular Assays</h4><div class="NLM_p last">Functional inhibition of CSF-1R was assessed using murine bone marrow-derived macrophages as previously described.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Macrophages were plated in 96-well culture plates at a density of 5000 cells/well in 100 μL of α-MEM containing 10% FCS. After overnight culture, wells were supplemented with the addition of 50 μL of media containing 15 ng/mL CSF-1, 3 μM indomethacin, and a dilution series of test compound. The cells were cultured for 30 h at 37 °C and 5% CO<sub>2</sub>. During the final 6 h, cultures were supplemented with an additional 30 μL of media containing a 1:500 dilution of bromodeoxyuridine (BrDU) reagent, and incorporation of BrDU into cellular DNA was quantified using a specific ELISA (catalog no. X1327K) from Exalpha Corporation (Watertown, MA). Inhibition of cellular LCK was determined as described.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(65)</a> Jurkat cells (10<sup>5</sup>/well) (ATCC) with graded concentrations of <b>23</b> were plated into wells precoated with CD3ε antibody (R&D Systems). PMA was added to a final concentration of 10 ng/mL, and IL-2 secreted into 24 h culture supernatants was measured by ELISA (R&D Systems). As described previously in detail, inhibition of cellular AXL was based on measurement of GAS6-induced AXL phosphorylation in HEK cells transfected to express AXL, and cellular ITD-FLT3, KIT, and TRKA inhibition were based assays of ITD-FLT3, KIT, and TRKA-dependent cell proliferation.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec800" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> MV-4-11 and M-o7e Leukemia Cell Line Proliferation Assays</h4><div class="NLM_p last">The functional impact on cellular FLT3 activity was determined by measuring compound inhibition of MV-4-11 (ATCC no. CRL-9591) cell proliferation, and M-07e (DSMZ no. ACC 104) cells were used to assess compound effects on cellular KIT activity. MV-4-11 cells grew independent of growth factor due to expression of a constitutive active FLT3 mutation, and M-07e cells were driven to proliferate in a KIT-dependent fashion by 25 ng/mL stem cell factor. Following a culture period of 72 h, relative cell numbers were determined using CellTiterGlo reagent (Promega).</div></div><div id="sec5_33_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Biochemical PD Mouse Model</h4><div class="NLM_p last">Groups of six B6C3F1 mice (Taconic Farms) were given oral doses of vehicle [aqueous 20% hydroxypropyl-β-cyclodextrin (HPβCD)] or test article in vehicle. Eight hours later, mice were administered saline alone or saline containing 1 μg of recombinant mouse CSF-1 (Cell Biosciences Inc., Norwood, MA) via the tail vein. Fifteen minutes after CSF-1 injection, mice were sacrificed, and spleens were isolated and snap-frozen on dry ice. The frozen tissue was homogenized in 1 mL of Trizol (Invitrogen) per 50 mg of tissue, RNA was purified, and RT-PCR was performed to assess c-fos mRNA expression as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec5_33_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> CIA-Induced Arthritis Model</h4><div class="NLM_p last">The CIA model was performed by Bolder BioPath, Inc. (Boulder, CO). Male B10RIII (Jackson Laboratories) were immunized with type II collagen (Elastin Products), in Freund's complete adjuvant (with supplemental <i>M. tuberculosis</i>4 mg/mL, Difco) on days 0 and 15. On day 12, animals were randomized by body weight into groups (<i>n</i> = 15), and dosing was initiated and continued every day (BID, 12 h intervals) for a total of 14 days. On day 26, mice were euthanized, paws were fixed in buffered formalin, and toluiodine blue stained sections were prepared for histopathology. Inflammation, cartilage damage, pannus invasion, and bone erosion were each scored using five-point scales corresponding to minimal, mild, moderate, marked, and severe changes. Inflammation was scored as the presence of inflammatory cells and edema. Pannus was scored as tissue invasion of cartilage and subchondral bone and destruction of joint architecture. Cartilage damage was scored as the loss of toluiodine blue staining, chondrocyte loss, and collagen disruption. Bone resorption was scored for areas of resorption of medulary trabecular and cortical bone and for the abundance of osteoclasts.</div></div><div id="sec5_33_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Adjuvant-Induced Arthritis Model</h4><div class="NLM_p last">The adjuvant-induced arthritis study was performed by Bolder BioPath, Inc. Male Lewis rats (Harlan catalog no. 1439444), 165–185 g, were anesthetized with isoflurane and injected with 100 μL of Freund's complete adjuvant (FCA, Sigma)/lipoidal amine (LA, Sigma) at the base of the tail on day 0. Twice daily oral dosing was initiated on day 8 (the first day of clinical disease) with <b>23</b> or vehicle (0.5% hydroxypropylmethylcellulose/0.5% Tween-80). Rats were sacrificed on day 14, and spleens and hind paws were weighed. Both hind paws were then fixed in formalin, decalcified in 5% formic acid, and processed for H&E microscopy. H&E sections of paws were scored for bone resorption using a five-point scale as described in detail previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Sections were scored additionally for inflammation using a five-point scale for minimal, mild, moderate, marked, and severe leukocytic infiltration and edema. Osteoclast counts (<i>n</i> = 5, 400× fields) were performed on ankles in the areas of greatest bone resorption. Histological sections prepared for ED1 immunohistochemistry were treated for 3 min with proteinase K to expose masked epitopes, and the endogenous peroxidase activity was deactivated with 3% hydrogen peroxidase. Sections were blocked for 1 h with 5% horse serum and for 30 min with Avidin–Biotin solution (SP-2001, Vector Corporation, Burlingane, CA) prior to a 1 h of incubation with ED1 primary antibody (mouse antirat CD68, MCA341R, Serotec, Oxford, United Kingdom). Bound antibody was detected using the ABC-AP Rat kit (PK-6102, Vector) and a DAB Substrate kit (SK-4100, Vector). The sections were lightly counterstained, and the each section was visually scanned under 40× magnification. Hot spots were defined as areas with markedly increased ED1 positive cell density containing >30 ED1 positive cells. Only hot spots in the soft tissue were counted to avoid inclusion of ED1 positive osteoclasts.</div></div><div id="sec5_33_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> SCW-Induced Arthritis Model</h4><div class="NLM_p last">Female Lewis rats (80–100 g each) were purchased from Charles River. SCW peptidoglycan-polysaccharide polymers (PG-PS 10S) were purchased from Becton Dickinson (catalog no. 210866). On day 0, rats were anesthetized using isoflurane and injected ip with PG-PS 10S equivalent to 15 μg of rhamnose/gram (body weight) in the lower left quadrant of the abdomen. Control rats were treated in a similar manner with sterile saline. On day 5, rats injected with PG-PS 10S that showed a robust acute phase arthritic response based on joint swelling were randomized into the treatment groups. In an initial study, animals were dosed orally BID beginning on day 8 until sacrifice on day 19. In a second study, animals were dosed orally BID beginning on day 18 until sacrifice on day 39. Compound <b>23</b> was formulated in 20% HPβCD, and the dose volume was 6 mL/kg. Calipers were used to measure the width (anterior to posterior surface) of the left and right hind ankles of each rat. Each ankle was measured three times and averaged. Hind paw inflammation clinical scores were assigned based on swelling and erythema as follows: 1 = ankle involvement only; 2 = involvement of ankle and proximal 1/2 of tarsal joint; 3 = involvement of the ankle and entire tarsal joint down to the metatarsal joints; and 4 = involvement of the entire paw including the digits. Scores of both hind paws were summed for a maximal score of 8. Digital radiographs of the left paws were prepared using a VetTek Universal AP500 (Del Medical Imaging Corporation, Franklin Park, IL). Hind paws were assessed for ED1 positive cells using immunohistochemistry as described above for the adjuvant arthritis model.</div></div><div id="sec5_33_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Statistical Analysis</h4><div class="NLM_p last">Ankle thickness, bone erosion scores, osteoclast counts, and c-fos expression values (means ± SEs) were analyzed for group differences using the Student's <i>t</i> test. Significance was set at <i>p</i> ≤ 0.05 unless indicated otherwise.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80"><a href="/doi/suppl/10.1021/jm200900q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Supplementary data collection, refinement statistics, and crystallization/soaking conditions for cocrystal structures of FMS with compounds <b>8</b> and <b>49</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200900q/suppl_file/jm200900q_si_001.pdf">jm200900q_si_001.pdf (91.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm200900q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52348" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52348" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl R. Illig</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f7c76737376785f766b6c31757175317c7072"><span class="__cf_email__" data-cfemail="d5b6bcb9b9bcb295bca1a6fbbfbbbffbb6bab8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl L. Manthey</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Wall</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanath K. Meegalla</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinsheng Chen</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth J. Wilson</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shelley K. Ballentine</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renee L. DesJarlais</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carsten Schubert</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carl S. Crysler</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanmin Chen</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Molloy</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margery A. Chaikin</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert R. Donatelli</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Yurkow</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhao Zhou</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark R. Player</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce E. Tomczuk</span> - <span class="hlFld-Affiliation affiliation">Johnson & Johnson Pharmaceutical
Research
& Development, Welsh & McKean Roads, Spring
House, Pennsylvania 19477, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack" id="ACK-d1240e6726-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Alison Bendele and Mike Bendele at Bolder BioPath Inc. for performing the mouse CIA and the rat adjuvant-induced arthritis studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i82" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i82"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i83" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i83"> Abbreviations</h2><tr><td class="NLM_term">BMDM</td><td class="NLM_def"><p class="first last">bone marrow-derived macrophage (cellular assay)</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">CSF-1</td><td class="NLM_def"><p class="first last">colony-stimulating factor-1</p></td></tr><tr><td class="NLM_term">CSF-1R</td><td class="NLM_def"><p class="first last">colony-stimulating factor-1 receptor</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cardiovascular</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450 enzyme</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N′-</i>ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">FMS</td><td class="NLM_def"><p class="first last">the product of the cellular proto-oncogene homologue of the feline McDonough sarcoma virus oncogene</p></td></tr><tr><td class="NLM_term">H&E stain</td><td class="NLM_def"><p class="first last">hematoxylin and eosin stain</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene potassium channel</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPβCD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">IDR</td><td class="NLM_def"><p class="first last">idiosyncratic drug reaction</p></td></tr><tr><td class="NLM_term">M-CSF</td><td class="NLM_def"><p class="first last">macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">M-CSFR</td><td class="NLM_def"><p class="first last">macrophage colony-stimulating factor receptor</p></td></tr><tr><td class="NLM_term">MTX</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">QT</td><td class="NLM_def"><p class="first last">the interval in a heartbeat measured from the beginning of the QRS complex to the end of the T wave</p></td></tr><tr><td class="NLM_term">SCW</td><td class="NLM_def"><p class="first last">streptococcal cell wall</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">trimethylsilylethoxymethyl</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lundkvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobelt, G.</span><span> </span><span class="NLM_article-title">The burden of rheumatoid arthritis and access to treatment: Health burden and costs</span> <span class="citation_source-journal">Eur. J. Health Econ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">S60</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=S49-S60&issue=Suppl.+2&author=J.+Lundkvistauthor=F.+Kastangauthor=G.+Kobelt&title=The+burden+of+rheumatoid+arthritis+and+access+to+treatment%3A+Health+burden+and+costs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLundkvist%26aufirst%3DJ.%26aulast%3DKastang%26aufirst%3DF.%26aulast%3DKobelt%26aufirst%3DG.%26atitle%3DThe%2520burden%2520of%2520rheumatoid%2520arthritis%2520and%2520access%2520to%2520treatment%253A%2520Health%2520burden%2520and%2520costs%26jtitle%3DEur.%2520J.%2520Health%2520Econ.%26date%3D2008%26volume%3D8%26issue%3DSuppl.%25202%26spage%3DS49%26epage%3DS60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Maggon, K.</span> Global arthritis market review 2008 (World top ten RA drugs); <a href="http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#" class="extLink">http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#</a> (accessed January 3,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maggon%2C+K.+Global+arthritis+market+review+2008+%28World+top+ten+RA+drugs%29%3B+http%3A%2F%2Fknol.google.com%2Fk%2Fglobal-arthritis-market-review-2008-world-top-ten-ra-drugs%23+%28accessed+January+3%2C+2011%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DMaggon%26aufirst%3DK.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lipsky, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijde, D. M. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clair, E. W.,  St.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalden, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, R. N.</span><span> </span><span class="NLM_article-title">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1056%2FNEJM200011303432202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=11096166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1594-1602&author=P.+E.+Lipskyauthor=D.+M.+F.+M.+van+der+Heijdeauthor=E.+W.+Clairauthor=D.+E.+Furstauthor=F.+C.+Breedveldauthor=J.+R.+Kaldenauthor=J.+S.+Smolenauthor=M.+Weismanauthor=P.+Emeryauthor=M.+Feldmannauthor=G.+R.+Harrimanauthor=R.+N.+Maini&title=Infliximab+and+methotrexate+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Lipsky, Peter E.; Van Der Heijde, Desiree M. F. M.; St. Clair, E. William; Furst, Daniel E.; Breedveld, Ferdinand C.; Kalden, Joachim R.; Smolen, Josef S.; Weisman, Michael; Emery, Paul; Feldmann, Marc; Harriman, Gregory R.; Maini, Ravinder N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1594-1602</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis.  However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.  We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in i.v. doses of 3 or 10 mg per kg of body wt. every 4 or 8 wk in combination with oral methotrexate for 54 wk.  We assessed clin. responses with use of the criteria of the American College of Rheumatol., the quality of life with a health-status questionnaire, and the effect on joint damage radiog.  The combination of infliximab and methotrexate was well tolerated and resulted in a sustained redn. in the symptoms and signs of rheumatoid arthritis that was significantly greater than the redn. assocd. with methotrexate therapy alone (clin. response, 51.8 % vs. 17.0 %; P<0.001).  The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone.  Radiog. evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiog. score, 7.0 vs. 0.6; P<0.001).  Radiog. evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clin. response.  In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clin. benefit and halted the progression of joint damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqasmJKB3fqgrVg90H21EOLACvtfcHk0ljDPIu6jZQ8EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D&md5=b67ff09ce24a2c808a265204aac20e53</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432202%26sid%3Dliteratum%253Aachs%26aulast%3DLipsky%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BM.%2BF.%2BM.%26aulast%3DClair%26aufirst%3DE.%2BW.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeisman%26aufirst%3DM.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DHarriman%26aufirst%3DG.%2BR.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26atitle%3DInfliximab%2520and%2520methotrexate%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1594%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_contrib-group">Esposito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuzzocrea, S.</span><span> </span><span class="NLM_article-title">TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3152</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F092986709788803024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19689289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvVynu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=3152-3167&author=E.+Espositoauthor=S.+Cuzzocrea&title=TNF-alpha+as+a+therapeutic+target+in+inflammatory+diseases%2C+ischemia-reperfusion+injury+and+trauma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma</span></div><div class="casAuthors">Esposito, E.; Cuzzocrea, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3152-3167</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor necrosis factor-α (TNF-α) is a central regulator of inflammation, and TNF-α antagonists may be effective in treating inflammatory disorders in which TNF-α plays an important pathogenetic role.  Recombinant or modified proteins are an emerging class of therapeutic agents.  To date, several recombinant or modified proteins which acts as TNF antagonists have been disclosed.  In particular, antibodies that bind to and neutralize TNF have been sought as a means to inhibit TNF activity.  Inhibition of TNF has proven to be an effective therapy for patients with rheumatoid arthritis and other forms of inflammatory disease including psoriasis, psoriatic arthritis, and ankylosing spondylitis, inflammatory bowel disease.  Addnl., the efficacy of preventing septic shock and AIDS has been questioned as a result of recent research.  The currently available therapies include a sol. p75 TNF receptor:Fc construct, etanercept, a chimeric monoclonal antibody, infliximab, and a fully human monoclonal antibody, adalimumab.  Certolizumab pegol is a novel TNF inhibitor which is an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to increase half-life, and thus is Fc-domain-free.  In this review, the authors discuss briefly the present understanding of TNF-α-mediated biol. and the current therapies in clin. use, and focus on some of the new therapeutic approaches with small-mol. inhibitors.  Moreover, the authors examine recent reports providing important insights into the understanding of efficacy of thalidomide and its analogs, as TNF-α activity inhibitors, esp. in therapies of several inflammatory diseases within the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcxBS9PcZ2Z7Vg90H21EOLACvtfcHk0li9A8njKRg1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvVynu78%253D&md5=6a011a209d4b7b8616c12e1a9e293efa</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2174%2F092986709788803024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709788803024%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DE.%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DTNF-alpha%2520as%2520a%2520therapeutic%2520target%2520in%2520inflammatory%2520diseases%252C%2520ischemia-reperfusion%2520injury%2520and%2520trauma%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D3152%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_contrib-group">Ranganathan, P.</span><span> </span><span class="NLM_article-title">An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents</span> <span class="citation_source-journal">Curr. Opin. Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19051134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=562-567&author=P.+Ranganathan&title=An+update+on+pharmacogenomics+in+rheumatoid+arthritis+with+a+focus+on+TNF-blocking+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents</span></div><div class="casAuthors">Ranganathan, Prabha</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-8431</span>.
    
            (<span class="NLM_cas:orgname">Thomson Reuters</span>)
        </div><div class="casAbstract">A review.  TNFα is a proinflammatory cytokine, which is crucial in the pathogenesis of rheumatoid arthritis (RA).  In recent years, biol. therapies which block the damaging effects of TNFα on synovium and cartilage have been developed.  TNF antagonists, such as etanercept, infliximab and adalimumab, although highly effective in RA, are expensive, totaling several thousand US dollars in yearly costs.  In addn., only approx. 60% of patients respond to these agents.  This has led to the need to prospectively identify patients most likely to respond to these agents, which can be achieved by pharmacogenomics approaches.  Polymorphisms in genes encoding for TNFα, the MHC region, and the Fcγ receptor IIIA, as well as their ability to predict disease progression in RA and response to anti-TNF therapies, have been the focus of a no. of studies, which are discussed in this review.  There is no consensus at present as to whether pharmacogenomics will allow prediction of anti-TNF therapy efficacy in RA.  Large, prospective, multicenter studies are needed to replicate and validate the results of the studies outlined in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr914kemmVLUbVg90H21EOLACvtfcHk0li9A8njKRg1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFKmug%253D%253D&md5=72f31e31f013fcbc2893a46339d12db8</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DP.%26atitle%3DAn%2520update%2520on%2520pharmacogenomics%2520in%2520rheumatoid%2520arthritis%2520with%2520a%2520focus%2520on%2520TNF-blocking%2520agents%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2008%26volume%3D10%26spage%3D562%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fujiwara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span> </span><span class="NLM_article-title">Macrophages in inflammation</span> <span class="citation_source-journal">Curr. Drug Target Inflamm. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1568010054022024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=16101534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=281-286&author=N.+Fujiwaraauthor=K.+Kobayashi&title=Macrophages+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages in inflammation</span></div><div class="casAuthors">Fujiwara, Nagatoshi; Kobayashi, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Inflammation & Allergy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-286</span>CODEN:
                <span class="NLM_cas:coden">CDTICU</span>;
        ISSN:<span class="NLM_cas:issn">1568-010X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The inflammatory process is usually tightly regulated, involving both signals that initiate and maintain inflammation and signals that shut the process down.  An imbalance between the two signals leaves inflammation unchecked, resulting in cellular and tissue damage.  Macrophages are a major component of the mononuclear phagocyte system that consists of closely related cells of bone marrow origin, including blood monocytes, and tissue macrophages.  From the blood, monocytes migrate into various tissues and transform macrophages.  In inflammation, macrophages have three major function; antigen presentation, phagocytosis, and immunomodulation through prodn. of various cytokines and growth factors.  Macrophages play a crit. role in the initiation, maintenance, and resoln. of inflammation.  They are activated and deactivated in the inflammatory process.  Activation signals include cytokines (interferon γ, granulocyte-monocyte colony stimulating factor, and tumor necrosis factor α), bacterial lipopolysaccharide, extracellular matrix proteins, and other chem. mediators.  Inhibition of inflammation by removal or deactivation of mediators and inflammatory effector cells permits the host to repair damages tissues.  Activated macrophages are deactivated by anti-inflammatory cytokines (interleukin 10 and transforming growth factor β) and cytokine antagonists that are mainly produced by macrophages.  Macrophages participate in the autoregulatory loop in the inflammatory process.  Because macrophages produce a wide range of biol. active mols. participated in both beneficial and detrimental outcomes in inflammation, therapeutic interventions targeted macrophages and their products may open new avenues for controlling inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9OWqdAk-DhLVg90H21EOLACvtfcHk0ljl6pJPVfhPEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFelsrY%253D&md5=4733a9003abbc00bd9f1906e8a183adf</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568010054022024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568010054022024%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DK.%26atitle%3DMacrophages%2520in%2520inflammation%26jtitle%3DCurr.%2520Drug%2520Target%2520Inflamm.%2520Allergy%26date%3D2005%26volume%3D4%26spage%3D281%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Tak, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daha, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinders, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span> </span><span class="NLM_article-title">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=9041933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=217-25&author=P.+P.+Takauthor=T.+J.+Smeetsauthor=M.+R.+Dahaauthor=P.+M.+Kluinauthor=K.+A.+Meijersauthor=R.+Brandauthor=A.+E.+Meindersauthor=F.+C.+Breedveld&title=Analysis+of+the+synovial+cell+infiltrate+in+early+rheumatoid+synovial+tissue+in+relation+to+disease+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</span></div><div class="casAuthors">Tak P P; Smeets T J; Daha M R; Kluin P M; Meijers K A; Brand R; Meinders A E; Breedveld F C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-25</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To define variations in the cellular infiltrate and in the expression of monokines in synovial tissue (ST) from rheumatoid arthritis (RA) patients with different durations of disease and different levels of disease activity.  METHODS:  The immunohistologic features of synovial biopsy specimens from 31 patients with early RA (< 1 year) and 35 patients with longstanding RA (> 5 years) were compared.  The possible associations between these features and local disease activity, as measured by the score for pain in the biopsied knee joint were also evaluated.  RESULTS:  The immunohistologic features were not dependent on disease duration.  We found a positive correlation between the scores for knee pain and the semiquantitative scores for the number of macrophages, as well as the expression of interleukin-6 and tumor necrosis factor alpha, whereas the correlation with the scores for CD4+ T cells was negative.  Multivariate analysis showed that these correlations were highly statistically significant (P < 0.003).  CONCLUSION:  The results do not support the view that inflammatory mechanisms in the synovial tissues of RA patients differ between early and late stages of the disease.  The findings presented here are consistent with the concept that early RA is the result of a synovitis process of longer duration and that macrophage-derived cytokines play an important role in maintaining the clinical signs of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7XPNbuR4ndNbHMBt0mMIXfW6udTcc2eaperZE0mmgirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D&md5=ce8d3e3ad53739d459b024a049a132cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.1780400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780400206%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DMeijers%26aufirst%3DK.%2BA.%26aulast%3DBrand%26aufirst%3DR.%26aulast%3DMeinders%26aufirst%3DA.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26atitle%3DAnalysis%2520of%2520the%2520synovial%2520cell%2520infiltrate%2520in%2520early%2520rheumatoid%2520synovial%2520tissue%2520in%2520relation%2520to%2520disease%2520activity%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26spage%3D217%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bresnihan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1136%2Fard.2004.029751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15576415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=834-838&author=J.+J.+Haringmanauthor=D.+M.+Gerlagauthor=A.+H.+Zwindermanauthor=T.+J.+M.+Smeetsauthor=M.+C.+Kraanauthor=D.+Baetenauthor=I.+B.+McInnesauthor=B.+Bresnihanauthor=P.+P.+Tak&title=Synovial+tissue+macrophages%3A+A+sensitive+biomarker+for+response+to+treatment+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">834-838</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Previous work identified synovial sublining macrophage nos. as a potential biomarker for clin. efficacy in rheumatoid arthritis.  Objective: To investigate the assocn. between changes in infiltration of synovial macrophages and clin. improvement after antirheumatic treatment.  Methods: 88 patients who participated in various clin. trials were studied.  All patients underwent serial arthroscopy before initiation of treatment and after different time intervals.  Immunohistochem. and digital image anal. were performed according to standardized procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28).  Statistical anal. was performed using one way anal. of variance, the independent samples t test, linear regression, and the standardized response mean (SRM).  Results: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages (mean (SEM) cells/mm2 -643 (124), -270 (64), and -95 (60), resp.; p<0.0003).  There was a significant correlation between the change in the no. of macrophages and the change in DAS28 (Pearson correlation 0.874, p<0.01).  The change in sublining macrophages explained 76% of the variation in the change in DAS28 (p<0.02).  The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3).  Conclusion: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDDuysAUtsbVg90H21EOLACvtfcHk0liRqaTGgistWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D&md5=3fdb6f7b0d2c170ca58e40af83af054f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.029751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.029751%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DZwinderman%26aufirst%3DA.%2BH.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBresnihan%26aufirst%3DB.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSynovial%2520tissue%2520macrophages%253A%2520A%2520sensitive%2520biomarker%2520for%2520response%2520to%2520treatment%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3D834%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0lhzRwZsttDpRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Colony-stimulating factors in inflammation and autoimmunity</span> <span class="citation_source-journal">Nature Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1038%2Fnri2356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=18551128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1ehs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=533-544&author=J.+A.+Hamilton&title=Colony-stimulating+factors+in+inflammation+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factors in inflammation and autoimmunity</span></div><div class="casAuthors">Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In addn. to their role as haematopoietic-cell growth factors, colony-stimulating factors have broader roles in immunity, and targeting these factors might have therapeutic benefits in inflammation and autoimmunity.  Although they were originally defined as haematopoietic-cell growth factors, colony-stimulating factors (CSFs) have been shown to have addnl. functions by acting directly on mature myeloid cells.  Recent data from animal models indicate that the depletion of CSFs has therapeutic benefit in many inflammatory and/or autoimmune conditions and as a result, early-phase clin. trials targeting granulocyte/macrophage colony-stimulating factor and macrophage colony-stimulating factor have now commenced.  The distinct biol. features of CSFs offer opportunities for specific targeting, but with some assocd. risks.  The author describes these biol. features, discusses the probable specific outcomes of targeting CSFs in vivo, and highlights outstanding questions that need to be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbRS4KJDObLVg90H21EOLACvtfcHk0lhJEEU7qnVdHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1ehs7k%253D&md5=13f4749ea0c4b1e5fdd5e3ebc4b14f72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnri2356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2356%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DColony-stimulating%2520factors%2520in%2520inflammation%2520and%2520autoimmunity%26jtitle%3DNature%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D533%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filonzi, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ianches, G.</span><span> </span><span class="NLM_article-title">Regulation of macrophage colony-stimulating factor (CSF-1) production in cultured human synovial fibroblasts</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1993&pages=157-65&author=J.+A.+Hamiltonauthor=E.+L.+Filonziauthor=G.+Ianches&title=Regulation+of+macrophage+colony-stimulating+factor+%28CSF-1%29+production+in+cultured+human+synovial+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26aulast%3DFilonzi%26aufirst%3DE.%2BL.%26aulast%3DIanches%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520production%2520in%2520cultured%2520human%2520synovial%2520fibroblasts%26jtitle%3DGrowth%2520Factors%26date%3D1993%26volume%3D9%26spage%3D157%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ianches, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Production of macrophage colony-stimulating factor (CSF-1) by human articular cartilage and chondrocytes. Modulation by interleukin-1 and tumor necrosis factor alpha</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1182</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=1993&pages=57-63&author=I.+K.+Campbellauthor=G.+Ianchesauthor=J.+A.+Hamilton&title=Production+of+macrophage+colony-stimulating+factor+%28CSF-1%29+by+human+articular+cartilage+and+chondrocytes.+Modulation+by+interleukin-1+and+tumor+necrosis+factor+alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DIanches%26aufirst%3DG.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DProduction%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520by%2520human%2520articular%2520cartilage%2520and%2520chondrocytes.%2520Modulation%2520by%2520interleukin-1%2520and%2520tumor%2520necrosis%2520factor%2520alpha%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1993%26volume%3D1182%26spage%3D57%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanikawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamukai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaguri, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=597-603&author=K.+Nakanoauthor=Y.+Okadaauthor=K.+Saitoauthor=R.+Tanikawaauthor=N.+Sawamukaiauthor=Y.+Sasaguriauthor=T.+Kohroauthor=Y.+Wadaauthor=T.+Kodamaauthor=Y.+Tanaka&title=Rheumatoid+synovial+endothelial+cells+produce+macrophage+colony-stimulating+factor+leading+to+osteoclastogenesis+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DTanikawa%26aufirst%3DR.%26aulast%3DSawamukai%26aufirst%3DN.%26aulast%3DSasaguri%26aufirst%3DY.%26aulast%3DKohro%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DRheumatoid%2520synovial%2520endothelial%2520cells%2520produce%2520macrophage%2520colony-stimulating%2520factor%2520leading%2520to%2520osteoclastogenesis%2520in%2520rheumatoid%2520arthritis%26jtitle%3DRheumatology%26date%3D2007%26volume%3D46%26spage%3D597%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomuro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, Y.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Nippon Ika Daigaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1272%2Fjnms1923.62.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=7615698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=260-270&author=H.+Kawajiauthor=K.+Yokomuroauthor=K.+Kikuchiauthor=Y.+Somotoauthor=Y.+Shirai&title=Macrophage+colony-stimulating+factor+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span></div><div class="casAuthors">Kawaji, Hidemi; Yokomuro, Kozo; Kikuchi, Kyoko; Somoto, Youki; Shirai, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Ika Daigaku Zasshi</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-70</span>CODEN:
                <span class="NLM_cas:coden">NIDZAJ</span>;
        ISSN:<span class="NLM_cas:issn">0048-0444</span>.
    </div><div class="casAbstract">We developed a new ELISA technique to measure macrophage colony-stimulating factor (M-CSF) levels in synovial fluid with high sensitivity and reproducibility.  The mean M-CSF level in the synovial fluid of patients with rheumatoid arthritis (RA) was 1.38 ± 0.56 ng/mL, and that of patients with osteoarthritis (OA) was 0.67 ± 0.13 ng/mL.  In contrast, serum levels of M-CSF in patients with RA and in normal controls were 1.32 ± 0.50 ng/mL and 0.90 ± 0.09 ng/mL, resp.  These differences were both statistically significant.  Since serum M-CSF levels correlate with inflammatory signs obtained from examn. of blood, they indicate the general condition of patients with RA.  Synovial fluid M-CSF levels increase even in the early phase of RA and remain high despite drug therapy, which suggests that they reflect the condition of affected joints including joint spaces and inflamed synovia more directly than do the levels of serum M-CSF.  Measurement of the M-CSF level in the synovial fluid may be useful in the diagnosis, clin. evaluation, and assessment of the effects of treatment in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomBgcRjuSmvLVg90H21EOLACvtfcHk0ljzZdOPYGtGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D&md5=2d5c872c01ea9a95560af0412a2967e2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1272%2Fjnms1923.62.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1272%252Fjnms1923.62.260%26sid%3Dliteratum%253Aachs%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DYokomuro%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DSomoto%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DY.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DNippon%2520Ika%2520Daigaku%2520Zasshi%26date%3D1995%26volume%3D62%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ritchlin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winchester, R.</span><span> </span><span class="NLM_article-title">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1111%2Fj.1365-3083.1994.tb03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8091128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=292-298&author=C.+Ritchlinauthor=E.+Dwyerauthor=R.+Bucalaauthor=R.+Winchester&title=Sustained+and+distinctive+patterns+of+gene+activation+in+synovial+fibroblasts+and+whole+synovial+tissue+obtained+from+inflammatory+synovitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span></div><div class="casAuthors">Ritchlin, C.; Dwyer, E.; Bucala, R.; Winchester, R.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-8</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    </div><div class="casAbstract">Fibroblastoid synovial lining cells isolated from rheumatoid and other chronic inflammatory synovial tissue exhibit distinctive and sustained alterations in serial culture not commonly found in similarly cultured cells from osteoarthritic synovium.  These are demonstrable using a multi-gene dot blot assay by labeling reverse transcribed fibroblast cDNA which is hybridized to plasmids contg. relevant target gene inserts.  Cultured synovial fibroblastoid cells from patients with chronic inflammatory synovitis expressed significantly higher levels of stromelysin, vimentin and TIMP-1 mRNA and lower levels of c-myc compared to cells isolated from osteoarthritis synovium although with considerable variation.  Early fetal synovial lining cells were similar to cells from osteoarthritis synovium but vimentin expression was higher.  Marked differences in patterns of gene expression between cell lines persisted through 10 serial passages over 6-8 mo.  In whole synovia, the av. level of mRNA for stromelysin, vimentin, IL-4, IL-6, TIMP-1, cathepsin D, gelatinase, TGFα, c-fms and DRβ were preferentially expressed in inflammatory tissue while c-myc expression was higher in osteoarthritis synovium.  Inflammatory synovium also expressed TNFα, IL-1α, IL-1β, IL-2, c-sis, tissue plasminogen activator, CSF-1, and GM-CSF.  This pattern resembles, in part, that found in cultured inflammatory fibroblasts but, in addn., gene products apparently reflecting the presence of activated monocytes and lymphocytes were detected.  These results provide evidence that profiles of certain gene activation in cells from patients with inflammatory synovitis differ from those with non-inflammatory disease and suggest that the fibroblastoid cells are responsible for a considerable proportion of the altered phenotypic expression pattern in whole tissue.  Furthermore, this modulated pattern of gene activation appears to be an intrinsic pro-inflammatory characteristic of the fibroblastoid cells initiated in response to chronic inflammation and persists for a prolonged period in the absence of other inflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUd6F-8PCMFbVg90H21EOLACvtfcHk0ljzZdOPYGtGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D&md5=0e00011784fe504612c79350cea6a90a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-3083.1994.tb03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-3083.1994.tb03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DE.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DWinchester%26aufirst%3DR.%26atitle%3DSustained%2520and%2520distinctive%2520patterns%2520of%2520gene%2520activation%2520in%2520synovial%2520fibroblasts%2520and%2520whole%2520synovial%2520tissue%2520obtained%2520from%2520inflammatory%2520synovitis%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1994%26volume%3D40%26spage%3D292%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Takei, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santavirta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span> </span><span class="NLM_article-title">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10782812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=894-899&author=I.+Takeiauthor=M.+Takagiauthor=H.+Idaauthor=T.+Oginoauthor=S.+Santavirtaauthor=Y.+T.+Konttinen&title=High+macrophage-colony+stimulating+factor+levels+in+synovial+fluid+of+loose+artificial+hip+joints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span></div><div class="casAuthors">Takei, Isao; Takagi, Michiaki; Ida, Hideo; Ogino, Toshihiko; Santavirta, Seppo; Konttinen, Yrjo T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-899</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To clarify a macrophage-colony stimulating factor (M-CSF) related mechanism of aseptic loosening of artificial hip joints.  Methods. Synovium-like interface tissues between bone and prosthesis, regenerated pseudocapsular tissues, and synovial fluid (SF) were collected from 9 patients with loose artificial hip joint at revision surgery.  Tissue distribution, prodn. site, and SF level of M-CSF in loose hip joints were investigated by immunohistochem., reverse transcription-polymerase chain reaction (RT-PCR), and ELISA, resp.  For a comparative assessment of the M-CSF level in loose hip joints, SF of active rheumatoid arthritis (RA) and mild osteoarthritis (OA) also were analyzed by ELISA.  Results. Immunohistochem. anal. showed the presence of M-CSF immunoreactive cells mainly in the interface tissues between bone and prosthesis and inner pseudocapsular tissues, both of which were in contact with joint fluid.  RT-PCR anal. confirmed the local prodn. of M-CSF in these periprosthetic tissues.  Significantly higher M-CSF level in loose hip joint fluid than in active RA and mild OA fluid was revealed by ELISA.  Conclusion. High M-CSF level in loose hip joint fluid suggests transportation of M-CSF from prodn. sites to joint fluid.  This indicates that not only polyethylene wear particles (reported to induce foreign body reaction at the bone-prosthesis interface), but also M-CSF, abundant in joint fluid, are transported to and affect the interface.  Thus, M-CSF is locally produced in periprosthetic tissues of loose hip joints and possibly contributes to periprosthetic weakening and osteolysis via joint fluid, leading to prosthetic loosening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlI9pPe59SQbVg90H21EOLACvtfcHk0lhTJqiBaS_ljA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D&md5=08e093f0c23066d5df935638e9fac9d0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakei%26aufirst%3DI.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DSantavirta%26aufirst%3DS.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26atitle%3DHigh%2520macrophage-colony%2520stimulating%2520factor%2520levels%2520in%2520synovial%2520fluid%2520of%2520loose%2520artificial%2520hip%2520joints%26jtitle%3DJ.%2520Rheumatol.%26date%3D2000%26volume%3D27%26spage%3D894%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafiropoulis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, I. K.</span><span> </span><span class="NLM_article-title">Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM-CSF): Evidence of macrophage infiltration and local proliferation</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1046%2Fj.1365-2249.2000.01125.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10632676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1eit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2000&pages=361-367&author=R.+J.+Bischofauthor=D.+Zafiropoulisauthor=J.+A.+Hamiltonauthor=I.+K.+Campbell&title=Exacerbation+of+acute+inflammatory+arthritis+by+the+colony-stimulating+factors+CSF-1+and+granulocyte+macrophage+%28GM-CSF%29%3A+Evidence+of+macrophage+infiltration+and+local+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM-CSF): evidence of macrophage infiltration and local proliferation</span></div><div class="casAuthors">Bischof, R. J.; Zafiropoulos, D.; Hamilton, J. A.; Campbell, I. K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">CSF-1 and GM-CSF have been implicated in the pathogenesis of rheumatoid arthritis.  We report the effects of CSF-1 and GM-CSF in the development of an acute methylated bovine serum albumin (mBSA)-induced murine arthritis model.  Examn. of histopathol. features revealed that the systemic administration of CSF-1 or GM-CSF following mBSA administration into the knee resulted in the exacerbation of arthritis.  This included synovial hyperplasia and joint inflammation, most evident at 7 and 14 days post-mBSA administration, and the appearance of erosive pannus tissue.  The exacerbation by CSF-1 and GM-CSF was not sustained but declined in incidence and severity by 21 days post-mBSA administration, similar to the effects of IL-1β in this model, reported here and previously.  Macrophages expressing Mac-2 and F4/80 were a prominent feature of the pathol. obsd., particularly the infiltration of Mac-2+ macrophages seen in all mice administered CSF-1, GM-CSF or IL-1β.  Present in inflamed knees was a locally dividing population of cells which included Mac-2+ and F4/80+ macrophages.  These studies demonstrate that CSF-1 and GM-CSF can exacerbate and prolong the histopathol. of acute inflammatory arthritis and lend support to monocytes/macrophages being a driving influence in the pathogenesis of inflammatory arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWH8ISBl0mQrVg90H21EOLACvtfcHk0ljga3a6H3ubWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1eit70%253D&md5=e252105e7672e8ae9651b602c729bf66</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2249.2000.01125.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2249.2000.01125.x%26sid%3Dliteratum%253Aachs%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DZafiropoulis%26aufirst%3DD.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26atitle%3DExacerbation%2520of%2520acute%2520inflammatory%2520arthritis%2520by%2520the%2520colony-stimulating%2520factors%2520CSF-1%2520and%2520granulocyte%2520macrophage%2520%2528GM-CSF%2529%253A%2520Evidence%2520of%2520macrophage%2520infiltration%2520and%2520local%2520proliferation%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2000%26volume%3D119%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Abd, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halliday, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span> </span><span class="NLM_article-title">The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate: actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents</span> <span class="citation_source-journal">Lymphokine Cytokine Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=1873358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK3MXks12ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=43-50&author=A.+H.+Abdauthor=N.+W.+Savageauthor=W.+J.+Hallidayauthor=D.+A.+Hume&title=The+role+of+macrophages+in+experimental+arthritis+induced+by+Streptococcus+agalactiae+sonicate%3A+actions+of+macrophage+colony-stimulating+factor+%28CSF-1%29+and+other+macrophage-modulating+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate:  actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents</span></div><div class="casAuthors">Abd, Abdul Hadi A.; Savage, Neil W.; Halliday, William J.; Hume, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Lymphokine and Cytokine Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">LCREEY</span>;
        ISSN:<span class="NLM_cas:issn">1056-5477</span>.
    </div><div class="casAbstract">The i.p. injection of S. agalactiae sonicated cells into Wistar rats causes a chronic relapsing polyarthritis resembling human rheumatoid arthritis.  Evidence is reported favoring a role for macrophages in the pathol. of this disease.  S. agalactiae injected i.p. induced a high level of tumor necrosis factor release by peritoneal macrophages isolated subsequently, and had a similar effect when added to control peritoneal macrophages in culture.  Ia antigen was induced on macrophages in both the peritoneum and affected joints following S. agalactiae injection.  The role of macrophages in the disease process was studied by treating animals prior to S. agalactiae injection with varying concns. of bacterial lipopolysaccharide (LPS), silica, and carrageenan, agents known to have a biphasic effect on macrophage function.  They aggravated the pathol. at low doses but prevented the disease at high doses.  The most specific alteration of macrophage levels was achieved by injection of recombinant human macrophage colony-stimulating factor (CSF-1).  Treatment with CSF-1 early in the disease lead to significant worsening of the pathol.  Administration of CSF-1 after 2 wk reactivated the disease and extended the chronic phase.  These data in combination with previous findings are consistent with nonimmune, macrophage-mediated pathol. for this model of arthritis.  The results have implications for therapeutic application of CSF-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofFEhOzL1k3LVg90H21EOLACvtfcHk0ljga3a6H3ubWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks12ktb8%253D&md5=38e265dc64062a8ac3ef4d9fde84b020</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbd%26aufirst%3DA.%2BH.%26aulast%3DSavage%26aufirst%3DN.%2BW.%26aulast%3DHalliday%26aufirst%3DW.%2BJ.%26aulast%3DHume%26aufirst%3DD.%2BA.%26atitle%3DThe%2520role%2520of%2520macrophages%2520in%2520experimental%2520arthritis%2520induced%2520by%2520Streptococcus%2520agalactiae%2520sonicate%253A%2520actions%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520and%2520other%2520macrophage-modulating%2520agents%26jtitle%3DLymphokine%2520Cytokine%2520Res.%26date%3D1991%26volume%3D10%26spage%3D43%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10914502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=144-150&author=I.+K.+Campbellauthor=M.+J.+Richauthor=R.+J.+Bischofauthor=J.+A.+Hamilton&title=The+colony-stimulating+factors+and+collagen-induced+arthritis%3A+Exacerbation+of+disease+by+M-CSF+and+G-CSF+and+requirement+for+endogenous+M-CSF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span></div><div class="casAuthors">Campbell, Ian K.; Rich, Melissa J.; Bischof, Robert J.; Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">There is increasing evidence that the colony-stimulating factors (CSFs) may play a part in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA).  The authors examd. the involvement of macrophage CSF (M-CSF or CSF-1) and granulocyte CSF (G-CSF) in collagen-induced arthritis (CIA), a murine model of RA.  Daily injections of M-CSF or G-CSF, 20-24 days postprimary immunization with type II collagen, exacerbated disease symptoms in suboptimally immunized DBA/1 mice.  Support for the involvement of endogenous M-CSF in CIA was obtained by studies in which neutralizing monoclonal antibody reduced the severity of established CIA and also by studies showing the resistance of M-CSF-deficient op/op mice to CIA induction.  These studies show that M-CSF and G-CSF can be proinflammatory in CIA and provide evidence that macrophage- and granulocyte-lineage cells can exacerbate CIA.  The authors' results also show that M-CSF-dependent cells are essential for CIA development, suggesting M-CSF may be a suitable target for therapeutic intervention in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobmj_XMRtR77Vg90H21EOLACvtfcHk0lgppSCIrCE--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D&md5=e37a81523dba2270449366102252c4b2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DRich%26aufirst%3DM.%2BJ.%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520colony-stimulating%2520factors%2520and%2520collagen-induced%2520arthritis%253A%2520Exacerbation%2520of%2520disease%2520by%2520M-CSF%2520and%2520G-CSF%2520and%2520requirement%2520for%2520endogenous%2520M-CSF%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2000%26volume%3D68%26spage%3D144%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokieda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohseki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-298&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohsekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-Fms+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhseki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-Fms%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1091</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801406h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1081-1091&author=H.+Huangauthor=D.+A.+Huttaauthor=J.+M.+Rinkerauthor=H.+Huauthor=W.+H.+Parsonsauthor=C.+Schubertauthor=R.+L.+DesJarlaisauthor=C.+S.+Cryslerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=Y.+Chenauthor=D.+Chengauthor=Z.+Zhouauthor=E.+Yurkowauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Pyrido%5B2%2C3-d%5Dpyrimidin-5-ones%3A+A+novel+class+of+antiinflammatory+macrophage+colony-stimulating+factor-1+receptor+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm801406h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801406h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DRinker%26aufirst%3DJ.%2BM.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2520A%2520novel%2520class%2520of%2520antiinflammatory%2520macrophage%2520colony-stimulating%2520factor-1%2520receptor%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1081%26epage%3D1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poda, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michener, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Sa. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1543-1547&author=M.+J.+Meyersauthor=M.+Pelcauthor=S.+Kamtekarauthor=J.+Dayauthor=G.+I.+Podaauthor=M.+K.+Hallauthor=M.+L.+Michenerauthor=B.+A.+Reitzauthor=K.+J.+Mathisauthor=B.+S.+Pierceauthor=M.+D.+Parikhauthor=D.+A.+Mischkeauthor=Sa.+A.+Longauthor=J.+J.+Parlowauthor=D.+A.+Andersonauthor=A.+Thorarensen&title=Structure-based+drug+design+enables+conversion+of+a+DFG-in+binding+CSF-1R+kinase+inhibitor+to+a+DFG-out+binding+mode"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DPelc%26aufirst%3DM.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DJ.%26aulast%3DPoda%26aufirst%3DG.%2BI.%26aulast%3DHall%26aufirst%3DM.%2BK.%26aulast%3DMichener%26aufirst%3DM.%2BL.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DLong%26aufirst%3DSa.%2BA.%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BA.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DStructure-based%2520drug%2520design%2520enables%2520conversion%2520of%2520a%2520DFG-in%2520binding%2520CSF-1R%2520kinase%2520inhibitor%2520to%2520a%2520DFG-out%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1543%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Paniagua, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariano, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, W. H.</span><span> </span><span class="NLM_article-title">c-Fms-mediated differentiation and priming of monocyte lineage cells plays a central role in autoimmune arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">R32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=R32&author=R.+T.+Paniaguaauthor=A.+Changauthor=M.+M.+Marianoauthor=E.+A.+Steinauthor=Q.+Wangauthor=T.+M.+Lindstromauthor=O.+Sharpeauthor=C.+Roscowauthor=P.+P.+Hoauthor=D.+M.+Leeauthor=W.+H.+Robinson&title=c-Fms-mediated+differentiation+and+priming+of+monocyte+lineage+cells+plays+a+central+role+in+autoimmune+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaniagua%26aufirst%3DR.%2BT.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DMariano%26aufirst%3DM.%2BM.%26aulast%3DStein%26aufirst%3DE.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLindstrom%26aufirst%3DT.%2BM.%26aulast%3DSharpe%26aufirst%3DO.%26aulast%3DRoscow%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26atitle%3Dc-Fms-mediated%2520differentiation%2520and%2520priming%2520of%2520monocyte%2520lineage%2520cells%2520plays%2520a%2520central%2520role%2520in%2520autoimmune%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3DR32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ando, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nampei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, H.</span><span> </span><span class="NLM_article-title">Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)</span> <span class="citation_source-journal">J. Bone Miner. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=274-282&author=W.+Andoauthor=J.+Hashimotoauthor=A.+Nampeiauthor=H.+Tsuboiauthor=K.+Tateishiauthor=T.+Onoauthor=N.+Nakamuraauthor=T.+Ochiauthor=H.+Yoshikawa&title=Imatinib+mesylate+inhibits+osteoclastogenesis+and+joint+destruction+in+rats+with+collagen-induced+arthritis+%28CIA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DW.%26aulast%3DHashimoto%26aufirst%3DJ.%26aulast%3DNampei%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DN.%26aulast%3DOchi%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DH.%26atitle%3DImatinib%2520mesylate%2520inhibits%2520osteoclastogenesis%2520and%2520joint%2520destruction%2520in%2520rats%2520with%2520collagen-induced%2520arthritis%2520%2528CIA%2529%26jtitle%3DJ.%2520Bone%2520Miner.%2520Metab.%26date%3D2006%26volume%3D24%26spage%3D274%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span> </span><span class="NLM_article-title">JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3151</span><span class="NLM_x">–</span> <span class="NLM_lpage">3161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1158%2F1535-7163.MCT-09-0255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19887542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3151-3161&author=C.+L.+Mantheyauthor=D.+L.+Johnsonauthor=C.+R.+Illigauthor=R.+W.+Tumanauthor=Z.+Zhouauthor=J.+F.+Bakerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=C.+F.+Franksauthor=L.+Zengauthor=C.+Cryslerauthor=Y.+Chenauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=S.+K.+Meegallaauthor=K.+J.+Wilsonauthor=M.+J.+Wallauthor=J.+Chenauthor=S.+K.+Ballentineauthor=H.+Ottauthor=C.+Baumannauthor=D.+Lawrenceauthor=B.+E.+Tomczukauthor=C.+J.+Molloy&title=JNJ-28312141%2C+a+novel+orally+active+colony-stimulating+factor-1+receptor%2FFMS-related+receptor+tyrosine+kinase-3+receptor+tyrosine+kinase+inhibitor+with+potential+utility+in+solid+tumors%2C+bone+metastases%2C+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia</span></div><div class="casAuthors">Manthey, Carl L.; Johnson, Dana L.; Illig, Carl R.; Tuman, Robert W.; Zhou, Zhao; Baker, Judith F.; Chaikin, Margery A.; Donatelli, Robert R.; Franks, Carol F.; Zeng, Lee; Crysler, Carl; Chen, Yanmin; Yurkow, Edward J.; Boczon, Lisa; Meegalla, Sanath K.; Wilson, Kenneth J.; Wall, Mark J.; Chen, Jinsheng; Ballentine, Shelley K.; Ott, Heidi; Baumann, Christian; Lawrence, Danielle; Tomczuk, Bruce E.; Molloy, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3151-3161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is increasing evidence that tumor-assocd. macrophages promote the malignancy of some cancers.  Colony-stimulating factor-1 (CSF-1) is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation.  Herein, we report the efficacy of a novel orally active CSF-1 receptor (CSF-1R) kinase inhibitor, JNJ-28312141, in proof of concept studies of solid tumor growth and tumor-induced bone erosion.  H460 lung adenocarcinoma cells did not express CSF-1R and were not growth inhibited by JNJ-28312141 in vitro.  Nevertheless, daily p.o. administration of JNJ-28312141 caused dose-dependent suppression of H460 tumor growth in nude mice that correlated with marked redns. in F4/80+ tumor-assocd. macrophages and with increased plasma CSF-1, a possible biomarker of CSF-1R inhibition.  Furthermore, the tumor microvasculature was reduced in JNJ-28312141-treated mice, consistent with a role for macrophages in tumor angiogenesis.  In sep. studies, JNJ-28312141 was compared with zoledronate in a model in which MRMT-1 mammary carcinoma cells inoculated into the tibias of rats led to severe cortical and trabecular bone lesions.  Both agents reduced tumor growth and preserved bone.  However, JNJ-28312141 reduced the no. of tumor-assocd. osteoclasts superior to zoledronate.  JNJ-28312141 exhibited addnl. activity against FMS-related receptor tyrosine kinase-3 (FLT3).  To more fully define the therapeutic potential of this new agent, JNJ-28312141 was evaluated in a FLT3-dependent acute myeloid leukemia tumor xenograft model and caused tumor regression.  In summary, this novel CSF-1R/FLT3 inhibitor represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoczFTUc5L_ULVg90H21EOLACvtfcHk0lggSyJX4Ktr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7zN&md5=075f93c0c1bb1b7efdf07f551cbda1ab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0255%26sid%3Dliteratum%253Aachs%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DTuman%26aufirst%3DR.%2BW.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBaker%26aufirst%3DJ.%2BF.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DFranks%26aufirst%3DC.%2BF.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DOtt%26aufirst%3DH.%26aulast%3DBaumann%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26atitle%3DJNJ-28312141%252C%2520a%2520novel%2520orally%2520active%2520colony-stimulating%2520factor-1%2520receptor%252FFMS-related%2520receptor%2520tyrosine%2520kinase-3%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potential%2520utility%2520in%2520solid%2520tumors%252C%2520bone%2520metastases%252C%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3151%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lggSyJX4Ktr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wustrow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Coupling of arylboronic acid with a partially reduced pyridine derivative</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-1991-26626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=993-995&author=D.+J.+Wustrowauthor=L.+D.+Wise&title=Coupling+of+arylboronic+acid+with+a+partially+reduced+pyridine+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of arylboronic acid with a partially reduced pyridine derivative</span></div><div class="casAuthors">Wustrow, David J.; Wise, Lawrence D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-5</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">1,2,3,6-Tetrahydro-4-[(trifluoromethyl)sulfonyloxy]pyridine-1-carboxylate I (R = tert-butoxycarbonyl, R1 = triflate) was prepd. and underwent palladium-catalyzed coupling reactions with a variety of substituted arylboronic acids to produce a series of tert-butyl-4-aryl-1,2,3,6-tetrahydropyridine-1-carboxylates I (R as above, R1 = substituted Ph, 1-naphthyl).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwI9XvXHB0iLVg90H21EOLACvtfcHk0ljrRXZQrqdAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D&md5=e585b1222bbd08f3a5afd0ffd64cc71f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-1991-26626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1991-26626%26sid%3Dliteratum%253Aachs%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DCoupling%2520of%2520arylboronic%2520acid%2520with%2520a%2520partially%2520reduced%2520pyridine%2520derivative%26jtitle%3DSynthesis%26date%3D1991%26spage%3D993%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Cyano-substituted 2-carboxyimidazoles: Synthesis of 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate potassium salt</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">3377</span><span class="NLM_x">–</span> <span class="NLM_lpage">3379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-0028-1083173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1an" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3377-3379&author=M.+J.+Wallauthor=C.+Schubertauthor=C.+R.+Illig&title=Cyano-substituted+2-carboxyimidazoles%3A+Synthesis+of+4-cyano-1-%7B%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl%7D-1H-imidazole-2-carboxylate+potassium+salt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cyano-substituted 2-carboxyimidazoles: synthesis of 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate potassium salt</span></div><div class="casAuthors">Wall, Mark J.; Schubert, Carsten; Illig, Carl R.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3377-3379</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The first example of a monocyano-substituted 2-carboxyimidazole is reported.  A synthesis of potassium 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate is demonstrated where the carboxyl group is introduced via Br-Mg exchange on a SEM-protected cyanoimidazole followed by reaction with EtO2CCN.  The synthesis includes the equil. of a regioisomeric mixt. of SEM-protected imidazoles to give a single product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES2QhohkQ-LVg90H21EOLACvtfcHk0ljrRXZQrqdAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1an&md5=4dfdfd44932ff10f4781fcbfb82e200f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1055%2Fs-0028-1083173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0028-1083173%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DCyano-substituted%25202-carboxyimidazoles%253A%2520Synthesis%2520of%25204-cyano-1-%257B%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%257D-1H-imidazole-2-carboxylate%2520potassium%2520salt%26jtitle%3DSynthesis%26date%3D2008%26spage%3D3377%26epage%3D3379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2097&author=M.+J.+Wallauthor=J.+Chenauthor=S.+Meegallaauthor=S.+K.+Ballentineauthor=K.+J.+Wilsonauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=M.+A.+Chaikinauthor=C.+S.+Cryslerauthor=I.+Petrouniaauthor=R.+R.+Donatelliauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=M.+Mazzulaauthor=M.+R.+Playerauthor=R.+J.+Patchauthor=C.+L.+Mantheyauthor=C.+J.+Molloyauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Synthesis+and+evaluation+of+novel+3%2C4%2C6-substituted+2-quinolones+as+FMS+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeegalla%26aufirst%3DS.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMazzula%26aufirst%3DM.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25203%252C4%252C6-substituted%25202-quinolones%2520as%2520FMS%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baindur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadra, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiadas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Potent 2-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6070&author=R.+J.+Patchauthor=B.+M.+Brandtauthor=D.+Asgariauthor=N.+Baindurauthor=N.+K.+Chadraauthor=T.+Georgiadasauthor=W.+S.+Cheungauthor=I.+Petrouniaauthor=R.+R.+Donatelliauthor=M.+A.+Chaikinauthor=M.+R.+Player&title=Potent+2-aminoanilide+inhibitors+of+cFMS+as+potential+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DBrandt%26aufirst%3DB.%2BM.%26aulast%3DAsgari%26aufirst%3DD.%26aulast%3DBaindur%26aufirst%3DN.%26aulast%3DChadra%26aufirst%3DN.%2BK.%26aulast%3DGeorgiadas%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DW.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPotent%25202-aminoanilide%2520inhibitors%2520of%2520cFMS%2520as%2520potential%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalk-Hihi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckman, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurlino, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><span class="NLM_x">–</span> <span class="NLM_lpage">4101</span><div class="note"><p class="first last">PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y">2I0Y</a></p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4094-4101&author=C.+Schubertauthor=C.+Schalk-Hihiauthor=G.+T.+Strubleauthor=H.+C.+Maauthor=I.+P.+Petrouniaauthor=B.+Brandtauthor=I.+C.+Deckmanauthor=R.+J.+Patchauthor=M.+R.+Playerauthor=J.+C.+Spurlinoauthor=B.+A.+Springer&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+colony-stimulating+factor-1+receptor+%28cFMS%29+in+complex+with+two+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DSchalk-Hihi%26aufirst%3DC.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DBrandt%26aufirst%3DB.%26aulast%3DDeckman%26aufirst%3DI.%2BC.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DSpurlino%26aufirst%3DJ.%2BC.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528cFMS%2529%2520in%2520complex%2520with%2520two%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4094%26epage%3D4101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, M. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Discovery of novel FMS kinase inhibitors as anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1642</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1642-1648&author=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=M.+J+Rudolphauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Discovery+of+novel+FMS+kinase+inhibitors+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DRudolph%26aufirst%3DM.%2BJ%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520FMS%2520kinase%2520inhibitors%2520as%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1642%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_contrib-group">Kaplowitz, N.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug hepatotoxicity</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=489-499&author=N.+Kaplowitz&title=Idiosyncratic+drug+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaplowitz%26aufirst%3DN.%26atitle%3DIdiosyncratic%2520drug%2520hepatotoxicity%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D489%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_contrib-group">Ju, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, J. P.</span><span> </span><span class="NLM_article-title">Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1389200023337333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12093356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=367-377&author=C.+Juauthor=J.+P.+Uetrecht&title=Mechanism+of+idiosyncratic+drug+reactions%3A+Reactive+metabolite+formation%2C+protein+binding+and+the+regulation+of+the+immune+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system</span></div><div class="casAuthors">Ju, C.; Uetrecht, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced adverse reactions, esp. type B reactions, represent a major clin. problem.  They also impart a significant degree of uncertainty into drug development because they are often not detected until the drug has been released onto the market.  Type B reactions are also termed idiosyncratic drug reactions by many investigators due to their unpredictable nature and our lack of understanding of the mechanisms involved.  It is currently believed that the majority of these reactions are immune-mediated and are caused by immunogenic conjugates formed from the reaction of a reactive metabolite of a drug with cellular proteins.  It has been shown that most drugs assocd. with idiosyncratic reactions form reactive metabolites to some degree.  Covalent binding of reactive metabolites to cellular proteins has also been shown in many cases.  However, studies to reveal the role of reactive metabolites and their protein-adducts in the mechanism of drug-induced idiosyncratic reactions are lacking.  This review will focus on our current understanding and speculative views on how a reactive metabolite of a drug might ultimately lead to immune-mediated toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpowmI5awuRjLVg90H21EOLACvtfcHk0liRRUu4qNSKsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCqtrg%253D&md5=c678c3f4bcf9a775bedb690c6986381e</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.2174%2F1389200023337333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337333%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DC.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DMechanism%2520of%2520idiosyncratic%2520drug%2520reactions%253A%2520Reactive%2520metabolite%2520formation%252C%2520protein%2520binding%2520and%2520the%2520regulation%2520of%2520the%2520immune%2520system%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D367%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva Elipe., M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arison, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgey, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx025635l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=198-207&author=R.+Singhauthor=M.+V.+Silva+Elipe.author=P.+G.+Pearsonauthor=B.+H.+Arisonauthor=B.+K.+Wongauthor=R.+Whiteauthor=X.+Yuauthor=C.+S.+Burgeyauthor=J.+H.+Linauthor=T.+A.+Baillie&title=Metabolic+activation+of+a+pyrazinone-containing+thrombin+inhibitor.+Evidence+for+novel+biotransformation+involving+pyrazinone+ring+oxidation%2C+rearrangement%2C+and+covalent+binding+to+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx025635l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx025635l%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSilva%2BElipe.%26aufirst%3DM.%2BV.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DArison%26aufirst%3DB.%2BH.%26aulast%3DWong%26aufirst%3DB.%2BK.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolic%2520activation%2520of%2520a%2520pyrazinone-containing%2520thrombin%2520inhibitor.%2520Evidence%2520for%2520novel%2520biotransformation%2520involving%2520pyrazinone%2520ring%2520oxidation%252C%2520rearrangement%252C%2520and%2520covalent%2520binding%2520to%2520proteins%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2003%26volume%3D16%26spage%3D198%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Structure-based optimization of a potent class of arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3632</span><span class="NLM_x">–</span> <span class="NLM_lpage">3637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3632-3637&author=S.+K.+Meegallaauthor=M.+J.+Wallauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Structure-based+optimization+of+a+potent+class+of+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DStructure-based%2520optimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3632%26epage%3D3637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Illig, C. R.; Ballentine, S. K.; Chen, J.; Meegalla, S.; Rudolph, J.; Wall, M. J.; Wilson, K. J.; Desjarlais, R.; Manthey, C. L.; Flores, C. M.; Molloy, C. J.</span><span> </span><span class="NLM_article-title">Preparation of aromatic amides as inhibitors of c-fms kinase</span>. PCT Int. Pat. Appl. WO 2006047504 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+R.+Illig&author=S.+K.+Ballentine&author=J.+Chen&author=S.+Meegalla&author=J.+Rudolph&author=M.+J.+Wall&author=K.+J.+Wilson&author=R.+Desjarlais&author=C.+L.+Manthey&author=C.+M.+Flores&author=C.+J.+Molloy&title=Preparation+of+aromatic+amides+as+inhibitors+of+c-fms+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DPreparation%2520of%2520aromatic%2520amides%2520as%2520inhibitors%2520of%2520c-fms%2520kinase%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">RCSB Protein Data Bank</span><span class="NLM_x">. An Information Portal to Biological MacromolecularStructures. </span><a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRL" class="extLink">http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRL</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RCSB+Protein+Data+Bank.+An+Information+Portal+to+Biological+MacromolecularStructures.+http%3A%2F%2Fwww.rcsb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D3KRL+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">RCSB Protein Data Bank</span><span class="NLM_x">. An Information Portal to Biological Macromolecular Structures. </span><a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRJ" class="extLink">http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRJ</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RCSB+Protein+Data+Bank.+An+Information+Portal+to+Biological+Macromolecular+Structures.+http%3A%2F%2Fwww.rcsb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D3KRJ+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">DeLano, W. L.</span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>; <span class="NLM_publisher-name">DeLano Scientific</span>: <span class="NLM_publisher-loc">Palo Alto, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span><span class="NLM_x">; </span><a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a> (accessed November 17,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=W.+L.+DeLano&title=The+PyMOL+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520Scientific%26date%3D2002%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Orlofsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1-induced gene expression in macrophages; dissociation from the mitogenic response</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2947</span><span class="NLM_x">–</span> <span class="NLM_lpage">2952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1987&pages=2947-2952&author=A.+Orlofskyauthor=E.+R.+Stanley&title=CSF-1-induced+gene+expression+in+macrophages%3B+dissociation+from+the+mitogenic+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlofsky%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1-induced%2520gene%2520expression%2520in%2520macrophages%253B%2520dissociation%2520from%2520the%2520mitogenic%2520response%26jtitle%3DEMBO%2520J.%26date%3D1987%26volume%3D6%26spage%3D2947%26epage%3D2952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit42"><span>The Cerep high-throughput profile consists of a broad collection of 50 transmembrane and soluble receptors, ion channels, and monoamine transporters designed to provide information not only on potential limitations or liabilities of drug candidates but also for off-target activity identification. For the test compounds, the results are expressed as a percent inhibition of control-specific binding (mean values, <i>n</i> = 2); <a href="http://www.cerep.fr/Cerep/Users/index.asp" class="extLink">http://www.cerep.fr/Cerep/Users/index.asp</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Cerep+high-throughput+profile+consists+of+a+broad+collection+of+50+transmembrane+and+soluble+receptors%2C+ion+channels%2C+and+monoamine+transporters+designed+to+provide+information+not+only+on+potential+limitations+or+liabilities+of+drug+candidates+but+also+for+off-target+activity+identification.+For+the+test+compounds%2C+the+results+are+expressed+as+a+percent+inhibition+of+control-specific+binding+%28mean+values%2C+n+%3D+2%29%3B+http%3A%2F%2Fwww.cerep.fr%2FCerep%2FUsers%2Findex.asp+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit43"><span>The p<i>K</i><sub>a</sub> of the conjugate acid of the piperidine was calculated using Advanced Chemistry Development (ACD/Labs) Software v12.0; <a href="http://www.acdlabs.com" class="extLink">http://www.acdlabs.com</a> (accessed September 10,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+pKa+of+the+conjugate+acid+of+the+piperidine+was+calculated+using+Advanced+Chemistry+Development+%28ACD%2FLabs%29+Software+v12.0%3B+http%3A%2F%2Fwww.acdlabs.com+%28accessed+September+10%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit44a"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+Dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+Roche+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520Dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520Roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit44b"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling promiscuity based on in vitro safety pharmacology profiling data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+J.+Jenkinsauthor=L.+Urban&title=Modeling+promiscuity+based+on+in+vitro+safety+pharmacology+profiling+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44bR"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0lh5i2UODm4QwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BJ.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520promiscuity%2520based%2520on%2520in%2520vitro%2520safety%2520pharmacology%2520profiling%2520data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit44c"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit44d"><span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span> </span><span class="NLM_article-title">Charting the chemical space of target sites: Insights into the binding modes of amine and amidine groups</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci800414v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44d&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlegtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=900-912&author=A.+Macchiaruloauthor=R.+Nutiauthor=G.+Erenauthor=R.+Pellicciari&title=Charting+the+chemical+space+of+target+sites%3A+Insights+into+the+binding+modes+of+amine+and+amidine+groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44dR"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Charting the Chemical Space of Target Sites: Insights into the Binding Modes of Amine and Amidine Groups</span></div><div class="casAuthors">Macchiarulo, Antonio; Nuti, Roberto; Eren, Gokcen; Pellicciari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">900-912</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nowadays there is growing awareness that the translation of the increasing no. of lead compds. into clin. candidates is still a slow and often inefficient process.  In order to facilitate the lead optimization procedure, due consideration must be given to the use of the correct bioisosteric replacements.  Very recently, it was reported that exploring a chem. space of binding sites is a more effective strategy for studying the bioisosteric relationships existing among functional groups.  As a continuation of the work in this field, the authors report herein the construction of a chem. space covered by binding sites of small mols. contg. diverse amine and amidine groups.  The anal. of the differences in some properties of the binding sites of these functional groups allow for gaining insights into the binding modes of pos. charged groups.  In addn., this study pinpoints that different types of interactions and bioisosteric relationships exist among primary, secondary, tertiary, quaternary amine, and amidine moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFrjE_jvqRMLVg90H21EOLACvtfcHk0ljqixdB9saccA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlegtbs%253D&md5=69a36dd8ca3908dad887954b510249ac</span></div><a href="/servlet/linkout?suffix=cit44d&amp;dbid=16384&amp;doi=10.1021%2Fci800414v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800414v%26sid%3Dliteratum%253Aachs%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DNuti%26aufirst%3DR.%26aulast%3DEren%26aufirst%3DG.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DCharting%2520the%2520chemical%2520space%2520of%2520target%2520sites%253A%2520Insights%2520into%2520the%2520binding%2520modes%2520of%2520amine%2520and%2520amidine%2520groups%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D900%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_contrib-group">Starmer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lastra, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, A. O.</span><span> </span><span class="NLM_article-title">Cardiac instability amplified by use-dependent sodium channel blockade</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">262</span><span class="NLM_x">, </span> <span class="NLM_fpage">H1305</span><span class="NLM_x">–</span> <span class="NLM_lpage">H1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1992&pages=H1305-H1310&author=C.+F.+Starmerauthor=A.+R.+Lancasterauthor=A.+A.+Lastraauthor=A.+O.+Grant&title=Cardiac+instability+amplified+by+use-dependent+sodium+channel+blockade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStarmer%26aufirst%3DC.%2BF.%26aulast%3DLancaster%26aufirst%3DA.%2BR.%26aulast%3DLastra%26aufirst%3DA.%2BA.%26aulast%3DGrant%26aufirst%3DA.%2BO.%26atitle%3DCardiac%2520instability%2520amplified%2520by%2520use-dependent%2520sodium%2520channel%2520blockade%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1992%26volume%3D262%26spage%3DH1305%26epage%3DH1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45b"><span><span class="NLM_contrib-group">Hiroaka, M.</span> In  <span class="citation_source-book">Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention</span>; <span class="NLM_contrib-group">Gussak, I.; Antzelevitch, C.; Wilde, A. A. M.; Friedman, P. A.; Ackerman, M. J.; Shen, W.-K.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1007%2F978-1-84628-854-8_49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=691-704&author=M.+Hiroakaauthor=I.+Gussak&author=C.+Antzelevitch&author=A.+A.+M.+Wilde&author=P.+A.+Friedman&author=M.+J.+Ackerman&author=W.-K.+Shen&title=Electrical+Diseases+of+the+Heart%3A+Genetics%2C+Mechanisms%2C+Treatment%2C+Prevention"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1007%2F978-1-84628-854-8_49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-84628-854-8_49%26sid%3Dliteratum%253Aachs%26aulast%3DHiroaka%26aufirst%3DM.%26btitle%3DElectrical%2520Diseases%2520of%2520the%2520Heart%253A%2520Genetics%252C%2520Mechanisms%252C%2520Treatment%252C%2520Prevention%26aulast%3DGussak%26aufirst%3DI.%26pub%3DSpringer%26date%3D2008%26spage%3D691%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_contrib-group">Clusin, W. T.</span><span> </span><span class="NLM_article-title">Calcium and cardiac arrhythmias: DADs, EADs, and alternans</span> <span class="citation_source-journal">Crit. Rev. Clin. Lab. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1080%2F713609356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12892319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVWhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2003&pages=337-375&author=W.+T.+Clusin&title=Calcium+and+cardiac+arrhythmias%3A+DADs%2C+EADs%2C+and+alternans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46aR"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium and cardiac arrhythmias: DADs, EADs, and alternans</span></div><div class="casAuthors">Clusin, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-375</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">CRC Press LLC</span>)
        </div><div class="casAbstract">A review.  Rapid progress has been made in understanding the mol. mechanisms by which calcium ions mediate certain cardiac arrhythmias.  Principal advances include imaging of cytosolic calcium in isolated cells and in intact tissues, use of fluorescent indicators and monophasic action potentials to record membrane potentials in isolated tissue, and sequencing of the genes that encode crit. ion channel proteins.  In this review, five types of arrhythmias are discussed where calcium ion currents, or currents controlled by calcium, appear to be responsible for arrythmogenesis.  These include: (1) the delayed afterpotential that occurs in conditions of intracellular calcium overload such as digitalis toxicity; (2) the early afterdepolarization that occurs when action potential duration is prolonged; (3) the slowly conducted calcium-dependent action potential (the slow response) in the SA and AV nodes; (4) the phenomenon of calcium transient alternans during ischemia, which is related to action potential duration alternans and t-wave alternans; (5) catecholamine-induced cardiac arrhythmias in families with mutations of the sarcoplasmic reticulum calcium-release channel.  For each type of arrhythmia, the clin. implications of emerging knowledge are discussed.  An esp. important issue is whether ventricular fibrillation during acute coronary artery occlusion is due to calcium transient alternans.  Ventricular fibrillation due to acute ischemia is an important subset of the 400,000 sudden cardiac deaths that occur annually in the U.S.  Certain drugs, including beta blockers, fish oils, verapamil, and diltiazem, seem to specifically prevent ventricular fibrillation in this setting, and in most cases an effect of the drug on cytosolic calcium appears to be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlOfaKoLDBnLVg90H21EOLACvtfcHk0ljIQ800CYMkIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVWhs7k%253D&md5=7c0eec58458a3e4102b97ebb3f2ca22a</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1080%2F713609356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F713609356%26sid%3Dliteratum%253Aachs%26aulast%3DClusin%26aufirst%3DW.%2BT.%26atitle%3DCalcium%2520and%2520cardiac%2520arrhythmias%253A%2520DADs%252C%2520EADs%252C%2520and%2520alternans%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2003%26volume%3D40%26spage%3D337%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit46b"><span><span class="NLM_contrib-group">Salhanick, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, M. W.</span><span> </span><span class="NLM_article-title">Management of calcium channel antagonist overdose</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2165%2F00002018-200326020-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12534324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1yqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=65-79&author=S.+D.+Salhanickauthor=M.+W.+Shannon&title=Management+of+calcium+channel+antagonist+overdose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46bR"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Management of calcium channel antagonist overdose</span></div><div class="casAuthors">Salhanick, Steven D.; Shannon, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-79</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Calcium channel antagonists are used primarily for the treatment of hypertension and tachyarrhythmias.  Overdose of calcium channel antagonists can be lethal.  Calcium channel antagonists act at the L-type calcium channels primarily in cardiac and vascular smooth muscle preventing calcium influx into cells with resultant decreases in vascular tone and cardiac inotropy and chronotropy.  The L-type calcium channel is a complex structure and is thus affected by a large no. of structurally diverse antagonists.  In the setting of overdose, patients may experience vasodilatation and bradycardia leading to a shock state.  Patients may also be hyperglycemic and acidotic due to the blockade of L-type calcium channels in the pancreatic islet cells that affect insulin secretion.  Aggressive therapy is warranted in the setting of toxicity.  Gut decontamination with charcoal, or whole bowel irrigation or multiple-dose charcoal in the setting of extended-release products is indicated.  Specific antidotes include calcium salts, glucagon and insulin.  Calcium salts may be given in bolus doses or may be employed as a continuous infusion.  Care should be exercised to avoid the administration of calcium in the setting of concomitant digoxin toxicity.  Insulin administration has been used effectively to increase cardiac inotropy and survival.  The likely mechanism involves a shift to carbohydrate metab. in the setting of decreased availability of carbohydrates due to decreased insulin secretion secondary to blockade of calcium channels in pancreatic islet cells.  Glucose should be administered as well to maintain euglycemia.  Supportive care including the use of phosphodiesterase inhibitors, adrenergic agents, cardiac pacing, balloon pump or extracorporeal bypass is frequently indicated if antidotal therapy is not effective.  Careful evaluation of asymptomatic patients, including and ECG and a period of observation, is indicated.  Patients ingesting a nonsustained-release product should be obsd. in a monitored setting for 12 h, while those who ingest a sustained-release prepn. should be obsd. for no less than 24 h.  Charcoal should be given to the asymptomatic patient with a history of calcium channel antagonist overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqOfWkIunbLVg90H21EOLACvtfcHk0ljIQ800CYMkIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1yqsL0%253D&md5=41407c8fbe641f8bc2da397848718a74</span></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=10.2165%2F00002018-200326020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200326020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DSalhanick%26aufirst%3DS.%2BD.%26aulast%3DShannon%26aufirst%3DM.%2BW.%26atitle%3DManagement%2520of%2520calcium%2520channel%2520antagonist%2520overdose%26jtitle%3DDrug%2520Saf.%26date%3D2003%26volume%3D26%26spage%3D65%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit46c"><span><span class="NLM_contrib-group">Packer, M.</span><span> </span><span class="NLM_article-title">Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">IV59</span><span class="NLM_x">–</span> <span class="NLM_lpage">IV67</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1989&pages=IV59-IV67&author=M.+Packer&title=Pathophysiological+mechanisms+underlying+the+adverse+effects+of+calcium+channel-blocking+drugs+in+patients+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26atitle%3DPathophysiological%2520mechanisms%2520underlying%2520the%2520adverse%2520effects%2520of%2520calcium%2520channel-blocking%2520drugs%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DCirculation%26date%3D1989%26volume%3D80%26spage%3DIV59%26epage%3DIV67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3925</span><span class="NLM_x">–</span> <span class="NLM_lpage">3929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3925-3929&author=K.+J.+Wilsonauthor=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=R.+Donatelliauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Reducing+ion+channel+activity+in+a+series+of+4-heterocyclic+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDonatelli%26aufirst%3DR.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DReducing%2520ion%2520channel%2520activity%2520in%2520a%2520series%2520of%25204-heterocyclic%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3925%26epage%3D3929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emms, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broten, T.</span><span> </span><span class="NLM_article-title">3-(1-Piperazinyl)-4,5-dihydro-1<i>H</i>-benzo[<i>g</i>]indazoles: High affinity ligands for the human dopamine D<sub>4</sub> receptor with improved selectivity over ion channels</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=743-753&author=I.+Collinsauthor=M.+Rowleyauthor=W.+B.+Daveyauthor=F.+Emmsauthor=R.+Marwoodauthor=S.+Patelauthor=S.+Patelauthor=A.+Fletcherauthor=I.+C.+Raganauthor=P.+D.+Leesonauthor=A.+L.+Scottauthor=T.+Broten&title=3-%281-Piperazinyl%29-4%2C5-dihydro-1H-benzo%5Bg%5Dindazoles%3A+High+affinity+ligands+for+the+human+dopamine+D4+receptor+with+improved+selectivity+over+ion+channels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDavey%26aufirst%3DW.%2BB.%26aulast%3DEmms%26aufirst%3DF.%26aulast%3DMarwood%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DA.%26aulast%3DRagan%26aufirst%3DI.%2BC.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DScott%26aufirst%3DA.%2BL.%26aulast%3DBroten%26aufirst%3DT.%26atitle%3D3-%25281-Piperazinyl%2529-4%252C5-dihydro-1H-benzo%255Bg%255Dindazoles%253A%2520High%2520affinity%2520ligands%2520for%2520the%2520human%2520dopamine%2520D4%2520receptor%2520with%2520improved%2520selectivity%2520over%2520ion%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D743%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_contrib-group">Ladduwahetty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boase, A. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchinson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span> </span><span class="NLM_article-title">A new class of selective, non-basic 5-HT2A receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3201</span><span class="NLM_x">–</span> <span class="NLM_lpage">3204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3201-3204&author=T.+Ladduwahettyauthor=A.+L+Boaseauthor=A.+Mitchinsonauthor=C.+Quinauthor=S.+Patelauthor=K.+Chapmanauthor=A.+M.+MacLeod&title=A+new+class+of+selective%2C+non-basic+5-HT2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadduwahetty%26aufirst%3DT.%26aulast%3DBoase%26aufirst%3DA.%2BL%26aulast%3DMitchinson%26aufirst%3DA.%26aulast%3DQuin%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520class%2520of%2520selective%252C%2520non-basic%25205-HT2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3201%26epage%3D3204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit49b"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rancovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49bR"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lhpW8UaH0UTHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRancovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Bertz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granneman, G. R.</span><span> </span><span class="NLM_article-title">Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2165%2F00003088-199732030-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=9084960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2sXisV2ks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1997&pages=210-258&author=R.+J.+Bertzauthor=G.+R.+Granneman&title=Use+of+in+vitro+and+in+vivo+data+to+estimate+the+likelihood+of+metabolic+pharmacokinetic+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions</span></div><div class="casAuthors">Bertz, Richard J.; Granneman, G. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-258</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">This article reviews with 681 refs. the information available to assist pharmacokineticists in the prediction of metabolic drug interactions.  Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P 450 (CYP) isoform(s) metabolizing a particular drug as well as the ability of a drug to inhibit a specific CYP isoform.  The major isoforms involved in human drug metab. are CYP3A, CYP2D6, CYP2C, CYP1A2 and CYP2E1.  Often patients are taking multiple concurrent medications, and thus an assessment of potential drug-drug interactions is imperative.  A database contg. information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquant. prediction of the magnitude of potential interactions with drugs under development.  With knowledge of the in vitro inhibition const. of a drug (Ki) for a particular CYP isoform, it is theor. possible to assess the likelihood of interactions for a drug cleared through CYP-mediated metab.  For many agents, the CYP isoform involved in metab. has not been identified and there is substantial uncertainty given the current knowledge base.  The math. concepts for prediction based on competitive enzyme inhibition are reviewed in this article.  These relationships become more complex if the inhibition is of a mixed competitive/noncompetitive nature.  Sources of un.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtRdmXMijOLVg90H21EOLACvtfcHk0lhu8-OEJdLZdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisV2ks7s%253D&md5=6c2f7e6452c1493598cc9eecf8f03f21</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2165%2F00003088-199732030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199732030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DBertz%26aufirst%3DR.%2BJ.%26aulast%3DGranneman%26aufirst%3DG.%2BR.%26atitle%3DUse%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520data%2520to%2520estimate%2520the%2520likelihood%2520of%2520metabolic%2520pharmacokinetic%2520interactions%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D32%26spage%3D210%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1386207013331101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=11375740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkt1Crt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=245-263&author=C.+M.+Masimirembwaauthor=R.+Thompsonauthor=T.+B.+Andersson&title=In+vitro+high+throughput+screening+of+compounds+for+favorable+metabolic+properties+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery</span></div><div class="casAuthors">Masimirembwa, Collen M.; Thompson, Richard; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry and High Throughput Screening</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-263</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Drug metab. can have profound effects on the pharmacol. and toxicol. profile of therapeutic agents.  In the pharmaceutical industry, many in vitro techniques are in place or under development to screen and optimize compds. for favorable metabolic properties in the drug discovery phase.  These in vitro technologies are meant to address important issues such as: (1) is the compd. a potent inhibitor of drug metabolizing enzymes (DMEs) (2) does the compd. induce the expression of DMEs (3) how labile is the compd. to metabolic degrdn. (4) which specific enzyme(s) is responsible for the compd.'s biotransformation and (5) to which metabolites is the compd. metabolized.  Answers to these questions provide a basis for judging whether a compd. is likely to have acceptable pharmacokinetic properties in vivo.  To address these issues on the increasing no. of compds. inundating the drug discovery programs, high throughput assays are essential.  A combination of biochem. advances in the understanding of the function and regulation of DMEs (in particular, cytochromes P 450, CYPs) and automated anal. technologies are revolutionizing drug metab. research.  Automated LC-MS based metabolic stability, fluorescence, radiometric and LC-MS based CYP inhibition assays are now in routine use.  Automatable models for studying CYP induction based on enzyme activity, quant. RT-PCR and reporter gene systems are being developed.  We will review the utility and limitations of these HTS approaches and highlight on-going developments and emerging technologies to answer metab. questions at the different stages of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMkDhwueLF7Vg90H21EOLACvtfcHk0lhu8-OEJdLZdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkt1Crt7w%253D&md5=17b5e9e3944e129ed1064682b37390c3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1386207013331101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207013331101%26sid%3Dliteratum%253Aachs%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DIn%2520vitro%2520high%2520throughput%2520screening%2520of%2520compounds%2520for%2520favorable%2520metabolic%2520properties%2520in%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2001%26volume%3D4%26spage%3D245%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwiezer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Roder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schwiezerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lh7r9VsCRBFjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchwiezer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit53a"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53aR"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lh7r9VsCRBFjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit53b"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitcheson, J. S.</span><span> </span><span class="NLM_article-title">Predicting drug-hERG channel interactions that cause acquired long QT syndrome</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=119-124&author=M.+C.+Sanguinettiauthor=J.+S.+Mitcheson&title=Predicting+drug-hERG+channel+interactions+that+cause+acquired+long+QT+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DMitcheson%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520drug-hERG%2520channel%2520interactions%2520that%2520cause%2520acquired%2520long%2520QT%2520syndrome%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D119%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit54a"><span><span class="NLM_contrib-group">Geissler, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D. E.</span><span> </span><span class="NLM_article-title">The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=185-192&author=E.+N.+Geisslerauthor=M.+A.+Ryanauthor=D.+E.+Housman&title=The+dominant-white+spotting+%28W%29+locus+of+the+mouse+encodes+the+c-kit+proto-oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeissler%26aufirst%3DE.%2BN.%26aulast%3DRyan%26aufirst%3DM.%2BA.%26aulast%3DHousman%26aufirst%3DD.%2BE.%26atitle%3DThe%2520dominant-white%2520spotting%2520%2528W%2529%2520locus%2520of%2520the%2520mouse%2520encodes%2520the%2520c-kit%2520proto-oncogene%26jtitle%3DCell%26date%3D1988%26volume%3D55%26spage%3D185%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit54b"><span><span class="NLM_contrib-group">Bijangi-Vishehsaraei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadatzadeh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson McKenzie, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichijo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haneline, L. S.</span><span> </span><span class="NLM_article-title">Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4124</span><span class="NLM_x">–</span> <span class="NLM_lpage">4130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=4124-4130&author=K.+Bijangi-Vishehsaraeiauthor=M.+R.+Saadatzadehauthor=A.+Werneauthor=K.+A.+Wilson+McKenzieauthor=R.+Kapurauthor=H.+Ichijoauthor=L.+S.+Haneline&title=Enhanced+TNF-alpha-induced+apoptosis+in+Fanconi+anemia+type+C-deficient+cells+is+dependent+on+apoptosis+signal-regulating+kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBijangi-Vishehsaraei%26aufirst%3DK.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DWerne%26aufirst%3DA.%26aulast%3DWilson%2BMcKenzie%26aufirst%3DK.%2BA.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DHaneline%26aufirst%3DL.%2BS.%26atitle%3DEnhanced%2520TNF-alpha-induced%2520apoptosis%2520in%2520Fanconi%2520anemia%2520type%2520C-deficient%2520cells%2520is%2520dependent%2520on%2520apoptosis%2520signal-regulating%2520kinase%25201%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D4124%26epage%3D4130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Trentham, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townes, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. H.</span><span> </span><span class="NLM_article-title">Autoimmunity to type II collagen: an experimental model of arthritis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=857-868&author=D.+E.+Trenthamauthor=A.+S.+Townesauthor=A.+H.+Kang&title=Autoimmunity+to+type+II+collagen%3A+an+experimental+model+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrentham%26aufirst%3DD.%2BE.%26aulast%3DTownes%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DA.%2BH.%26atitle%3DAutoimmunity%2520to%2520type%2520II%2520collagen%253A%2520an%2520experimental%2520model%2520of%2520arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D857%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Bendele, A. M.</span><span> </span><span class="NLM_article-title">Animal models of rheumatoid arthritis</span> <span class="citation_source-journal">J. Musculoskeletal Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15758488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=377-385&author=A.+M.+Bendele&title=Animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of rheumatoid arthritis</span></div><div class="casAuthors">Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Musculoskeletal & Neuronal Interactions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JMNIB3</span>;
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    
            (<span class="NLM_cas:orgname">Journal of Musculoskeletal and Neuronal Interactions</span>)
        </div><div class="casAbstract">A review.  Animal models of arthritis are used to study pathogenesis of disease and to evaluate potential anti-arthritic drugs for clin. use.  Therefore morphol. similarities to human disease and capacity of the model to predict efficacy in humans are important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability for efficacy in humans include: rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis and antigen-induced arthritis in several species.  Agents currently in clin. use (or trials) that are active in these models include: corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide interleukin-1 receptor antagonist (IL-1ra) and sol. TNF receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged dosing periods would preclude dosing in humans at levels that might provide disease modifying effects.  Data, conduct and features of the various models of these commonly utilized models of RA as well as some transgenic mouse models and less commonly utilized rodent models will be discussed with emphasis on their similarities to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhtLWBEJFcbVg90H21EOLACvtfcHk0ljz_PO-VmjP4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D&md5=21f16894bcfdad981a6b7d32773431cf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%2BM.%26atitle%3DAnimal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Musculoskeletal%2520Interact.%26date%3D2001%26volume%3D1%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Joosten, L. A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helsen, M. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Loo, F. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Berg, W. B.</span><span> </span><span class="NLM_article-title">Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780390513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8639177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK28XjsValtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=797-809&author=L.+A.+B.+Joostenauthor=M.+M.+A.+Helsenauthor=F.+A.+J.+Van+de+Looauthor=W.+B.+Van+den+Berg&title=Anticytokine+treatment+of+established+type+II+collagen-induced+arthritis+in+DBA%2F1+mice%3A+A+comparative+study+using+anti-TNF%CE%B1%2C+anti-IL-1%CE%B1%2F%CE%B2%2C+and+IL-1Ra"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra</span></div><div class="casAuthors">Joosten, Leo A. B.; Helsen, Monique M. A.; Van De Loo, Fons A. J.; Van Den Berg, Wim B.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">797-809</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The authors examd. the role of tumor necrosis factor α (TNF α), interleukin-1α (IL-1α), and IL-1β in collagen-induced arthritis (CIA), immediately after onset and during the phase of established arthritis.  Male DBA/1 mice with collagen-induced arthritis were treated with antibodies against murine TNF α and IL-1α/β at different time points of the disease.  IL-1 receptor antagonist (IL-1Ra) was administered using Alzet osmotic mini-pumps.  The effect of anti-cytokine treatment was monitored by visual scoring.  Histol. and cytokine reverse transcription polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period.  Anti-TNF α treatment showed efficacy shortly after onset of the disease, but had little effect on fully established CIA.  Histol. anal. after early treatment revealed that anti-TNF α significantly reduced joint pathol., as detd. by infiltration of inflammatory cells and cartilage damage.  Anti-IL-1α/β treatment ameliorated both early and full-blown CIA.  This clear suppression of established arthritis was confirmed by administration of high doses of IL-1Ra.  Dose-response expts. showed that a continuous supply of 1 mg/day was needed for optimal suppression.  Histol. anal. showed markedly reduced cartilage destruction both in the knee and the ankle joints.  Autoradiog. demonstrated full recovery of chondrocyte synthetic function of articular cartilage.  In addn., the authors found that the IL-1β isoform plays a dominant role in established CIA.  Profound suppression of CIA was obsd. with anti-IL-1β, although elimination of both IL-1α and IL-1β still gave better protection.  Anal. of mRNA with RT-PCR revealed that IL-1β was highly upregulated in synovium and cartilage at late stages of CIA, whereas anti-IL-1β treatment markedly reduced IL-1β message in the synovium.  The present study identified different TNFα/IL-1 dependencies in various stages of CIA and revealed that blocking of TNFα does not necessarily eliminate IL-1.  Continuous, high doses of IL-1Ra are needed to block CIA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPs5rv07Iyo7Vg90H21EOLACvtfcHk0liCJg6EPVanVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsValtLc%253D&md5=cb86f131237c1b630e0d039215f52d72</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fart.1780390513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780390513%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%2BA.%26aulast%3DVan%2Bde%2BLoo%26aufirst%3DF.%2BA.%2BJ.%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DW.%2BB.%26atitle%3DAnticytokine%2520treatment%2520of%2520established%2520type%2520II%2520collagen-induced%2520arthritis%2520in%2520DBA%252F1%2520mice%253A%2520A%2520comparative%2520study%2520using%2520anti-TNF%25CE%25B1%252C%2520anti-IL-1%25CE%25B1%252F%25CE%25B2%252C%2520and%2520IL-1Ra%26jtitle%3DArthritis%2520Rheum.%26date%3D1996%26volume%3D39%26spage%3D797%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">De Clerck, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Aubioul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rossem, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Ammel, K.</span><span> </span><span class="NLM_article-title">In vivo measurement of QT prolongation, dispersion and arrythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1046%2Fj.1472-8206.2002.00081.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12031065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFOrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=125-140&author=F.+De+Clerckauthor=A.+Van+de+Waterauthor=J.+D%E2%80%99Aubioulauthor=H.+R.+Luauthor=K.+van+Rossemauthor=A.+Hermansauthor=K.+Van+Ammel&title=In+vivo+measurement+of+QT+prolongation%2C+dispersion+and+arrythmogenesis%3A+Application+to+the+preclinical+cardiovascular+safety+pharmacology+of+a+new+chemical+entity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity</span></div><div class="casAuthors">De Clerck, Fred; Van de Water, Andre; D'Aubioul, Jan; Lu, Hua Rong; van Rossem, Koen; Hermans, An; Van Ammel, Karel</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-140</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review.  In addn. to in silico and in vitro measurements, cardiac electrophysiol. in exptl. animals plays a decisive role in the selection of a potential "cardio-safe" new chem. entity (NCE).  The present synopsis critically reviews such in vivo techniques in exptl. animals.  In anesthetized guinea-pigs, surface eCG recordings readily identify the typical effects of Class I to IV anti-arrhythmic compds. and of If blockers such as zatebradine on eCG intervals and morphol., but also of non-cardiovascular NCEs affecting cardiac elec. activity via ion channels or neurogenic mechanisms.  QT/RR plots indicate that bradycardia is a dominant effect of IKr blockers (dual modulation by IKr of sinus node activity and ventricular repolarization).  Nevertheless, correction of QT with Bazett's formula usually distinguishes between drug-induced heart rate redn. and real prolongation of ventricular repolarization (QTc).  The anesthetized guinea-pig model thus is a useful tool for first line in vivo testing of an NCE for effects on cardiac electrophysiol., in particular when combined with measurements of drug levels in plasma and heart tissues.  In anesthetized dogs, advanced eCG analyses identify drug-induced effects on atrial and ventricular intervals, on temporal and transmural dispersion of ventricular repolarization and on incidences of early after-depolarizations.  This can be combined with complete hemodynamic, pulmonary and pharmacokinetic analyses in one prepn.  However, compd. doses/plasma levels needed for effects on ventricular repolarization in this model are substantially higher than those identified in guinea-pigs, at least for IKr blocking compds.  Therefore, the authors use this "information-rich" canine model as a second line approach.  In awake, trained and appropriately instrumented dogs, readings of surface eCG in combination with cardio-hemodynamic and behavioral assessments can be performed after the administration of an NCE via the expected therapeutic route, including oral medication.  However, at higher doses the compd. under scrutiny may induce overall behavioral side-effects, related to its primary pharmacol. action, such as gastrokinetic repercussions or CNS-mediated sedation or excitation.  Such primary pharmacol. effects are bound to compromise the evaluation of real drug-induced changes on cardiac electrophysiol., readily identified by resource-friendly setups in smaller animals.  Therefore, the authors use such paradigms as an imperative, final cardiovascular check-up, before a "First in Man" administration of the NCE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbEqHYy5WNvLVg90H21EOLACvtfcHk0liCJg6EPVanVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFOrurY%253D&md5=b12da3b167ed603fe3239b6285ce0122</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1046%2Fj.1472-8206.2002.00081.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1472-8206.2002.00081.x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Aubioul%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%2BR.%26aulast%3Dvan%2BRossem%26aufirst%3DK.%26aulast%3DHermans%26aufirst%3DA.%26aulast%3DVan%2BAmmel%26aufirst%3DK.%26atitle%3DIn%2520vivo%2520measurement%2520of%2520QT%2520prolongation%252C%2520dispersion%2520and%2520arrythmogenesis%253A%2520Application%2520to%2520the%2520preclinical%2520cardiovascular%2520safety%2520pharmacology%2520of%2520a%2520new%2520chemical%2520entity%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D16%26spage%3D125%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigenobu, K.</span><span> </span><span class="NLM_article-title">Positive inotropic and chronotropic effects of beraprost sodium, a stable analog of prostacyclin, in isolated guinea pig myocardium</span> <span class="citation_source-journal">Gen. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2F0306-3623%2895%2900095-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8742503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK28XhsVKmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=101-103&author=Y.+Uenoauthor=S.+Okazakiauthor=M.+Isogayaauthor=S.+Nishioauthor=H.+Tanakaauthor=Y.+Katoauthor=K.+Shigenobu&title=Positive+inotropic+and+chronotropic+effects+of+beraprost+sodium%2C+a+stable+analog+of+prostacyclin%2C+in+isolated+guinea+pig+myocardium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Positive inotropic and chronotropic effects of beraprost sodium, a stable analog of prostacyclin, in isolated guinea pig myocardium</span></div><div class="casAuthors">Ueno, Yuji; Okazaki, Seiji; Isogaya, Masafumi; Nishio, Shintaro; Tanaka, Hikaru; Kato, Yoshimitsu; Shigenobu, Koki</div><div class="citationInfo"><span class="NLM_cas:title">General Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-3</span>CODEN:
                <span class="NLM_cas:coden">GEPHDP</span>;
        ISSN:<span class="NLM_cas:issn">0306-3623</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inotropic and chronotropic effects of beraprost sodium, a chem. stable prostacyclin analog, were examd. in isolated myocardial prepns. of guinea pigs.  In the left atria, 10-9-10-7 M beraprost had no significant effect on the contractile force, but 10-6 and 10-5M produced a concn.-dependent pos. inotropic response.  This effect was antagonized by S-145, a potent and selective thromboxane A2 (TXA2) receptor antagonist, but not by propranolol.  Beraprost, from 10-9 to 10-5M, had no significant inotropic effect in the right ventricular papillary muscles.  In the right atria, 10-9 and 10-8 M beraprost had no significant effect, but 10-7-10-5 M caused an increase in beating rate; this effect was not affected by S-145.  The present study demonstrates that beraprost has pos. inotropic and chronotropic effects at high doses on isolated guinea pig atria.  The inotropic effect may be mediated by the TXA2 receptor, but some mechanism other than the TXA2 receptor is responsible for the chronotropic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetmYYbPqAJrVg90H21EOLACvtfcHk0liq8Tw35uAP8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVKmtL4%253D&md5=c23cd007f38eb8d55b2c6355b1d246c4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0306-3623%2895%2900095-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0306-3623%252895%252900095-X%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DNishio%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DShigenobu%26aufirst%3DK.%26atitle%3DPositive%2520inotropic%2520and%2520chronotropic%2520effects%2520of%2520beraprost%2520sodium%252C%2520a%2520stable%2520analog%2520of%2520prostacyclin%252C%2520in%2520isolated%2520guinea%2520pig%2520myocardium%26jtitle%3DGen.%2520Pharmacol.%26date%3D1996%26volume%3D27%26spage%3D101%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Pearson, C. M.</span><span> </span><span class="NLM_article-title">Development of arthritis, periarthritis and periostitis in rats given adjuvants</span> <span class="citation_source-journal">Proc. Soc. Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1956</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.3181%2F00379727-91-22179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=13297719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A280%3ADyaG28%252FltVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1956&pages=95-100&author=C.+M.+Pearson&title=Development+of+arthritis%2C+periarthritis+and+periostitis+in+rats+given+adjuvants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development of arthritis, periarthritis and periostitis in rats given adjuvants</span></div><div class="casAuthors">PEARSON C M</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSFGkgyxtxpckU0YCbOU3EfW6udTcc2eYo7Q11RWhF4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG28%252FltVSjtw%253D%253D&md5=a368faa14a24fea59b49350ed73e076a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3181%2F00379727-91-22179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-91-22179%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DC.%2BM.%26atitle%3DDevelopment%2520of%2520arthritis%252C%2520periarthritis%2520and%2520periostitis%2520in%2520rats%2520given%2520adjuvants%26jtitle%3DProc.%2520Soc.%2520Exp.%2520Biol.%2520Med.%26date%3D1956%26volume%3D91%26spage%3D95%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Carlson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datko, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Neil-Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blazek, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delustro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beideman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, A. J.</span><span> </span><span class="NLM_article-title">Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats</span> <span class="citation_source-journal">Int. J. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2F0192-0561%2885%2990043-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=4077344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaL28XkvFKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1985&pages=811-826&author=R.+P.+Carlsonauthor=L.+J.+Datkoauthor=L.+O%27Neil-Davisauthor=E.+M.+Blazekauthor=F.+Delustroauthor=R.+Beidemanauthor=A.+J.+Lewis&title=Comparison+of+inflammatory+changes+in+established+type+II+collagen+and+adjuvant+induced+arthritis+using+outbred+Wistar+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of inflammatory changes in established type II collagen- and adjuvant-induced arthritis using outbred Wistar rats</span></div><div class="casAuthors">Carlson, Richard P.; Datko, Louis J.; O'Neill-Davis, Lynn; Blazek, Eileen M.; DeLustro, Frank; Beideman, Robert; Lewis, Alan J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-26</span>CODEN:
                <span class="NLM_cas:coden">IJIMDS</span>;
        ISSN:<span class="NLM_cas:issn">0192-0561</span>.
    </div><div class="casAbstract">Type II collagen- and adjuvant-induced arthritis in outbred Wistar rats were compared using parameters that measured the inflammatory response, cellular and humoral immunity, blood protein changes, drug metab., and histopathol. and bony changes of the inflamed paws.  There was a lesser incidence and severity of arthritic disease in collagen-injected rats (40-70%) than in the adjuvant model (incidence ∼100%).  The use of muramyl dipeptide (MDP) increased the incidence and severity of collagen arthritis.  The acute phase protein response (plasma fibrinogen) was similar in both models during the peak of inflammatory response.  Drug metab. was inhibited in both type II collagen boosted with MDP or in adjuvant arthritic (Mycobacterium butyricum-sensitized) rats; however, arthritic rats sensitized with collagen alone produced no inhibition.  Only collagen arthritic rats produced type II collagen antibody and exhibited delayed hypersensitivity to type II collagen.  Bony changes as assessed by radiog. evaluation were more severe in adjuvant arthritic rats than in the collagen arthritic model; histopathol. findings from these animals confirmed this observation.  The primary lesions in both models were periosteal reaction of the bone and ankylosis.  Several classes of antiarthritic drugs were compared in both models using paw edema measurements and bony changes by radiog. evaluation.  Drugs with inhibitory activity in both models were indomethacin, methylprednisolone, D-penicillamine, and Au Na thiomalate.  Levamisole, chloroquine, and auranofin were inactive in both models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya0z88A9WpLVg90H21EOLACvtfcHk0lhkntMNLT_LEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XkvFKqsw%253D%253D&md5=8a7dadcbab41d96452fb0747660710bd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2F0192-0561%2885%2990043-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0192-0561%252885%252990043-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BP.%26aulast%3DDatko%26aufirst%3DL.%2BJ.%26aulast%3DO%2527Neil-Davis%26aufirst%3DL.%26aulast%3DBlazek%26aufirst%3DE.%2BM.%26aulast%3DDelustro%26aufirst%3DF.%26aulast%3DBeideman%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26atitle%3DComparison%2520of%2520inflammatory%2520changes%2520in%2520established%2520type%2520II%2520collagen%2520and%2520adjuvant%2520induced%2520arthritis%2520using%2520outbred%2520Wistar%2520rats%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D1985%26volume%3D7%26spage%3D811%26epage%3D826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Benslay, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A. M.</span><span> </span><span class="NLM_article-title">Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats</span> <span class="citation_source-journal">Agents Actions</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1007%2FBF01993296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=1793040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFOlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=254-256&author=D.+N.+Benslayauthor=A.+M.+Bendele&title=Development+of+a+rapid+screen+for+detecting+and+differentiating+immunomodulatory+vs.+anti-inflammatory+compounds+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats</span></div><div class="casAuthors">Benslay, D. N.; Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Agents and Actions</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">254-6</span>CODEN:
                <span class="NLM_cas:coden">AGACBH</span>;
        ISSN:<span class="NLM_cas:issn">0065-4299</span>.
    </div><div class="casAbstract">Polyarthritis can be induced in rats using a synthetic adjuvant, N,N-dioctyldecyl-N',N-bis(2-hydroxyethyl)propanediamine (LA) suspended in oil.  The disease is morphol. indistinguishable from the classic adjuvant arthritis induced by Freund's complete adjuvant (FCA).  LA injection (7.5 mg/animal) consistently induced paw swelling, splenomegaly and fibrinogen level increases at certain time points.  Studied evaluating various protocols and parameters detd. that a 15 day assay where agents administered from days 9 through 13, would differentiate immunomodulatory and anti-inflammatory compds.  Parameters utilized were body wt., paw vols., spleen wts., and fibrinogen levels.  Immunomodulatory agents reduce paw swelling, splenomegaly and in some cases fibrinogen levels.  NSAIDS reduce paw swelling, increase splenomegaly, and have no effect on fibrinogen levels.  These results indicate that compds. active in the traditional FCA assay can be detected and differentiated with respect to anti-inflammatory vs. immunomodulatory activity in a rapid screen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaOPxv0iZBLVg90H21EOLACvtfcHk0lgCk_CfI6iVwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFOlsrs%253D&md5=52253efcd376b8765edb0c4f34a9f9fc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2FBF01993296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01993296%26sid%3Dliteratum%253Aachs%26aulast%3DBenslay%26aufirst%3DD.%2BN.%26aulast%3DBendele%26aufirst%3DA.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520rapid%2520screen%2520for%2520detecting%2520and%2520differentiating%2520immunomodulatory%2520vs.%2520anti-inflammatory%2520compounds%2520in%2520rats%26jtitle%3DAgents%2520Actions%26date%3D1991%26volume%3D34%26spage%3D254%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Chang, Y.</span><span> </span><span class="NLM_article-title">Adjuvant polyarthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780230111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=7352945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaL3cXhsVCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=62-71&author=Y.+Chang&title=Adjuvant+polyarthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant polyarthritis.  IV.  Induction by a synthetic adjuvant:  immunologic, histopathologic, and other studies</span></div><div class="casAuthors">Chang, Yi-Han; Pearson, Carl M.; Abe, Chiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">A soln. of an apparently nonimmunogenic synthetic compd., N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)propanediamine (CP-20961), suspended in mineral oil or olive oil (50 mg/mL), induced an acute, as well as a chronic, polyarthritis when single intradermal injections were made in the tail or hind paw of Lewis rats.  The polyarthritis was morphol. almost indistinguishable from classic adjuvant arthritis induced by Freund's complete adjuvant.  CP-20961-induced arthritis was suppressed by an immunosuppressive agent (cyclophosphamide) or an antiinflammatory drug (phenylbutazone).  CP-20961 was a potent adjuvant.  These findings suggest that the immunogen responsible for the development of adjuvant arthritis is endogenous, e.g., a constituent of host tissue, a viral protein, or some complex of the two.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw9Tqkr0ix0bVg90H21EOLACvtfcHk0lgCk_CfI6iVwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsVCntLs%253D&md5=5bfb607d29a2a4b94817a9f6b976a7de</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fart.1780230111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780230111%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%26atitle%3DAdjuvant%2520polyarthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D1980%26volume%3D23%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Cromartie, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderlie, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span> </span><span class="NLM_article-title">Arthritis in rats after systemic injection of streptococcal cells or cell walls</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=1585-1602&author=W.+J.+Cromartieauthor=J.+G.+Craddockauthor=J.+H.+Schwabauthor=S.+K.+Anderlieauthor=C.+Yang&title=Arthritis+in+rats+after+systemic+injection+of+streptococcal+cells+or+cell+walls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCromartie%26aufirst%3DW.%2BJ.%26aulast%3DCraddock%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DJ.%2BH.%26aulast%3DAnderlie%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DArthritis%2520in%2520rats%2520after%2520systemic%2520injection%2520of%2520streptococcal%2520cells%2520or%2520cell%2520walls%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D1585%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Richards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. S.</span><span> </span><span class="NLM_article-title">Suppression of chronic streptococcal cell wall-induced arthritis in lewis rats by liposomal clodronate</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">978</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=978-987&author=P.+J.+Richardsauthor=B.+D.+Williamsauthor=A.+S.+Williams&title=Suppression+of+chronic+streptococcal+cell+wall-induced+arthritis+in+lewis+rats+by+liposomal+clodronate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26atitle%3DSuppression%2520of%2520chronic%2520streptococcal%2520cell%2520wall-induced%2520arthritis%2520in%2520lewis%2520rats%2520by%2520liposomal%2520clodronate%26jtitle%3DRheumatology%26date%3D2001%26volume%3D40%26spage%3D978%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Wustrow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Coupling of arylboronic acids with a partially reduced pyridine derivative</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-1991-26626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=993-995&author=D.+J.+Wustrowauthor=L.+D.+Wise&title=Coupling+of+arylboronic+acids+with+a+partially+reduced+pyridine+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of arylboronic acid with a partially reduced pyridine derivative</span></div><div class="casAuthors">Wustrow, David J.; Wise, Lawrence D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-5</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">1,2,3,6-Tetrahydro-4-[(trifluoromethyl)sulfonyloxy]pyridine-1-carboxylate I (R = tert-butoxycarbonyl, R1 = triflate) was prepd. and underwent palladium-catalyzed coupling reactions with a variety of substituted arylboronic acids to produce a series of tert-butyl-4-aryl-1,2,3,6-tetrahydropyridine-1-carboxylates I (R as above, R1 = substituted Ph, 1-naphthyl).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwI9XvXHB0iLVg90H21EOLACvtfcHk0lj8j1CqCOLt1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D&md5=e585b1222bbd08f3a5afd0ffd64cc71f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1055%2Fs-1991-26626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1991-26626%26sid%3Dliteratum%253Aachs%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DCoupling%2520of%2520arylboronic%2520acids%2520with%2520a%2520partially%2520reduced%2520pyridine%2520derivative%26jtitle%3DSynthesis%26date%3D1991%26spage%3D993%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Maier, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugel, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golebiowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufersweiler, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanRens, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easwaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janusz, M. J.</span><span> </span><span class="NLM_article-title">Development of <i>N</i>-4,6-pyrimidine-<i>N</i>-alkyl-<i>N</i>′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3646</span><span class="NLM_x">–</span> <span class="NLM_lpage">3650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3646-3650&author=J.+A.+Maierauthor=T.+A.+Brugelauthor=M.+Sabatauthor=A.+Golebiowskiauthor=M.+J.+Laufersweilerauthor=J.+C.+VanRensauthor=C.+R.+Hopkinsauthor=B.+Deauthor=L.+C.+Hsiehauthor=K.+K.+Brownauthor=V.+Easwaranauthor=M.+J.+Janusz&title=Development+of+N-4%2C6-pyrimidine-N-alkyl-N%E2%80%B2-phenyl+ureas+as+orally+active+inhibitors+of+lymphocyte+specific+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DJ.%2BA.%26aulast%3DBrugel%26aufirst%3DT.%2BA.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DGolebiowski%26aufirst%3DA.%26aulast%3DLaufersweiler%26aufirst%3DM.%2BJ.%26aulast%3DVanRens%26aufirst%3DJ.%2BC.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DHsieh%26aufirst%3DL.%2BC.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DEaswaran%26aufirst%3DV.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26atitle%3DDevelopment%2520of%2520N-4%252C6-pyrimidine-N-alkyl-N%25E2%2580%25B2-phenyl%2520ureas%2520as%2520orally%2520active%2520inhibitors%2520of%2520lymphocyte%2520specific%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3646%26epage%3D3650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref38':['cit38'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44a','cit44b','cit44c','cit44d'],'ref45':['cit45a','cit45b'],'ref46':['cit46a','cit46b','cit46c'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49a','cit49b'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53a','cit53b'],'ref54':['cit54a','cit54b'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Barbara Czako, Joseph. R. Marszalek, Jason P. Burke, Pijus Mandal, Paul G. Leonard, Jason B. Cross, Faika Mseeh, Yongying Jiang, Edward Q. Chang, Erika Suzuki, Jeffrey J. Kovacs, Ningping Feng, Sonal Gera, Angela L. Harris, Zhen Liu, Robert A. Mullinax, Jihai Pang, Connor A. Parker, Nakia D. Spencer, Simon S. Yu, Qi Wu, Martin R. Tremblay, Keith Mikule, Keith Wilcoxen, Timothy P. Heffernan, Giulio F. Draetta, <span class="NLM_string-name hlFld-ContribAuthor">Philip Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9888-9911. <a href="https://doi.org/10.1021/acs.jmedchem.0c00936" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00936</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00936%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BIACS-9439%25252C%252Ba%252BPotent%25252C%252BExquisitely%252BSelective%25252C%252Band%252BOrally%252BBioavailable%252BInhibitor%252Bof%252BCSF1R%26aulast%3DCzako%26aufirst%3DBarbara%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18062020%26date%3D18082020%26date%3D29072020%26volume%3D63%26issue%3D17%26spage%3D9888%26epage%3D9911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhicheng Xie, Bing Wu, Yingqiang Liu, Wenming Ren, Linjiang Tong, Caigui Xiang, Aihuan Wei, Yuanzhuo Gao, Limin Zeng, Hua Xie, Wei Tang, <span class="NLM_string-name hlFld-ContribAuthor">Youhong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1397-1414. <a href="https://doi.org/10.1021/acs.jmedchem.9b01912" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01912%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BClass%252Bof%252BColony-Stimulating%252BFactor%252B1%252BReceptor%252BKinase%252BInhibitors%252BBased%252Bon%252Ban%252Bo-Aminopyridyl%252BAlkynyl%252BScaffold%252Bas%252BPotential%252BTreatment%252Bfor%252BInflammatory%252BDisorders%26aulast%3DXie%26aufirst%3DZhicheng%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26112019%26date%3D14012020%26volume%3D63%26issue%3D3%26spage%3D1397%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changcheng  Wang</span>, <span class="hlFld-ContribAuthor ">Jialin  Lai</span>, <span class="hlFld-ContribAuthor ">Cantao  Chen</span>, <span class="hlFld-ContribAuthor ">Xuechen  Li</span>, and <span class="hlFld-ContribAuthor ">Hua  Cao</span>  . </span><span class="cited-content_cbyCitation_article-title">Ag-Catalyzed Tandem Three-Component Reaction toward the Synthesis of Multisubstituted Imidazoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (24)
                                     , 13740-13745. <a href="https://doi.org/10.1021/acs.joc.7b02612" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02612%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAg-Catalyzed%252BTandem%252BThree-Component%252BReaction%252Btoward%252Bthe%252BSynthesis%252Bof%252BMultisubstituted%252BImidazoles%26aulast%3DWang%26aufirst%3DChangcheng%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13102017%26date%3D01122017%26date%3D15122017%26date%3D21112017%26volume%3D82%26issue%3D24%26spage%3D13740%26epage%3D13745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Brian T.  Campbell</span>, <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>, <span class="hlFld-ContribAuthor ">Julia M.  Ford Pulido</span>, <span class="hlFld-ContribAuthor ">Helen  Hua</span>, <span class="hlFld-ContribAuthor ">Dana  Gitnick</span>, <span class="hlFld-ContribAuthor ">Michael F.  Gardner</span>, <span class="hlFld-ContribAuthor ">Joyce  James</span>, <span class="hlFld-ContribAuthor ">Mike A.  Breider</span>, <span class="hlFld-ContribAuthor ">Daniel  Brigham</span>, <span class="hlFld-ContribAuthor ">Barbara  Belli</span>, <span class="hlFld-ContribAuthor ">Robert C.  Armstrong</span>, and <span class="hlFld-ContribAuthor ">Daniel K.  Treiber</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>3 </em>
                                    (12)
                                     , 997-1002. <a href="https://doi.org/10.1021/ml300214g" title="DOI URL">https://doi.org/10.1021/ml300214g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml300214g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml300214g%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BAC710%25252C%252Ba%252BGlobally%252BSelective%252BInhibitor%252Bof%252BPlatelet-Derived%252BGrowth%252BFactor%252BReceptor-Family%252BKinases%26aulast%3DLiu%26aufirst%3DGang%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D30072012%26date%3D24092012%26date%3D28092012%26date%3D13122012%26date%3D24092012%26volume%3D3%26issue%3D12%26spage%3D997%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Berend  van der Wildt</span>, <span class="hlFld-ContribAuthor ">Madina  Nezam</span>, <span class="hlFld-ContribAuthor ">Esther J.M.  Kooijman</span>, <span class="hlFld-ContribAuthor ">Samantha T.  Reyes</span>, <span class="hlFld-ContribAuthor ">Bin  Shen</span>, <span class="hlFld-ContribAuthor ">Albert D.  Windhorst</span>, <span class="hlFld-ContribAuthor ">Frederick T.  Chin</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>42 </em>, 116245. <a href="https://doi.org/10.1016/j.bmc.2021.116245" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116245%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DEvaluation%252Bof%252Bcarbon-11%252Blabeled%252B5-%2525281-methyl-1H-pyrazol-4-yl%252529-N-%2525282-methyl-5-%2525283-%252528trifluoromethyl%252529benzamido%252529phenyl%252529nicotinamide%252Bas%252BPET%252Btracer%252Bfor%252Bimaging%252Bof%252BCSF-1R%252Bexpression%252Bin%252Bthe%252Bbrain%26aulast%3Dvan%2Bder%2BWildt%26aufirst%3DBerend%26date%3D2021%26volume%3D42%26spage%3D116245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao-Ju  Chen</span>, <span class="hlFld-ContribAuthor ">Yu-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 130. <a href="https://doi.org/10.3390/ph14020130" title="DOI URL">https://doi.org/10.3390/ph14020130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14020130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14020130%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DMERTK%252BInhibition%25253A%252BPotential%252Bas%252Ba%252BTreatment%252BStrategy%252Bin%252BEGFR%252BTyrosine%252BKinase%252BInhibitor-Resistant%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DChao-Ju%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule CSF1R kinase inhibitors; review of patents 2015-present. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (2)
                                     , 107-117. <a href="https://doi.org/10.1080/13543776.2021.1839414" title="DOI URL">https://doi.org/10.1080/13543776.2021.1839414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1839414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1839414%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252BCSF1R%252Bkinase%252Binhibitors%25253B%252Breview%252Bof%252Bpatents%252B2015-present%26aulast%3DDenny%26aufirst%3DWilliam%2BA.%26date%3D2021%26date%3D2020%26volume%3D31%26issue%3D2%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuju  Xun</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Xianglong  Hu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule CSF1R Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (23)
                                     , 3944-3966. <a href="https://doi.org/10.2174/1573394715666190618121649" title="DOI URL">https://doi.org/10.2174/1573394715666190618121649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573394715666190618121649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573394715666190618121649%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BCSF1R%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DXun%26aufirst%3DQiuju%26date%3D2020%26volume%3D27%26issue%3D23%26spage%3D3944%26epage%3D3966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Selma  Bal</span>, <span class="hlFld-ContribAuthor ">Ruya  Kaya</span>, <span class="hlFld-ContribAuthor ">Yetkin  Gök</span>, <span class="hlFld-ContribAuthor ">Parham  Taslimi</span>, <span class="hlFld-ContribAuthor ">Aydın  Aktaş</span>, <span class="hlFld-ContribAuthor ">Muhammet  Karaman</span>, <span class="hlFld-ContribAuthor ">İlhami  Gülçin</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2-methylimidazolium salts: Synthesis, characterization, molecular docking, and carbonic anhydrase and acetylcholinesterase inhibitory properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103468. <a href="https://doi.org/10.1016/j.bioorg.2019.103468" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103468%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B2-methylimidazolium%252Bsalts%25253A%252BSynthesis%25252C%252Bcharacterization%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bcarbonic%252Banhydrase%252Band%252Bacetylcholinesterase%252Binhibitory%252Bproperties%26aulast%3DBal%26aufirst%3DSelma%26date%3D2020%26volume%3D94%26spage%3D103468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazutaka  Ikegashira</span>, <span class="hlFld-ContribAuthor ">Taku  Ikenogami</span>, <span class="hlFld-ContribAuthor ">Takayuki  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Takahiro  Oka</span>, <span class="hlFld-ContribAuthor ">Yasunori  Hase</span>, <span class="hlFld-ContribAuthor ">Naoki  Miyagawa</span>, <span class="hlFld-ContribAuthor ">Koji  Inagaki</span>, <span class="hlFld-ContribAuthor ">Iichiro  Kawahara</span>, <span class="hlFld-ContribAuthor ">Yoshihisa  Koga</span>, <span class="hlFld-ContribAuthor ">Hiromasa  Hashimoto</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (7)
                                     , 873-877. <a href="https://doi.org/10.1016/j.bmcl.2019.02.006" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.02.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.02.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252Ban%252Bazetidine%252Bseries%252Bas%252Binhibitors%252Bof%252Bcolony%252Bstimulating%252Bfactor-1%252Breceptor%252B%252528CSF-1R%252529%252BType%252BII%252Bto%252Blead%252Bto%252Bthe%252Bclinical%252Bcandidate%252BJTE-952%26aulast%3DIkegashira%26aufirst%3DKazutaka%26date%3D2019%26volume%3D29%26issue%3D7%26spage%3D873%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonya M.  Hanson</span>, <span class="hlFld-ContribAuthor ">George  Georghiou</span>, <span class="hlFld-ContribAuthor ">Manish K.  Thakur</span>, <span class="hlFld-ContribAuthor ">W. Todd  Miller</span>, <span class="hlFld-ContribAuthor ">Joshua S.  Rest</span>, <span class="hlFld-ContribAuthor ">John D.  Chodera</span>, <span class="hlFld-ContribAuthor ">Markus A.  Seeliger</span>. </span><span class="cited-content_cbyCitation_article-title">What Makes a Kinase Promiscuous for Inhibitors?. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (3)
                                     , 390-399.e5. <a href="https://doi.org/10.1016/j.chembiol.2018.11.005" title="DOI URL">https://doi.org/10.1016/j.chembiol.2018.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2018.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2018.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DWhat%252BMakes%252Ba%252BKinase%252BPromiscuous%252Bfor%252BInhibitors%25253F%26aulast%3DHanson%26aufirst%3DSonya%2BM.%26date%3D2019%26volume%3D26%26issue%3D3%26spage%3D390%26epage%3D399.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazutaka  Ikegashira</span>, <span class="hlFld-ContribAuthor ">Taku  Ikenogami</span>, <span class="hlFld-ContribAuthor ">Takayuki  Yamasaki</span>, <span class="hlFld-ContribAuthor ">Yasunori  Hase</span>, <span class="hlFld-ContribAuthor ">Takayuki  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Koji  Inagaki</span>, <span class="hlFld-ContribAuthor ">Satoki  Doi</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Adachi</span>, <span class="hlFld-ContribAuthor ">Yoshihisa  Koga</span>, <span class="hlFld-ContribAuthor ">Hiromasa  Hashimoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors by the use of docking models. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (1)
                                     , 115-118. <a href="https://doi.org/10.1016/j.bmcl.2018.10.051" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.10.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.10.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.10.051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bazetidine%252Bscaffold%252Bfor%252Bcolony%252Bstimulating%252Bfactor-1%252Breceptor%252B%252528CSF-1R%252529%252BType%252BII%252Binhibitors%252Bby%252Bthe%252Buse%252Bof%252Bdocking%252Bmodels%26aulast%3DIkegashira%26aufirst%3DKazutaka%26date%3D2019%26volume%3D29%26issue%3D1%26spage%3D115%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Archana  Kumari</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>, <span class="hlFld-ContribAuthor ">Rajesh K.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2018,</strong> <em>103 </em>, 662-679. <a href="https://doi.org/10.1016/j.biopha.2018.04.046" title="DOI URL">https://doi.org/10.1016/j.biopha.2018.04.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2018.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2018.04.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DRecent%252Badvances%252Bin%252Bcolony%252Bstimulating%252Bfactor-1%252Breceptor%25252Fc-FMS%252Bas%252Ban%252Bemerging%252Btarget%252Bfor%252Bvarious%252Btherapeutic%252Bimplications%26aulast%3DKumari%26aufirst%3DArchana%26date%3D2018%26volume%3D103%26spage%3D662%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">4-(Hetero)Arylpiperidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 155-193. <a href="https://doi.org/10.1002/9781118686263.ch5" title="DOI URL">https://doi.org/10.1002/9781118686263.ch5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch5%26sid%3Dliteratum%253Aachs%26atitle%3D4-%252528Hetero%252529Arylpiperidines%26date%3D2018%26date%3D2018%26spage%3D155%26epage%3D193%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun-Ming  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian-Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">1,3-Dipolar Cycloaddition of Imidazole Derivatives with Nitrile Oxide: Synthesis of Imidazo[1,2,4]oxadiazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>6 </em>
                                    (11)
                                     , 1620-1627. <a href="https://doi.org/10.1002/ajoc.201700347" title="DOI URL">https://doi.org/10.1002/ajoc.201700347</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201700347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201700347%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3D1%25252C3-Dipolar%252BCycloaddition%252Bof%252BImidazole%252BDerivatives%252Bwith%252BNitrile%252BOxide%25253A%252BSynthesis%252Bof%252BImidazo%25255B1%25252C2%25252C4%25255Doxadiazole%252BDerivatives%26aulast%3DJiang%26aufirst%3DKun-Ming%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D11%26spage%3D1620%26epage%3D1627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madani  Hedidi</span>, <span class="hlFld-ContribAuthor ">Julien  Maillard</span>, <span class="hlFld-ContribAuthor ">William  Erb</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lassagne</span>, <span class="hlFld-ContribAuthor ">Yury S.  Halauko</span>, <span class="hlFld-ContribAuthor ">Oleg A.  Ivashkevich</span>, <span class="hlFld-ContribAuthor ">Vadim E.  Matulis</span>, <span class="hlFld-ContribAuthor ">Thierry  Roisnel</span>, <span class="hlFld-ContribAuthor ">Vincent  Dorcet</span>, <span class="hlFld-ContribAuthor ">Monzer  Hamzé</span>, <span class="hlFld-ContribAuthor ">Ziad  Fajloun</span>, <span class="hlFld-ContribAuthor ">Blandine  Baratte</span>, <span class="hlFld-ContribAuthor ">Sandrine  Ruchaud</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bach</span>, <span class="hlFld-ContribAuthor ">Ghenia  Bentabed-Ababsa</span>, <span class="hlFld-ContribAuthor ">Florence  Mongin</span>. </span><span class="cited-content_cbyCitation_article-title">Fused Systems Based on 2-Aminopyrimidines: Synthesis Combining Deprotolithiation-in situ Zincation with
              N
              -Arylation Reactions and Biological Properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>2017 </em>
                                    (39)
                                     , 5903-5915. <a href="https://doi.org/10.1002/ejoc.201701004" title="DOI URL">https://doi.org/10.1002/ejoc.201701004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFused%252BSystems%252BBased%252Bon%252B2-Aminopyrimidines%25253A%252BSynthesis%252BCombining%252BDeprotolithiation-in%252Bsitu%252BZincation%252Bwith%252BN%252B-Arylation%252BReactions%252Band%252BBiological%252BProperties%26aulast%3DHedidi%26aufirst%3DMadani%26date%3D2017%26date%3D2017%26volume%3D2017%26issue%3D39%26spage%3D5903%26epage%3D5915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K  Byrgazov</span>, <span class="hlFld-ContribAuthor ">R  Kastner</span>, <span class="hlFld-ContribAuthor ">M  Gorna</span>, <span class="hlFld-ContribAuthor ">G  Hoermann</span>, <span class="hlFld-ContribAuthor ">M  Koenig</span>, <span class="hlFld-ContribAuthor ">C B  Lucini</span>, <span class="hlFld-ContribAuthor ">R  Ulreich</span>, <span class="hlFld-ContribAuthor ">M  Benesch</span>, <span class="hlFld-ContribAuthor ">V  Strenger</span>, <span class="hlFld-ContribAuthor ">H  Lackner</span>, <span class="hlFld-ContribAuthor ">W  Schwinger</span>, <span class="hlFld-ContribAuthor ">P  Sovinz</span>, <span class="hlFld-ContribAuthor ">O A  Haas</span>, <span class="hlFld-ContribAuthor ">M  van den Heuvel-Eibrink</span>, <span class="hlFld-ContribAuthor ">C M  Niemeyer</span>, <span class="hlFld-ContribAuthor ">O  Hantschel</span>, <span class="hlFld-ContribAuthor ">P  Valent</span>, <span class="hlFld-ContribAuthor ">G  Superti-Furga</span>, <span class="hlFld-ContribAuthor ">C  Urban</span>, <span class="hlFld-ContribAuthor ">M N  Dworzak</span>, <span class="hlFld-ContribAuthor ">T  Lion</span>. </span><span class="cited-content_cbyCitation_article-title">NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2017,</strong> <em>31 </em>
                                    (1)
                                     , 237-240. <a href="https://doi.org/10.1038/leu.2016.250" title="DOI URL">https://doi.org/10.1038/leu.2016.250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2016.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2016.250%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DNDEL1-PDGFRB%252Bfusion%252Bgene%252Bin%252Ba%252Bmyeloid%252Bmalignancy%252Bwith%252Beosinophilia%252Bassociated%252Bwith%252Bresistance%252Bto%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DByrgazov%26aufirst%3DK%26date%3D2017%26date%3D2015%26volume%3D31%26issue%3D1%26spage%3D237%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey S.  Laev</span>, <span class="hlFld-ContribAuthor ">Nariman F.  Salakhutdinov</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-arthritic agents: Progress and potential. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (13)
                                     , 3059-3080. <a href="https://doi.org/10.1016/j.bmc.2015.05.010" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAnti-arthritic%252Bagents%25253A%252BProgress%252Band%252Bpotential%26aulast%3DLaev%26aufirst%3DSergey%2BS.%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3059%26epage%3D3080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin-Mei  Peng</span>, <span class="hlFld-ContribAuthor ">Guri L. V.  Damu</span>, <span class="hlFld-ContribAuthor ">Rong-Xia  Geng</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2014,</strong> <em>34 </em>
                                    (2)
                                     , 340-437. <a href="https://doi.org/10.1002/med.21290" title="DOI URL">https://doi.org/10.1002/med.21290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21290%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DComprehensive%252BReview%252Bin%252BCurrent%252BDevelopments%252Bof%252BImidazole-Based%252BMedicinal%252BChemistry%26aulast%3DZhang%26aufirst%3DLing%26date%3D2014%26date%3D2013%26volume%3D34%26issue%3D2%26spage%3D340%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carl R.  Illig</span>, <span class="hlFld-ContribAuthor ">Carl L.  Manthey</span>, <span class="hlFld-ContribAuthor ">Sanath K.  Meegalla</span>, <span class="hlFld-ContribAuthor ">Mark J.  Wall</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Renee L.  DesJarlais</span>, <span class="hlFld-ContribAuthor ">Shelley K.  Ballentine</span>, <span class="hlFld-ContribAuthor ">Carsten  Schubert</span>, <span class="hlFld-ContribAuthor ">Carl S.  Crysler</span>, <span class="hlFld-ContribAuthor ">Yanmin  Chen</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Molloy</span>, <span class="hlFld-ContribAuthor ">Margery A.  Chaikin</span>, <span class="hlFld-ContribAuthor ">Robert R.  Donatelli</span>, <span class="hlFld-ContribAuthor ">Edward  Yurkow</span>, <span class="hlFld-ContribAuthor ">Zhao  Zhou</span>, <span class="hlFld-ContribAuthor ">Mark R.  Player</span>, <span class="hlFld-ContribAuthor ">Bruce E.  Tomczuk</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (23)
                                     , 6363-6369. <a href="https://doi.org/10.1016/j.bmcl.2013.09.061" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.09.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.09.061%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DEnhancement%252Bof%252Bkinase%252Bselectivity%252Bin%252Ba%252Bpotent%252Bclass%252Bof%252Barylamide%252BFMS%252Binhibitors%26aulast%3DIllig%26aufirst%3DCarl%2BR.%26date%3D2013%26volume%3D23%26issue%3D23%26spage%3D6363%26epage%3D6369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Archana  Kumari</span>, <span class="hlFld-ContribAuthor ">Maninder  Kaur</span>, <span class="hlFld-ContribAuthor ">Malkeet Singh  Bahia</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2013,</strong> <em>22 </em>
                                    (11)
                                     , 5167-5183. <a href="https://doi.org/10.1007/s00044-013-0513-8" title="DOI URL">https://doi.org/10.1007/s00044-013-0513-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-013-0513-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-013-0513-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3D3D-QSAR%252Banalysis%252Bof%252Banilinoquinoline%252Binhibitors%252Bof%252Bcolony%252Bstimulating%252Bfactor-1%252Bkinase%252B%252528cFMS%252529%25253A%252Bimplementation%252Bof%252Bfield-based%252Bmolecular%252Balignment%26aulast%3DKumari%26aufirst%3DArchana%26date%3D2013%26date%3D2013%26volume%3D22%26issue%3D11%26spage%3D5167%26epage%3D5183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dana  Ferraris</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Yang</span>, <span class="hlFld-ContribAuthor ">Derek  Welsbie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2013,</strong> <em>5 </em>
                                    (16)
                                     , 1923-1934. <a href="https://doi.org/10.4155/fmc.13.150" title="DOI URL">https://doi.org/10.4155/fmc.13.150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.13.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.13.150%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bleucine%252Bzipper%252Bkinase%252Bas%252Ba%252Btherapeutic%252Btarget%252Bfor%252Bneurodegenerative%252Bconditions%26aulast%3DFerraris%26aufirst%3DDana%26date%3D2013%26volume%3D5%26issue%3D16%26spage%3D1923%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A.  Scott</span>, <span class="hlFld-ContribAuthor ">Les A.  Dakin</span>, <span class="hlFld-ContribAuthor ">Kevin  Daly</span>, <span class="hlFld-ContribAuthor ">David J.  Del Valle</span>, <span class="hlFld-ContribAuthor ">R. Bruce  Diebold</span>, <span class="hlFld-ContribAuthor ">Lisa  Drew</span>, <span class="hlFld-ContribAuthor ">Jayachandran  Ezhuthachan</span>, <span class="hlFld-ContribAuthor ">Thomas W.  Gero</span>, <span class="hlFld-ContribAuthor ">Claude A.  Ogoe</span>, <span class="hlFld-ContribAuthor ">Charles A.  Omer</span>, <span class="hlFld-ContribAuthor ">Sean P.  Redmond</span>, <span class="hlFld-ContribAuthor ">Galina  Repik</span>, <span class="hlFld-ContribAuthor ">Kumar  Thakur</span>, <span class="hlFld-ContribAuthor ">Qing  Ye</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (16)
                                     , 4591-4596. <a href="https://doi.org/10.1016/j.bmcl.2013.06.031" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.06.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.06.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMitigation%252Bof%252Bcardiovascular%252Btoxicity%252Bin%252Ba%252Bseries%252Bof%252BCSF-1R%252Binhibitors%25252C%252Band%252Bthe%252Bidentification%252Bof%252BAZD7507%26aulast%3DScott%26aufirst%3DDavid%2BA.%26date%3D2013%26volume%3D23%26issue%3D16%26spage%3D4591%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, LiCl, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, 2 h. (b) H<sub>2</sub>, 10% Pd/C, MeOH, 20 psi, 1 h. (c) NBS, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 10 h. (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, toluene, EtOH, 80 °C, 3 h. (e) EDCI, HOBt, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 10 h. (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 1 h.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-Fluoropyridine, DMA, 120 °C. (b) Acrylonitrile, Et<sub>3</sub>N, MeOH, DCE, 80 °C. (c) Aldehyde or ketone, NaBH(OAc)<sub>3</sub>, DIEA, 1,2-dichloroethane, room temperature. (d) DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (e) TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temperature. (f) 4-(2-Chloroethyl)morpholine HCl, NaI, DMA, 80 °C.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (b) DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (c) EDCI, HOBt, DIEA or Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (d) EDCI, HOBt, DIEA, DMF, room temperature. (e) PyBrop, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (f) Triphosgene, DIEA, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>OH, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C, then TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (g) TMS-NCO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (h) 2 M HCl, MeOH–H<sub>2</sub>O, room temperature. (i) TFA, EtOH, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (j) Na(OAc)<sub>3</sub>BH, glyoxal, CH<sub>2</sub>Cl<sub>2</sub>, room temperature. (k) Na(OAc)<sub>3</sub>BH, CH<sub>2</sub>O, MeOH, room temperature.</p></p></figure><figure data-id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of FMS, cyan carbons, with furan-containing compound <b>49</b>, brown carbons (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL">3KRL</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (B) Model of FMS, cyan carbons, with pyrrole-containing compound <b>50</b>, salmon carbons. (C) Crystal structure of FMS, cyan carbons, with imidazole-containing compound <b>8</b>, orange carbons (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ">3KRJ</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(37)</a> Hydrogen bonds between the inhibitor and FMS and the inhibitor intramolecular hydrogen bonds are shown as green dashed lines. The figures were prepared with PyMol.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>15</b>, <b>20</b>, and <b>23</b> reduced four-paw histopathology summary scores in mouse CIA. CIA was induced in mice as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Group mean values (SEM) are plotted, and percent inhibition values relative to the vehicle-treated disease control are indicated in text within the bars (mpk = mg/kg); *<i>p</i> < 0.01 vs disease control (vehicle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>15</b>, <b>20</b>, and <b>23</b> reduced the histopathology evidence of inflammation, pannus, cartilage, and bone damage. CIA was induced in mice, and scores for each histopathology parameters were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Group mean values (SEM) are plotted. *<i>p</i> < 0.01 vs disease control (vehicle).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>23</b> reduced disease activity in rats with adjuvant arthritis. Adjuvant arthritis was induced in rats as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Commencing on day 8, adjuvant-induced rats (Adj) received twice daily oral doses of vehicle (veh) or 5, 20, or 60 mg/kg of <b>23</b> until study termination on day 14. An additional group of rats was not adjuvant induced and served as the disease-free (normal) control. All end points were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. (A) Hind paws were severed at the level of the medial and lateral malleolus and weighed. (B) H&E-stained sections of formalin-fixed hind paws were scored for inflammation by histopathology assessment using a five-point scale. (C) Soft tissue regions of sections stained for ED-1 antigen (CD68) positive macrophages were assessed for the number of areas (hot spots) with marked numbers of positive cells. (D) Spleens were weighed at necropsy. (E) H&E-stained sections of formalin-fixed hind paws were scored for bone erosions using a five-point scale. All values represent group means (<i>n</i> = 16 hind limbs or 8 spleens). Error bars represent standard errors of the means. Percent inhibition values relative to adjuvant-induced, vehicle-treated rats were provided as white text within bars. *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>23</b> prevented the chronic phase of SCW arthritis and the recruitment of macrophages and osteoclasts and bone erosion. Arthritis was induced in rats following a single ip injection of SCW as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Following partial resolution of the acute phase, twice daily oral dosing was commenced on day 8 with vehicle or with 20 mg/kg compound <b>23</b>. Ankle thickness was determined using calipers (A), and clinical scores were assigned as described in the <a class="ref internalNav" href="#sec5" aria-label="Experiment Section">Experiment Section</a> (B). Immunohistochemistry was used to assess formalin-fixed sections of hind-limb ankles for ED-1 antigen positive cells. Representative low power (20×) fields of rats treated with vehicle (C) or with 20 mg/kg compound <b>23</b> (D) are provided. The arrow head indicates periarticular tissue with intense infiltration of macrophages. Arrows indicated erosions in trabecular bone associated with large numbers of osteoclasts. All values represent group means (<i>n</i> = 6). Error bars represent standard errors of the means. *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>23</b> prevented the development of bone deformation. Following necropsy on day 19, microradiographic images were prepared of tibial tarsal joints. Representative images are shown obtained from a disease-free rat (A), a rat with adjuvant arthritis treated with vehicle (B), and a rat with adjuvant arthritis treated with 20 mg/kg <b>23</b> (C). Bones in vehicle-treated rats with adjuvant arthritis appeared pitted and lacked fine definition, while bones from rats treated with <b>23</b> appeared normal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/medium/jm-2011-00900q_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0015.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. SCW model of arthritis. Dosing commenced after the establishment of chronic arthritis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-22/jm200900q/production/images/large/jm-2011-00900q_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200900q&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36741" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36741" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lundkvist, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobelt, G.</span><span> </span><span class="NLM_article-title">The burden of rheumatoid arthritis and access to treatment: Health burden and costs</span> <span class="citation_source-journal">Eur. J. Health Econ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">S60</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=S49-S60&issue=Suppl.+2&author=J.+Lundkvistauthor=F.+Kastangauthor=G.+Kobelt&title=The+burden+of+rheumatoid+arthritis+and+access+to+treatment%3A+Health+burden+and+costs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLundkvist%26aufirst%3DJ.%26aulast%3DKastang%26aufirst%3DF.%26aulast%3DKobelt%26aufirst%3DG.%26atitle%3DThe%2520burden%2520of%2520rheumatoid%2520arthritis%2520and%2520access%2520to%2520treatment%253A%2520Health%2520burden%2520and%2520costs%26jtitle%3DEur.%2520J.%2520Health%2520Econ.%26date%3D2008%26volume%3D8%26issue%3DSuppl.%25202%26spage%3DS49%26epage%3DS60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Maggon, K.</span> Global arthritis market review 2008 (World top ten RA drugs); <a href="http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#" class="extLink">http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#</a> (accessed January 3,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maggon%2C+K.+Global+arthritis+market+review+2008+%28World+top+ten+RA+drugs%29%3B+http%3A%2F%2Fknol.google.com%2Fk%2Fglobal-arthritis-market-review-2008-world-top-ten-ra-drugs%23+%28accessed+January+3%2C+2011%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DMaggon%26aufirst%3DK.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lipsky, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heijde, D. M. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clair, E. W.,  St.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furst, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalden, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maini, R. N.</span><span> </span><span class="NLM_article-title">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1594</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1056%2FNEJM200011303432202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=11096166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1594-1602&author=P.+E.+Lipskyauthor=D.+M.+F.+M.+van+der+Heijdeauthor=E.+W.+Clairauthor=D.+E.+Furstauthor=F.+C.+Breedveldauthor=J.+R.+Kaldenauthor=J.+S.+Smolenauthor=M.+Weismanauthor=P.+Emeryauthor=M.+Feldmannauthor=G.+R.+Harrimanauthor=R.+N.+Maini&title=Infliximab+and+methotrexate+in+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Infliximab and methotrexate in the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Lipsky, Peter E.; Van Der Heijde, Desiree M. F. M.; St. Clair, E. William; Furst, Daniel E.; Breedveld, Ferdinand C.; Kalden, Joachim R.; Smolen, Josef S.; Weisman, Michael; Emery, Paul; Feldmann, Marc; Harriman, Gregory R.; Maini, Ravinder N.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1594-1602</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis.  However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.  We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α, in i.v. doses of 3 or 10 mg per kg of body wt. every 4 or 8 wk in combination with oral methotrexate for 54 wk.  We assessed clin. responses with use of the criteria of the American College of Rheumatol., the quality of life with a health-status questionnaire, and the effect on joint damage radiog.  The combination of infliximab and methotrexate was well tolerated and resulted in a sustained redn. in the symptoms and signs of rheumatoid arthritis that was significantly greater than the redn. assocd. with methotrexate therapy alone (clin. response, 51.8 % vs. 17.0 %; P<0.001).  The quality of life was also significantly better with infliximab plus methotrexate than with methotrexate alone.  Radiog. evidence of joint damage increased in the group given methotrexate, but not in the groups given infliximab and methotrexate (mean change in radiog. score, 7.0 vs. 0.6; P<0.001).  Radiog. evidence of progression of joint damage was absent in infliximab-treated patients whether or not they had a clin. response.  In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotrexate provided clin. benefit and halted the progression of joint damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqasmJKB3fqgrVg90H21EOLACvtfcHk0liBeMaScJo-eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLk%253D&md5=b67ff09ce24a2c808a265204aac20e53</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432202%26sid%3Dliteratum%253Aachs%26aulast%3DLipsky%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%2BM.%2BF.%2BM.%26aulast%3DClair%26aufirst%3DE.%2BW.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DKalden%26aufirst%3DJ.%2BR.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeisman%26aufirst%3DM.%26aulast%3DEmery%26aufirst%3DP.%26aulast%3DFeldmann%26aufirst%3DM.%26aulast%3DHarriman%26aufirst%3DG.%2BR.%26aulast%3DMaini%26aufirst%3DR.%2BN.%26atitle%3DInfliximab%2520and%2520methotrexate%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1594%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_contrib-group">Esposito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuzzocrea, S.</span><span> </span><span class="NLM_article-title">TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3152</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F092986709788803024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19689289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvVynu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=3152-3167&author=E.+Espositoauthor=S.+Cuzzocrea&title=TNF-alpha+as+a+therapeutic+target+in+inflammatory+diseases%2C+ischemia-reperfusion+injury+and+trauma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma</span></div><div class="casAuthors">Esposito, E.; Cuzzocrea, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3152-3167</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor necrosis factor-α (TNF-α) is a central regulator of inflammation, and TNF-α antagonists may be effective in treating inflammatory disorders in which TNF-α plays an important pathogenetic role.  Recombinant or modified proteins are an emerging class of therapeutic agents.  To date, several recombinant or modified proteins which acts as TNF antagonists have been disclosed.  In particular, antibodies that bind to and neutralize TNF have been sought as a means to inhibit TNF activity.  Inhibition of TNF has proven to be an effective therapy for patients with rheumatoid arthritis and other forms of inflammatory disease including psoriasis, psoriatic arthritis, and ankylosing spondylitis, inflammatory bowel disease.  Addnl., the efficacy of preventing septic shock and AIDS has been questioned as a result of recent research.  The currently available therapies include a sol. p75 TNF receptor:Fc construct, etanercept, a chimeric monoclonal antibody, infliximab, and a fully human monoclonal antibody, adalimumab.  Certolizumab pegol is a novel TNF inhibitor which is an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to increase half-life, and thus is Fc-domain-free.  In this review, the authors discuss briefly the present understanding of TNF-α-mediated biol. and the current therapies in clin. use, and focus on some of the new therapeutic approaches with small-mol. inhibitors.  Moreover, the authors examine recent reports providing important insights into the understanding of efficacy of thalidomide and its analogs, as TNF-α activity inhibitors, esp. in therapies of several inflammatory diseases within the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcxBS9PcZ2Z7Vg90H21EOLACvtfcHk0ljmRoKVVH03UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvVynu78%253D&md5=6a011a209d4b7b8616c12e1a9e293efa</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2174%2F092986709788803024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709788803024%26sid%3Dliteratum%253Aachs%26aulast%3DEsposito%26aufirst%3DE.%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DTNF-alpha%2520as%2520a%2520therapeutic%2520target%2520in%2520inflammatory%2520diseases%252C%2520ischemia-reperfusion%2520injury%2520and%2520trauma%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D3152%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_contrib-group">Ranganathan, P.</span><span> </span><span class="NLM_article-title">An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents</span> <span class="citation_source-journal">Curr. Opin. Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19051134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFKmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=562-567&author=P.+Ranganathan&title=An+update+on+pharmacogenomics+in+rheumatoid+arthritis+with+a+focus+on+TNF-blocking+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents</span></div><div class="casAuthors">Ranganathan, Prabha</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">562-567</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-8431</span>.
    
            (<span class="NLM_cas:orgname">Thomson Reuters</span>)
        </div><div class="casAbstract">A review.  TNFα is a proinflammatory cytokine, which is crucial in the pathogenesis of rheumatoid arthritis (RA).  In recent years, biol. therapies which block the damaging effects of TNFα on synovium and cartilage have been developed.  TNF antagonists, such as etanercept, infliximab and adalimumab, although highly effective in RA, are expensive, totaling several thousand US dollars in yearly costs.  In addn., only approx. 60% of patients respond to these agents.  This has led to the need to prospectively identify patients most likely to respond to these agents, which can be achieved by pharmacogenomics approaches.  Polymorphisms in genes encoding for TNFα, the MHC region, and the Fcγ receptor IIIA, as well as their ability to predict disease progression in RA and response to anti-TNF therapies, have been the focus of a no. of studies, which are discussed in this review.  There is no consensus at present as to whether pharmacogenomics will allow prediction of anti-TNF therapy efficacy in RA.  Large, prospective, multicenter studies are needed to replicate and validate the results of the studies outlined in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr914kemmVLUbVg90H21EOLACvtfcHk0ljmRoKVVH03UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFKmug%253D%253D&md5=72f31e31f013fcbc2893a46339d12db8</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRanganathan%26aufirst%3DP.%26atitle%3DAn%2520update%2520on%2520pharmacogenomics%2520in%2520rheumatoid%2520arthritis%2520with%2520a%2520focus%2520on%2520TNF-blocking%2520agents%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2008%26volume%3D10%26spage%3D562%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fujiwara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span> </span><span class="NLM_article-title">Macrophages in inflammation</span> <span class="citation_source-journal">Curr. Drug Target Inflamm. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">281</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1568010054022024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=16101534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFelsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=281-286&author=N.+Fujiwaraauthor=K.+Kobayashi&title=Macrophages+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages in inflammation</span></div><div class="casAuthors">Fujiwara, Nagatoshi; Kobayashi, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Inflammation & Allergy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-286</span>CODEN:
                <span class="NLM_cas:coden">CDTICU</span>;
        ISSN:<span class="NLM_cas:issn">1568-010X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The inflammatory process is usually tightly regulated, involving both signals that initiate and maintain inflammation and signals that shut the process down.  An imbalance between the two signals leaves inflammation unchecked, resulting in cellular and tissue damage.  Macrophages are a major component of the mononuclear phagocyte system that consists of closely related cells of bone marrow origin, including blood monocytes, and tissue macrophages.  From the blood, monocytes migrate into various tissues and transform macrophages.  In inflammation, macrophages have three major function; antigen presentation, phagocytosis, and immunomodulation through prodn. of various cytokines and growth factors.  Macrophages play a crit. role in the initiation, maintenance, and resoln. of inflammation.  They are activated and deactivated in the inflammatory process.  Activation signals include cytokines (interferon γ, granulocyte-monocyte colony stimulating factor, and tumor necrosis factor α), bacterial lipopolysaccharide, extracellular matrix proteins, and other chem. mediators.  Inhibition of inflammation by removal or deactivation of mediators and inflammatory effector cells permits the host to repair damages tissues.  Activated macrophages are deactivated by anti-inflammatory cytokines (interleukin 10 and transforming growth factor β) and cytokine antagonists that are mainly produced by macrophages.  Macrophages participate in the autoregulatory loop in the inflammatory process.  Because macrophages produce a wide range of biol. active mols. participated in both beneficial and detrimental outcomes in inflammation, therapeutic interventions targeted macrophages and their products may open new avenues for controlling inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9OWqdAk-DhLVg90H21EOLACvtfcHk0lgMT5o-WUoQNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFelsrY%253D&md5=4733a9003abbc00bd9f1906e8a183adf</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568010054022024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568010054022024%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DK.%26atitle%3DMacrophages%2520in%2520inflammation%26jtitle%3DCurr.%2520Drug%2520Target%2520Inflamm.%2520Allergy%26date%3D2005%26volume%3D4%26spage%3D281%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Tak, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daha, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluin, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijers, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinders, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span> </span><span class="NLM_article-title">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780400206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=9041933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=217-25&author=P.+P.+Takauthor=T.+J.+Smeetsauthor=M.+R.+Dahaauthor=P.+M.+Kluinauthor=K.+A.+Meijersauthor=R.+Brandauthor=A.+E.+Meindersauthor=F.+C.+Breedveld&title=Analysis+of+the+synovial+cell+infiltrate+in+early+rheumatoid+synovial+tissue+in+relation+to+disease+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</span></div><div class="casAuthors">Tak P P; Smeets T J; Daha M R; Kluin P M; Meijers K A; Brand R; Meinders A E; Breedveld F C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-25</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To define variations in the cellular infiltrate and in the expression of monokines in synovial tissue (ST) from rheumatoid arthritis (RA) patients with different durations of disease and different levels of disease activity.  METHODS:  The immunohistologic features of synovial biopsy specimens from 31 patients with early RA (< 1 year) and 35 patients with longstanding RA (> 5 years) were compared.  The possible associations between these features and local disease activity, as measured by the score for pain in the biopsied knee joint were also evaluated.  RESULTS:  The immunohistologic features were not dependent on disease duration.  We found a positive correlation between the scores for knee pain and the semiquantitative scores for the number of macrophages, as well as the expression of interleukin-6 and tumor necrosis factor alpha, whereas the correlation with the scores for CD4+ T cells was negative.  Multivariate analysis showed that these correlations were highly statistically significant (P < 0.003).  CONCLUSION:  The results do not support the view that inflammatory mechanisms in the synovial tissues of RA patients differ between early and late stages of the disease.  The findings presented here are consistent with the concept that early RA is the result of a synovitis process of longer duration and that macrophage-derived cytokines play an important role in maintaining the clinical signs of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7XPNbuR4ndNbHMBt0mMIXfW6udTcc2eZQDQm6HGlPvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7psVCqtw%253D%253D&md5=ce8d3e3ad53739d459b024a049a132cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fart.1780400206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780400206%26sid%3Dliteratum%253Aachs%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DKluin%26aufirst%3DP.%2BM.%26aulast%3DMeijers%26aufirst%3DK.%2BA.%26aulast%3DBrand%26aufirst%3DR.%26aulast%3DMeinders%26aufirst%3DA.%2BE.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26atitle%3DAnalysis%2520of%2520the%2520synovial%2520cell%2520infiltrate%2520in%2520early%2520rheumatoid%2520synovial%2520tissue%2520in%2520relation%2520to%2520disease%2520activity%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26spage%3D217%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Haringman, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwinderman, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeets, T. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baeten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bresnihan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tak, P. P.</span><span> </span><span class="NLM_article-title">Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">838</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1136%2Fard.2004.029751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15576415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=834-838&author=J.+J.+Haringmanauthor=D.+M.+Gerlagauthor=A.+H.+Zwindermanauthor=T.+J.+M.+Smeetsauthor=M.+C.+Kraanauthor=D.+Baetenauthor=I.+B.+McInnesauthor=B.+Bresnihanauthor=P.+P.+Tak&title=Synovial+tissue+macrophages%3A+A+sensitive+biomarker+for+response+to+treatment+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</span></div><div class="casAuthors">Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">834-838</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: Previous work identified synovial sublining macrophage nos. as a potential biomarker for clin. efficacy in rheumatoid arthritis.  Objective: To investigate the assocn. between changes in infiltration of synovial macrophages and clin. improvement after antirheumatic treatment.  Methods: 88 patients who participated in various clin. trials were studied.  All patients underwent serial arthroscopy before initiation of treatment and after different time intervals.  Immunohistochem. and digital image anal. were performed according to standardized procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28).  Statistical anal. was performed using one way anal. of variance, the independent samples t test, linear regression, and the standardized response mean (SRM).  Results: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages (mean (SEM) cells/mm2 -643 (124), -270 (64), and -95 (60), resp.; p<0.0003).  There was a significant correlation between the change in the no. of macrophages and the change in DAS28 (Pearson correlation 0.874, p<0.01).  The change in sublining macrophages explained 76% of the variation in the change in DAS28 (p<0.02).  The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3).  Conclusion: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDDuysAUtsbVg90H21EOLACvtfcHk0ljniJaaEX4Jaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1als70%253D&md5=3fdb6f7b0d2c170ca58e40af83af054f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1136%2Fard.2004.029751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2004.029751%26sid%3Dliteratum%253Aachs%26aulast%3DHaringman%26aufirst%3DJ.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DZwinderman%26aufirst%3DA.%2BH.%26aulast%3DSmeets%26aufirst%3DT.%2BJ.%2BM.%26aulast%3DKraan%26aufirst%3DM.%2BC.%26aulast%3DBaeten%26aufirst%3DD.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DBresnihan%26aufirst%3DB.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DSynovial%2520tissue%2520macrophages%253A%2520A%2520sensitive%2520biomarker%2520for%2520response%2520to%2520treatment%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2005%26volume%3D64%26spage%3D834%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pixley, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1 regulation of the wandering macrophage: complexity in action</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2Fj.tcb.2004.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15519852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=628-638&author=F.+J.+Pixleyauthor=E.+R.+Stanley&title=CSF-1+regulation+of+the+wandering+macrophage%3A+complexity+in+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 regulation of the wandering macrophage: complexity in action</span></div><div class="casAuthors">Pixley, Fiona J.; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">628-638</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Most tissue macrophages and osteoclasts are regulated by colony-stimulating factor-1 (CSF-1, also known as macrophage CSF).  The effects of CSF-1 are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R), through autophosphorylation of CSF-1R and the subsequent phosphorylation of downstream mols.  Triggering this phosphorylation cascade increases gene transcription and protein translation, and induces cytoskeletal remodeling by several signaling pathways, leading to the survival, proliferation and differentiation of target cells.  CSF-1-regulated tissue macrophages are important for innate immunity and for tissue development and function.  Because CSF-1 regulates the survival, proliferation and chemotaxis of macrophages and supports their activation, this factor is involved in the pathogenesis of several diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouh_AnBDWTs7Vg90H21EOLACvtfcHk0li0PkhlaYUqGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsrw%253D&md5=0b2639ed4de1366b5fba48fc6c3758ba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1%2520regulation%2520of%2520the%2520wandering%2520macrophage%253A%2520complexity%2520in%2520action%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D628%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Colony-stimulating factors in inflammation and autoimmunity</span> <span class="citation_source-journal">Nature Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1038%2Fnri2356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=18551128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1ehs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=533-544&author=J.+A.+Hamilton&title=Colony-stimulating+factors+in+inflammation+and+autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factors in inflammation and autoimmunity</span></div><div class="casAuthors">Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In addn. to their role as haematopoietic-cell growth factors, colony-stimulating factors have broader roles in immunity, and targeting these factors might have therapeutic benefits in inflammation and autoimmunity.  Although they were originally defined as haematopoietic-cell growth factors, colony-stimulating factors (CSFs) have been shown to have addnl. functions by acting directly on mature myeloid cells.  Recent data from animal models indicate that the depletion of CSFs has therapeutic benefit in many inflammatory and/or autoimmune conditions and as a result, early-phase clin. trials targeting granulocyte/macrophage colony-stimulating factor and macrophage colony-stimulating factor have now commenced.  The distinct biol. features of CSFs offer opportunities for specific targeting, but with some assocd. risks.  The author describes these biol. features, discusses the probable specific outcomes of targeting CSFs in vivo, and highlights outstanding questions that need to be addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbRS4KJDObLVg90H21EOLACvtfcHk0ljnKYtZK1K55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1ehs7k%253D&md5=13f4749ea0c4b1e5fdd5e3ebc4b14f72</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnri2356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2356%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DColony-stimulating%2520factors%2520in%2520inflammation%2520and%2520autoimmunity%26jtitle%3DNature%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D533%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Hamilton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filonzi, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ianches, G.</span><span> </span><span class="NLM_article-title">Regulation of macrophage colony-stimulating factor (CSF-1) production in cultured human synovial fibroblasts</span> <span class="citation_source-journal">Growth Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1993&pages=157-65&author=J.+A.+Hamiltonauthor=E.+L.+Filonziauthor=G.+Ianches&title=Regulation+of+macrophage+colony-stimulating+factor+%28CSF-1%29+production+in+cultured+human+synovial+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26aulast%3DFilonzi%26aufirst%3DE.%2BL.%26aulast%3DIanches%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520production%2520in%2520cultured%2520human%2520synovial%2520fibroblasts%26jtitle%3DGrowth%2520Factors%26date%3D1993%26volume%3D9%26spage%3D157%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ianches, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">Production of macrophage colony-stimulating factor (CSF-1) by human articular cartilage and chondrocytes. Modulation by interleukin-1 and tumor necrosis factor alpha</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">1182</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=1993&pages=57-63&author=I.+K.+Campbellauthor=G.+Ianchesauthor=J.+A.+Hamilton&title=Production+of+macrophage+colony-stimulating+factor+%28CSF-1%29+by+human+articular+cartilage+and+chondrocytes.+Modulation+by+interleukin-1+and+tumor+necrosis+factor+alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DIanches%26aufirst%3DG.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DProduction%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520by%2520human%2520articular%2520cartilage%2520and%2520chondrocytes.%2520Modulation%2520by%2520interleukin-1%2520and%2520tumor%2520necrosis%2520factor%2520alpha%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1993%26volume%3D1182%26spage%3D57%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nakano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanikawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamukai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaguri, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=597-603&author=K.+Nakanoauthor=Y.+Okadaauthor=K.+Saitoauthor=R.+Tanikawaauthor=N.+Sawamukaiauthor=Y.+Sasaguriauthor=T.+Kohroauthor=Y.+Wadaauthor=T.+Kodamaauthor=Y.+Tanaka&title=Rheumatoid+synovial+endothelial+cells+produce+macrophage+colony-stimulating+factor+leading+to+osteoclastogenesis+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakano%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DTanikawa%26aufirst%3DR.%26aulast%3DSawamukai%26aufirst%3DN.%26aulast%3DSasaguri%26aufirst%3DY.%26aulast%3DKohro%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DRheumatoid%2520synovial%2520endothelial%2520cells%2520produce%2520macrophage%2520colony-stimulating%2520factor%2520leading%2520to%2520osteoclastogenesis%2520in%2520rheumatoid%2520arthritis%26jtitle%3DRheumatology%26date%3D2007%26volume%3D46%26spage%3D597%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokomuro, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, Y.</span><span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Nippon Ika Daigaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1272%2Fjnms1923.62.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=7615698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=260-270&author=H.+Kawajiauthor=K.+Yokomuroauthor=K.+Kikuchiauthor=Y.+Somotoauthor=Y.+Shirai&title=Macrophage+colony-stimulating+factor+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor in patients with rheumatoid arthritis</span></div><div class="casAuthors">Kawaji, Hidemi; Yokomuro, Kozo; Kikuchi, Kyoko; Somoto, Youki; Shirai, Yasumasa</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Ika Daigaku Zasshi</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-70</span>CODEN:
                <span class="NLM_cas:coden">NIDZAJ</span>;
        ISSN:<span class="NLM_cas:issn">0048-0444</span>.
    </div><div class="casAbstract">We developed a new ELISA technique to measure macrophage colony-stimulating factor (M-CSF) levels in synovial fluid with high sensitivity and reproducibility.  The mean M-CSF level in the synovial fluid of patients with rheumatoid arthritis (RA) was 1.38 ± 0.56 ng/mL, and that of patients with osteoarthritis (OA) was 0.67 ± 0.13 ng/mL.  In contrast, serum levels of M-CSF in patients with RA and in normal controls were 1.32 ± 0.50 ng/mL and 0.90 ± 0.09 ng/mL, resp.  These differences were both statistically significant.  Since serum M-CSF levels correlate with inflammatory signs obtained from examn. of blood, they indicate the general condition of patients with RA.  Synovial fluid M-CSF levels increase even in the early phase of RA and remain high despite drug therapy, which suggests that they reflect the condition of affected joints including joint spaces and inflamed synovia more directly than do the levels of serum M-CSF.  Measurement of the M-CSF level in the synovial fluid may be useful in the diagnosis, clin. evaluation, and assessment of the effects of treatment in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomBgcRjuSmvLVg90H21EOLACvtfcHk0ljGZymR3f9MNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1WhtrY%253D&md5=2d5c872c01ea9a95560af0412a2967e2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1272%2Fjnms1923.62.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1272%252Fjnms1923.62.260%26sid%3Dliteratum%253Aachs%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DYokomuro%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DSomoto%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DY.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DNippon%2520Ika%2520Daigaku%2520Zasshi%26date%3D1995%26volume%3D62%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ritchlin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucala, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winchester, R.</span><span> </span><span class="NLM_article-title">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1111%2Fj.1365-3083.1994.tb03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8091128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=292-298&author=C.+Ritchlinauthor=E.+Dwyerauthor=R.+Bucalaauthor=R.+Winchester&title=Sustained+and+distinctive+patterns+of+gene+activation+in+synovial+fibroblasts+and+whole+synovial+tissue+obtained+from+inflammatory+synovitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis</span></div><div class="casAuthors">Ritchlin, C.; Dwyer, E.; Bucala, R.; Winchester, R.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-8</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    </div><div class="casAbstract">Fibroblastoid synovial lining cells isolated from rheumatoid and other chronic inflammatory synovial tissue exhibit distinctive and sustained alterations in serial culture not commonly found in similarly cultured cells from osteoarthritic synovium.  These are demonstrable using a multi-gene dot blot assay by labeling reverse transcribed fibroblast cDNA which is hybridized to plasmids contg. relevant target gene inserts.  Cultured synovial fibroblastoid cells from patients with chronic inflammatory synovitis expressed significantly higher levels of stromelysin, vimentin and TIMP-1 mRNA and lower levels of c-myc compared to cells isolated from osteoarthritis synovium although with considerable variation.  Early fetal synovial lining cells were similar to cells from osteoarthritis synovium but vimentin expression was higher.  Marked differences in patterns of gene expression between cell lines persisted through 10 serial passages over 6-8 mo.  In whole synovia, the av. level of mRNA for stromelysin, vimentin, IL-4, IL-6, TIMP-1, cathepsin D, gelatinase, TGFα, c-fms and DRβ were preferentially expressed in inflammatory tissue while c-myc expression was higher in osteoarthritis synovium.  Inflammatory synovium also expressed TNFα, IL-1α, IL-1β, IL-2, c-sis, tissue plasminogen activator, CSF-1, and GM-CSF.  This pattern resembles, in part, that found in cultured inflammatory fibroblasts but, in addn., gene products apparently reflecting the presence of activated monocytes and lymphocytes were detected.  These results provide evidence that profiles of certain gene activation in cells from patients with inflammatory synovitis differ from those with non-inflammatory disease and suggest that the fibroblastoid cells are responsible for a considerable proportion of the altered phenotypic expression pattern in whole tissue.  Furthermore, this modulated pattern of gene activation appears to be an intrinsic pro-inflammatory characteristic of the fibroblastoid cells initiated in response to chronic inflammation and persists for a prolonged period in the absence of other inflammatory cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUd6F-8PCMFbVg90H21EOLACvtfcHk0ljGZymR3f9MNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1yls7g%253D&md5=0e00011784fe504612c79350cea6a90a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-3083.1994.tb03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-3083.1994.tb03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%26aulast%3DDwyer%26aufirst%3DE.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DWinchester%26aufirst%3DR.%26atitle%3DSustained%2520and%2520distinctive%2520patterns%2520of%2520gene%2520activation%2520in%2520synovial%2520fibroblasts%2520and%2520whole%2520synovial%2520tissue%2520obtained%2520from%2520inflammatory%2520synovitis%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1994%26volume%3D40%26spage%3D292%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Takei, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santavirta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span> </span><span class="NLM_article-title">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">894</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10782812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=894-899&author=I.+Takeiauthor=M.+Takagiauthor=H.+Idaauthor=T.+Oginoauthor=S.+Santavirtaauthor=Y.+T.+Konttinen&title=High+macrophage-colony+stimulating+factor+levels+in+synovial+fluid+of+loose+artificial+hip+joints"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints</span></div><div class="casAuthors">Takei, Isao; Takagi, Michiaki; Ida, Hideo; Ogino, Toshihiko; Santavirta, Seppo; Konttinen, Yrjo T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-899</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective. To clarify a macrophage-colony stimulating factor (M-CSF) related mechanism of aseptic loosening of artificial hip joints.  Methods. Synovium-like interface tissues between bone and prosthesis, regenerated pseudocapsular tissues, and synovial fluid (SF) were collected from 9 patients with loose artificial hip joint at revision surgery.  Tissue distribution, prodn. site, and SF level of M-CSF in loose hip joints were investigated by immunohistochem., reverse transcription-polymerase chain reaction (RT-PCR), and ELISA, resp.  For a comparative assessment of the M-CSF level in loose hip joints, SF of active rheumatoid arthritis (RA) and mild osteoarthritis (OA) also were analyzed by ELISA.  Results. Immunohistochem. anal. showed the presence of M-CSF immunoreactive cells mainly in the interface tissues between bone and prosthesis and inner pseudocapsular tissues, both of which were in contact with joint fluid.  RT-PCR anal. confirmed the local prodn. of M-CSF in these periprosthetic tissues.  Significantly higher M-CSF level in loose hip joint fluid than in active RA and mild OA fluid was revealed by ELISA.  Conclusion. High M-CSF level in loose hip joint fluid suggests transportation of M-CSF from prodn. sites to joint fluid.  This indicates that not only polyethylene wear particles (reported to induce foreign body reaction at the bone-prosthesis interface), but also M-CSF, abundant in joint fluid, are transported to and affect the interface.  Thus, M-CSF is locally produced in periprosthetic tissues of loose hip joints and possibly contributes to periprosthetic weakening and osteolysis via joint fluid, leading to prosthetic loosening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlI9pPe59SQbVg90H21EOLACvtfcHk0lg_3DGvXav2og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFOrsb8%253D&md5=08e093f0c23066d5df935638e9fac9d0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakei%26aufirst%3DI.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DOgino%26aufirst%3DT.%26aulast%3DSantavirta%26aufirst%3DS.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26atitle%3DHigh%2520macrophage-colony%2520stimulating%2520factor%2520levels%2520in%2520synovial%2520fluid%2520of%2520loose%2520artificial%2520hip%2520joints%26jtitle%3DJ.%2520Rheumatol.%26date%3D2000%26volume%3D27%26spage%3D894%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zafiropoulis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, I. K.</span><span> </span><span class="NLM_article-title">Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM-CSF): Evidence of macrophage infiltration and local proliferation</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1046%2Fj.1365-2249.2000.01125.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10632676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1eit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2000&pages=361-367&author=R.+J.+Bischofauthor=D.+Zafiropoulisauthor=J.+A.+Hamiltonauthor=I.+K.+Campbell&title=Exacerbation+of+acute+inflammatory+arthritis+by+the+colony-stimulating+factors+CSF-1+and+granulocyte+macrophage+%28GM-CSF%29%3A+Evidence+of+macrophage+infiltration+and+local+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM-CSF): evidence of macrophage infiltration and local proliferation</span></div><div class="casAuthors">Bischof, R. J.; Zafiropoulos, D.; Hamilton, J. A.; Campbell, I. K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">CSF-1 and GM-CSF have been implicated in the pathogenesis of rheumatoid arthritis.  We report the effects of CSF-1 and GM-CSF in the development of an acute methylated bovine serum albumin (mBSA)-induced murine arthritis model.  Examn. of histopathol. features revealed that the systemic administration of CSF-1 or GM-CSF following mBSA administration into the knee resulted in the exacerbation of arthritis.  This included synovial hyperplasia and joint inflammation, most evident at 7 and 14 days post-mBSA administration, and the appearance of erosive pannus tissue.  The exacerbation by CSF-1 and GM-CSF was not sustained but declined in incidence and severity by 21 days post-mBSA administration, similar to the effects of IL-1β in this model, reported here and previously.  Macrophages expressing Mac-2 and F4/80 were a prominent feature of the pathol. obsd., particularly the infiltration of Mac-2+ macrophages seen in all mice administered CSF-1, GM-CSF or IL-1β.  Present in inflamed knees was a locally dividing population of cells which included Mac-2+ and F4/80+ macrophages.  These studies demonstrate that CSF-1 and GM-CSF can exacerbate and prolong the histopathol. of acute inflammatory arthritis and lend support to monocytes/macrophages being a driving influence in the pathogenesis of inflammatory arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWH8ISBl0mQrVg90H21EOLACvtfcHk0lg4UkouckFwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1eit70%253D&md5=e252105e7672e8ae9651b602c729bf66</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2249.2000.01125.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2249.2000.01125.x%26sid%3Dliteratum%253Aachs%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DZafiropoulis%26aufirst%3DD.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26atitle%3DExacerbation%2520of%2520acute%2520inflammatory%2520arthritis%2520by%2520the%2520colony-stimulating%2520factors%2520CSF-1%2520and%2520granulocyte%2520macrophage%2520%2528GM-CSF%2529%253A%2520Evidence%2520of%2520macrophage%2520infiltration%2520and%2520local%2520proliferation%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2000%26volume%3D119%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Abd, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halliday, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span> </span><span class="NLM_article-title">The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate: actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents</span> <span class="citation_source-journal">Lymphokine Cytokine Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=1873358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK3MXks12ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=43-50&author=A.+H.+Abdauthor=N.+W.+Savageauthor=W.+J.+Hallidayauthor=D.+A.+Hume&title=The+role+of+macrophages+in+experimental+arthritis+induced+by+Streptococcus+agalactiae+sonicate%3A+actions+of+macrophage+colony-stimulating+factor+%28CSF-1%29+and+other+macrophage-modulating+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate:  actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents</span></div><div class="casAuthors">Abd, Abdul Hadi A.; Savage, Neil W.; Halliday, William J.; Hume, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Lymphokine and Cytokine Research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">LCREEY</span>;
        ISSN:<span class="NLM_cas:issn">1056-5477</span>.
    </div><div class="casAbstract">The i.p. injection of S. agalactiae sonicated cells into Wistar rats causes a chronic relapsing polyarthritis resembling human rheumatoid arthritis.  Evidence is reported favoring a role for macrophages in the pathol. of this disease.  S. agalactiae injected i.p. induced a high level of tumor necrosis factor release by peritoneal macrophages isolated subsequently, and had a similar effect when added to control peritoneal macrophages in culture.  Ia antigen was induced on macrophages in both the peritoneum and affected joints following S. agalactiae injection.  The role of macrophages in the disease process was studied by treating animals prior to S. agalactiae injection with varying concns. of bacterial lipopolysaccharide (LPS), silica, and carrageenan, agents known to have a biphasic effect on macrophage function.  They aggravated the pathol. at low doses but prevented the disease at high doses.  The most specific alteration of macrophage levels was achieved by injection of recombinant human macrophage colony-stimulating factor (CSF-1).  Treatment with CSF-1 early in the disease lead to significant worsening of the pathol.  Administration of CSF-1 after 2 wk reactivated the disease and extended the chronic phase.  These data in combination with previous findings are consistent with nonimmune, macrophage-mediated pathol. for this model of arthritis.  The results have implications for therapeutic application of CSF-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofFEhOzL1k3LVg90H21EOLACvtfcHk0lg4UkouckFwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXks12ktb8%253D&md5=38e265dc64062a8ac3ef4d9fde84b020</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbd%26aufirst%3DA.%2BH.%26aulast%3DSavage%26aufirst%3DN.%2BW.%26aulast%3DHalliday%26aufirst%3DW.%2BJ.%26aulast%3DHume%26aufirst%3DD.%2BA.%26atitle%3DThe%2520role%2520of%2520macrophages%2520in%2520experimental%2520arthritis%2520induced%2520by%2520Streptococcus%2520agalactiae%2520sonicate%253A%2520actions%2520of%2520macrophage%2520colony-stimulating%2520factor%2520%2528CSF-1%2529%2520and%2520other%2520macrophage-modulating%2520agents%26jtitle%3DLymphokine%2520Cytokine%2520Res.%26date%3D1991%26volume%3D10%26spage%3D43%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Campbell, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. A.</span><span> </span><span class="NLM_article-title">The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=10914502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=144-150&author=I.+K.+Campbellauthor=M.+J.+Richauthor=R.+J.+Bischofauthor=J.+A.+Hamilton&title=The+colony-stimulating+factors+and+collagen-induced+arthritis%3A+Exacerbation+of+disease+by+M-CSF+and+G-CSF+and+requirement+for+endogenous+M-CSF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF</span></div><div class="casAuthors">Campbell, Ian K.; Rich, Melissa J.; Bischof, Robert J.; Hamilton, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">There is increasing evidence that the colony-stimulating factors (CSFs) may play a part in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA).  The authors examd. the involvement of macrophage CSF (M-CSF or CSF-1) and granulocyte CSF (G-CSF) in collagen-induced arthritis (CIA), a murine model of RA.  Daily injections of M-CSF or G-CSF, 20-24 days postprimary immunization with type II collagen, exacerbated disease symptoms in suboptimally immunized DBA/1 mice.  Support for the involvement of endogenous M-CSF in CIA was obtained by studies in which neutralizing monoclonal antibody reduced the severity of established CIA and also by studies showing the resistance of M-CSF-deficient op/op mice to CIA induction.  These studies show that M-CSF and G-CSF can be proinflammatory in CIA and provide evidence that macrophage- and granulocyte-lineage cells can exacerbate CIA.  The authors' results also show that M-CSF-dependent cells are essential for CIA development, suggesting M-CSF may be a suitable target for therapeutic intervention in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobmj_XMRtR77Vg90H21EOLACvtfcHk0liHmW3frpHDEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVGmtrw%253D&md5=e37a81523dba2270449366102252c4b2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DI.%2BK.%26aulast%3DRich%26aufirst%3DM.%2BJ.%26aulast%3DBischof%26aufirst%3DR.%2BJ.%26aulast%3DHamilton%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520colony-stimulating%2520factors%2520and%2520collagen-induced%2520arthritis%253A%2520Exacerbation%2520of%2520disease%2520by%2520M-CSF%2520and%2520G-CSF%2520and%2520requirement%2520for%2520endogenous%2520M-CSF%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2000%26volume%3D68%26spage%3D144%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ohno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokieda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohseki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serizawa, I.</span><span> </span><span class="NLM_article-title">The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model</span> <span class="citation_source-journal">Eur. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=283-298&author=H.+Ohnoauthor=Y.+Uemuraauthor=H.+Murookaauthor=H.+Takanashiauthor=T.+Tokiedaauthor=Y.+Ohsekiauthor=K.+Kuboauthor=I.+Serizawa&title=The+orally-active+and+selective+c-Fms+tyrosine+kinase+inhibitor+Ki20227+inhibits+disease+progression+in+a+collagen-induced+arthritis+mouse+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DTokieda%26aufirst%3DT.%26aulast%3DOhseki%26aufirst%3DY.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520orally-active%2520and%2520selective%2520c-Fms%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520inhibits%2520disease%2520progression%2520in%2520a%2520collagen-induced%2520arthritis%2520mouse%2520model%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2008%26volume%3D38%26spage%3D283%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutta, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-5-ones: A novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1081</span><span class="NLM_x">–</span> <span class="NLM_lpage">1091</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801406h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1081-1091&author=H.+Huangauthor=D.+A.+Huttaauthor=J.+M.+Rinkerauthor=H.+Huauthor=W.+H.+Parsonsauthor=C.+Schubertauthor=R.+L.+DesJarlaisauthor=C.+S.+Cryslerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=Y.+Chenauthor=D.+Chengauthor=Z.+Zhouauthor=E.+Yurkowauthor=C.+L.+Mantheyauthor=M.+R.+Player&title=Pyrido%5B2%2C3-d%5Dpyrimidin-5-ones%3A+A+novel+class+of+antiinflammatory+macrophage+colony-stimulating+factor-1+receptor+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm801406h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801406h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHutta%26aufirst%3DD.%2BA.%26aulast%3DRinker%26aufirst%3DJ.%2BM.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DParsons%26aufirst%3DW.%2BH.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYurkow%26aufirst%3DE.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-5-ones%253A%2520A%2520novel%2520class%2520of%2520antiinflammatory%2520macrophage%2520colony-stimulating%2520factor-1%2520receptor%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1081%26epage%3D1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Meyers, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamtekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poda, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michener, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Sa. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorarensen, A.</span><span> </span><span class="NLM_article-title">Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1543-1547&author=M.+J.+Meyersauthor=M.+Pelcauthor=S.+Kamtekarauthor=J.+Dayauthor=G.+I.+Podaauthor=M.+K.+Hallauthor=M.+L.+Michenerauthor=B.+A.+Reitzauthor=K.+J.+Mathisauthor=B.+S.+Pierceauthor=M.+D.+Parikhauthor=D.+A.+Mischkeauthor=Sa.+A.+Longauthor=J.+J.+Parlowauthor=D.+A.+Andersonauthor=A.+Thorarensen&title=Structure-based+drug+design+enables+conversion+of+a+DFG-in+binding+CSF-1R+kinase+inhibitor+to+a+DFG-out+binding+mode"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeyers%26aufirst%3DM.%2BJ.%26aulast%3DPelc%26aufirst%3DM.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DJ.%26aulast%3DPoda%26aufirst%3DG.%2BI.%26aulast%3DHall%26aufirst%3DM.%2BK.%26aulast%3DMichener%26aufirst%3DM.%2BL.%26aulast%3DReitz%26aufirst%3DB.%2BA.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DLong%26aufirst%3DSa.%2BA.%26aulast%3DParlow%26aufirst%3DJ.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BA.%26aulast%3DThorarensen%26aufirst%3DA.%26atitle%3DStructure-based%2520drug%2520design%2520enables%2520conversion%2520of%2520a%2520DFG-in%2520binding%2520CSF-1R%2520kinase%2520inhibitor%2520to%2520a%2520DFG-out%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1543%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Paniagua, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariano, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindstrom, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, W. H.</span><span> </span><span class="NLM_article-title">c-Fms-mediated differentiation and priming of monocyte lineage cells plays a central role in autoimmune arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">R32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=R32&author=R.+T.+Paniaguaauthor=A.+Changauthor=M.+M.+Marianoauthor=E.+A.+Steinauthor=Q.+Wangauthor=T.+M.+Lindstromauthor=O.+Sharpeauthor=C.+Roscowauthor=P.+P.+Hoauthor=D.+M.+Leeauthor=W.+H.+Robinson&title=c-Fms-mediated+differentiation+and+priming+of+monocyte+lineage+cells+plays+a+central+role+in+autoimmune+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaniagua%26aufirst%3DR.%2BT.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DMariano%26aufirst%3DM.%2BM.%26aulast%3DStein%26aufirst%3DE.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLindstrom%26aufirst%3DT.%2BM.%26aulast%3DSharpe%26aufirst%3DO.%26aulast%3DRoscow%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26atitle%3Dc-Fms-mediated%2520differentiation%2520and%2520priming%2520of%2520monocyte%2520lineage%2520cells%2520plays%2520a%2520central%2520role%2520in%2520autoimmune%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3DR32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ando, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nampei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuboi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tateishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, H.</span><span> </span><span class="NLM_article-title">Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)</span> <span class="citation_source-journal">J. Bone Miner. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=274-282&author=W.+Andoauthor=J.+Hashimotoauthor=A.+Nampeiauthor=H.+Tsuboiauthor=K.+Tateishiauthor=T.+Onoauthor=N.+Nakamuraauthor=T.+Ochiauthor=H.+Yoshikawa&title=Imatinib+mesylate+inhibits+osteoclastogenesis+and+joint+destruction+in+rats+with+collagen-induced+arthritis+%28CIA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DW.%26aulast%3DHashimoto%26aufirst%3DJ.%26aulast%3DNampei%26aufirst%3DA.%26aulast%3DTsuboi%26aufirst%3DH.%26aulast%3DTateishi%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DN.%26aulast%3DOchi%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DH.%26atitle%3DImatinib%2520mesylate%2520inhibits%2520osteoclastogenesis%2520and%2520joint%2520destruction%2520in%2520rats%2520with%2520collagen-induced%2520arthritis%2520%2528CIA%2529%26jtitle%3DJ.%2520Bone%2520Miner.%2520Metab.%26date%3D2006%26volume%3D24%26spage%3D274%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span> </span><span class="NLM_article-title">JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3151</span><span class="NLM_x">–</span> <span class="NLM_lpage">3161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1158%2F1535-7163.MCT-09-0255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=19887542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3151-3161&author=C.+L.+Mantheyauthor=D.+L.+Johnsonauthor=C.+R.+Illigauthor=R.+W.+Tumanauthor=Z.+Zhouauthor=J.+F.+Bakerauthor=M.+A.+Chaikinauthor=R.+R.+Donatelliauthor=C.+F.+Franksauthor=L.+Zengauthor=C.+Cryslerauthor=Y.+Chenauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=S.+K.+Meegallaauthor=K.+J.+Wilsonauthor=M.+J.+Wallauthor=J.+Chenauthor=S.+K.+Ballentineauthor=H.+Ottauthor=C.+Baumannauthor=D.+Lawrenceauthor=B.+E.+Tomczukauthor=C.+J.+Molloy&title=JNJ-28312141%2C+a+novel+orally+active+colony-stimulating+factor-1+receptor%2FFMS-related+receptor+tyrosine+kinase-3+receptor+tyrosine+kinase+inhibitor+with+potential+utility+in+solid+tumors%2C+bone+metastases%2C+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia</span></div><div class="casAuthors">Manthey, Carl L.; Johnson, Dana L.; Illig, Carl R.; Tuman, Robert W.; Zhou, Zhao; Baker, Judith F.; Chaikin, Margery A.; Donatelli, Robert R.; Franks, Carol F.; Zeng, Lee; Crysler, Carl; Chen, Yanmin; Yurkow, Edward J.; Boczon, Lisa; Meegalla, Sanath K.; Wilson, Kenneth J.; Wall, Mark J.; Chen, Jinsheng; Ballentine, Shelley K.; Ott, Heidi; Baumann, Christian; Lawrence, Danielle; Tomczuk, Bruce E.; Molloy, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3151-3161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is increasing evidence that tumor-assocd. macrophages promote the malignancy of some cancers.  Colony-stimulating factor-1 (CSF-1) is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation.  Herein, we report the efficacy of a novel orally active CSF-1 receptor (CSF-1R) kinase inhibitor, JNJ-28312141, in proof of concept studies of solid tumor growth and tumor-induced bone erosion.  H460 lung adenocarcinoma cells did not express CSF-1R and were not growth inhibited by JNJ-28312141 in vitro.  Nevertheless, daily p.o. administration of JNJ-28312141 caused dose-dependent suppression of H460 tumor growth in nude mice that correlated with marked redns. in F4/80+ tumor-assocd. macrophages and with increased plasma CSF-1, a possible biomarker of CSF-1R inhibition.  Furthermore, the tumor microvasculature was reduced in JNJ-28312141-treated mice, consistent with a role for macrophages in tumor angiogenesis.  In sep. studies, JNJ-28312141 was compared with zoledronate in a model in which MRMT-1 mammary carcinoma cells inoculated into the tibias of rats led to severe cortical and trabecular bone lesions.  Both agents reduced tumor growth and preserved bone.  However, JNJ-28312141 reduced the no. of tumor-assocd. osteoclasts superior to zoledronate.  JNJ-28312141 exhibited addnl. activity against FMS-related receptor tyrosine kinase-3 (FLT3).  To more fully define the therapeutic potential of this new agent, JNJ-28312141 was evaluated in a FLT3-dependent acute myeloid leukemia tumor xenograft model and caused tumor regression.  In summary, this novel CSF-1R/FLT3 inhibitor represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoczFTUc5L_ULVg90H21EOLACvtfcHk0lgBgNuqUa7dYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7zN&md5=075f93c0c1bb1b7efdf07f551cbda1ab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0255%26sid%3Dliteratum%253Aachs%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DTuman%26aufirst%3DR.%2BW.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBaker%26aufirst%3DJ.%2BF.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DFranks%26aufirst%3DC.%2BF.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DCrysler%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DOtt%26aufirst%3DH.%26aulast%3DBaumann%26aufirst%3DC.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26atitle%3DJNJ-28312141%252C%2520a%2520novel%2520orally%2520active%2520colony-stimulating%2520factor-1%2520receptor%252FFMS-related%2520receptor%2520tyrosine%2520kinase-3%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potential%2520utility%2520in%2520solid%2520tumors%252C%2520bone%2520metastases%252C%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3151%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lj_u1WIq5lVVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wustrow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Coupling of arylboronic acid with a partially reduced pyridine derivative</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-1991-26626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=993-995&author=D.+J.+Wustrowauthor=L.+D.+Wise&title=Coupling+of+arylboronic+acid+with+a+partially+reduced+pyridine+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of arylboronic acid with a partially reduced pyridine derivative</span></div><div class="casAuthors">Wustrow, David J.; Wise, Lawrence D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-5</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">1,2,3,6-Tetrahydro-4-[(trifluoromethyl)sulfonyloxy]pyridine-1-carboxylate I (R = tert-butoxycarbonyl, R1 = triflate) was prepd. and underwent palladium-catalyzed coupling reactions with a variety of substituted arylboronic acids to produce a series of tert-butyl-4-aryl-1,2,3,6-tetrahydropyridine-1-carboxylates I (R as above, R1 = substituted Ph, 1-naphthyl).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwI9XvXHB0iLVg90H21EOLACvtfcHk0lhN8OpRah0Ktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D&md5=e585b1222bbd08f3a5afd0ffd64cc71f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-1991-26626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1991-26626%26sid%3Dliteratum%253Aachs%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DCoupling%2520of%2520arylboronic%2520acid%2520with%2520a%2520partially%2520reduced%2520pyridine%2520derivative%26jtitle%3DSynthesis%26date%3D1991%26spage%3D993%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Cyano-substituted 2-carboxyimidazoles: Synthesis of 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate potassium salt</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">3377</span><span class="NLM_x">–</span> <span class="NLM_lpage">3379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-0028-1083173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1an" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=3377-3379&author=M.+J.+Wallauthor=C.+Schubertauthor=C.+R.+Illig&title=Cyano-substituted+2-carboxyimidazoles%3A+Synthesis+of+4-cyano-1-%7B%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl%7D-1H-imidazole-2-carboxylate+potassium+salt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cyano-substituted 2-carboxyimidazoles: synthesis of 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate potassium salt</span></div><div class="casAuthors">Wall, Mark J.; Schubert, Carsten; Illig, Carl R.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3377-3379</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">The first example of a monocyano-substituted 2-carboxyimidazole is reported.  A synthesis of potassium 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate is demonstrated where the carboxyl group is introduced via Br-Mg exchange on a SEM-protected cyanoimidazole followed by reaction with EtO2CCN.  The synthesis includes the equil. of a regioisomeric mixt. of SEM-protected imidazoles to give a single product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES2QhohkQ-LVg90H21EOLACvtfcHk0lgO2t4b164F4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1an&md5=4dfdfd44932ff10f4781fcbfb82e200f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1055%2Fs-0028-1083173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0028-1083173%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DCyano-substituted%25202-carboxyimidazoles%253A%2520Synthesis%2520of%25204-cyano-1-%257B%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%257D-1H-imidazole-2-carboxylate%2520potassium%2520salt%26jtitle%3DSynthesis%26date%3D2008%26spage%3D3377%26epage%3D3379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurkow, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boczon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2097&author=M.+J.+Wallauthor=J.+Chenauthor=S.+Meegallaauthor=S.+K.+Ballentineauthor=K.+J.+Wilsonauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=M.+A.+Chaikinauthor=C.+S.+Cryslerauthor=I.+Petrouniaauthor=R.+R.+Donatelliauthor=E.+J.+Yurkowauthor=L.+Boczonauthor=M.+Mazzulaauthor=M.+R.+Playerauthor=R.+J.+Patchauthor=C.+L.+Mantheyauthor=C.+J.+Molloyauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Synthesis+and+evaluation+of+novel+3%2C4%2C6-substituted+2-quinolones+as+FMS+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeegalla%26aufirst%3DS.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DYurkow%26aufirst%3DE.%2BJ.%26aulast%3DBoczon%26aufirst%3DL.%26aulast%3DMazzula%26aufirst%3DM.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%25203%252C4%252C6-substituted%25202-quinolones%2520as%2520FMS%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baindur, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadra, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgiadas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span> </span><span class="NLM_article-title">Potent 2-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6070&author=R.+J.+Patchauthor=B.+M.+Brandtauthor=D.+Asgariauthor=N.+Baindurauthor=N.+K.+Chadraauthor=T.+Georgiadasauthor=W.+S.+Cheungauthor=I.+Petrouniaauthor=R.+R.+Donatelliauthor=M.+A.+Chaikinauthor=M.+R.+Player&title=Potent+2-aminoanilide+inhibitors+of+cFMS+as+potential+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DBrandt%26aufirst%3DB.%2BM.%26aulast%3DAsgari%26aufirst%3DD.%26aulast%3DBaindur%26aufirst%3DN.%26aulast%3DChadra%26aufirst%3DN.%2BK.%26aulast%3DGeorgiadas%26aufirst%3DT.%26aulast%3DCheung%26aufirst%3DW.%2BS.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DDonatelli%26aufirst%3DR.%2BR.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DPotent%25202-aminoanilide%2520inhibitors%2520of%2520cFMS%2520as%2520potential%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalk-Hihi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deckman, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurlino, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, B. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">4094</span><span class="NLM_x">–</span> <span class="NLM_lpage">4101</span><div class="note"><p class="first last">PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y">2I0Y</a></p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=4094-4101&author=C.+Schubertauthor=C.+Schalk-Hihiauthor=G.+T.+Strubleauthor=H.+C.+Maauthor=I.+P.+Petrouniaauthor=B.+Brandtauthor=I.+C.+Deckmanauthor=R.+J.+Patchauthor=M.+R.+Playerauthor=J.+C.+Spurlinoauthor=B.+A.+Springer&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+colony-stimulating+factor-1+receptor+%28cFMS%29+in+complex+with+two+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DSchalk-Hihi%26aufirst%3DC.%26aulast%3DStruble%26aufirst%3DG.%2BT.%26aulast%3DMa%26aufirst%3DH.%2BC.%26aulast%3DPetrounia%26aufirst%3DI.%2BP.%26aulast%3DBrandt%26aufirst%3DB.%26aulast%3DDeckman%26aufirst%3DI.%2BC.%26aulast%3DPatch%26aufirst%3DR.%2BJ.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DSpurlino%26aufirst%3DJ.%2BC.%26aulast%3DSpringer%26aufirst%3DB.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528cFMS%2529%2520in%2520complex%2520with%2520two%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D4094%26epage%3D4101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, M. J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Discovery of novel FMS kinase inhibitors as anti-inflammatory agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1642</span><span class="NLM_x">–</span> <span class="NLM_lpage">1648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1642-1648&author=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=M.+J+Rudolphauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Discovery+of+novel+FMS+kinase+inhibitors+as+anti-inflammatory+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DRudolph%26aufirst%3DM.%2BJ%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DDiscovery%2520of%2520novel%2520FMS%2520kinase%2520inhibitors%2520as%2520anti-inflammatory%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1642%26epage%3D1648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_contrib-group">Kaplowitz, N.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug hepatotoxicity</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=489-499&author=N.+Kaplowitz&title=Idiosyncratic+drug+hepatotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaplowitz%26aufirst%3DN.%26atitle%3DIdiosyncratic%2520drug%2520hepatotoxicity%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D489%26epage%3D499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_contrib-group">Ju, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, J. P.</span><span> </span><span class="NLM_article-title">Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1389200023337333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12093356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=367-377&author=C.+Juauthor=J.+P.+Uetrecht&title=Mechanism+of+idiosyncratic+drug+reactions%3A+Reactive+metabolite+formation%2C+protein+binding+and+the+regulation+of+the+immune+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system</span></div><div class="casAuthors">Ju, C.; Uetrecht, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-377</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug-induced adverse reactions, esp. type B reactions, represent a major clin. problem.  They also impart a significant degree of uncertainty into drug development because they are often not detected until the drug has been released onto the market.  Type B reactions are also termed idiosyncratic drug reactions by many investigators due to their unpredictable nature and our lack of understanding of the mechanisms involved.  It is currently believed that the majority of these reactions are immune-mediated and are caused by immunogenic conjugates formed from the reaction of a reactive metabolite of a drug with cellular proteins.  It has been shown that most drugs assocd. with idiosyncratic reactions form reactive metabolites to some degree.  Covalent binding of reactive metabolites to cellular proteins has also been shown in many cases.  However, studies to reveal the role of reactive metabolites and their protein-adducts in the mechanism of drug-induced idiosyncratic reactions are lacking.  This review will focus on our current understanding and speculative views on how a reactive metabolite of a drug might ultimately lead to immune-mediated toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpowmI5awuRjLVg90H21EOLACvtfcHk0lgr8RKJXz7Few"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCqtrg%253D&md5=c678c3f4bcf9a775bedb690c6986381e</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.2174%2F1389200023337333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337333%26sid%3Dliteratum%253Aachs%26aulast%3DJu%26aufirst%3DC.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DMechanism%2520of%2520idiosyncratic%2520drug%2520reactions%253A%2520Reactive%2520metabolite%2520formation%252C%2520protein%2520binding%2520and%2520the%2520regulation%2520of%2520the%2520immune%2520system%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D367%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva Elipe., M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arison, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgey, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx025635l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=198-207&author=R.+Singhauthor=M.+V.+Silva+Elipe.author=P.+G.+Pearsonauthor=B.+H.+Arisonauthor=B.+K.+Wongauthor=R.+Whiteauthor=X.+Yuauthor=C.+S.+Burgeyauthor=J.+H.+Linauthor=T.+A.+Baillie&title=Metabolic+activation+of+a+pyrazinone-containing+thrombin+inhibitor.+Evidence+for+novel+biotransformation+involving+pyrazinone+ring+oxidation%2C+rearrangement%2C+and+covalent+binding+to+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx025635l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx025635l%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSilva%2BElipe.%26aufirst%3DM.%2BV.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DArison%26aufirst%3DB.%2BH.%26aulast%3DWong%26aufirst%3DB.%2BK.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolic%2520activation%2520of%2520a%2520pyrazinone-containing%2520thrombin%2520inhibitor.%2520Evidence%2520for%2520novel%2520biotransformation%2520involving%2520pyrazinone%2520ring%2520oxidation%252C%2520rearrangement%252C%2520and%2520covalent%2520binding%2520to%2520proteins%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2003%26volume%3D16%26spage%3D198%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Meegalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span> </span><span class="NLM_article-title">Structure-based optimization of a potent class of arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3632</span><span class="NLM_x">–</span> <span class="NLM_lpage">3637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3632-3637&author=S.+K.+Meegallaauthor=M.+J.+Wallauthor=J.+Chenauthor=K.+J.+Wilsonauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=C.+Schubertauthor=C.+S.+Cryslerauthor=Y.+Chenauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=C.+R.+Illig&title=Structure-based+optimization+of+a+potent+class+of+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DStructure-based%2520optimization%2520of%2520a%2520potent%2520class%2520of%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3632%26epage%3D3637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Illig, C. R.; Ballentine, S. K.; Chen, J.; Meegalla, S.; Rudolph, J.; Wall, M. J.; Wilson, K. J.; Desjarlais, R.; Manthey, C. L.; Flores, C. M.; Molloy, C. J.</span><span> </span><span class="NLM_article-title">Preparation of aromatic amides as inhibitors of c-fms kinase</span>. PCT Int. Pat. Appl. WO 2006047504 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+R.+Illig&author=S.+K.+Ballentine&author=J.+Chen&author=S.+Meegalla&author=J.+Rudolph&author=M.+J.+Wall&author=K.+J.+Wilson&author=R.+Desjarlais&author=C.+L.+Manthey&author=C.+M.+Flores&author=C.+J.+Molloy&title=Preparation+of+aromatic+amides+as+inhibitors+of+c-fms+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIllig%26aufirst%3DC.%2BR.%26atitle%3DPreparation%2520of%2520aromatic%2520amides%2520as%2520inhibitors%2520of%2520c-fms%2520kinase%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">RCSB Protein Data Bank</span><span class="NLM_x">. An Information Portal to Biological MacromolecularStructures. </span><a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRL" class="extLink">http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRL</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RCSB+Protein+Data+Bank.+An+Information+Portal+to+Biological+MacromolecularStructures.+http%3A%2F%2Fwww.rcsb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D3KRL+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">RCSB Protein Data Bank</span><span class="NLM_x">. An Information Portal to Biological Macromolecular Structures. </span><a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRJ" class="extLink">http://www.rcsb.org/pdb/explore/explore.do?structureId=3KRJ</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RCSB+Protein+Data+Bank.+An+Information+Portal+to+Biological+Macromolecular+Structures.+http%3A%2F%2Fwww.rcsb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D3KRJ+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">DeLano, W. L.</span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>; <span class="NLM_publisher-name">DeLano Scientific</span>: <span class="NLM_publisher-loc">Palo Alto, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span><span class="NLM_x">; </span><a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a> (accessed November 17,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=W.+L.+DeLano&title=The+PyMOL+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520Scientific%26date%3D2002%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Orlofsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, E. R.</span><span> </span><span class="NLM_article-title">CSF-1-induced gene expression in macrophages; dissociation from the mitogenic response</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2947</span><span class="NLM_x">–</span> <span class="NLM_lpage">2952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1987&pages=2947-2952&author=A.+Orlofskyauthor=E.+R.+Stanley&title=CSF-1-induced+gene+expression+in+macrophages%3B+dissociation+from+the+mitogenic+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrlofsky%26aufirst%3DA.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DCSF-1-induced%2520gene%2520expression%2520in%2520macrophages%253B%2520dissociation%2520from%2520the%2520mitogenic%2520response%26jtitle%3DEMBO%2520J.%26date%3D1987%26volume%3D6%26spage%3D2947%26epage%3D2952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit42"><span>The Cerep high-throughput profile consists of a broad collection of 50 transmembrane and soluble receptors, ion channels, and monoamine transporters designed to provide information not only on potential limitations or liabilities of drug candidates but also for off-target activity identification. For the test compounds, the results are expressed as a percent inhibition of control-specific binding (mean values, <i>n</i> = 2); <a href="http://www.cerep.fr/Cerep/Users/index.asp" class="extLink">http://www.cerep.fr/Cerep/Users/index.asp</a> (accessed December 30,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Cerep+high-throughput+profile+consists+of+a+broad+collection+of+50+transmembrane+and+soluble+receptors%2C+ion+channels%2C+and+monoamine+transporters+designed+to+provide+information+not+only+on+potential+limitations+or+liabilities+of+drug+candidates+but+also+for+off-target+activity+identification.+For+the+test+compounds%2C+the+results+are+expressed+as+a+percent+inhibition+of+control-specific+binding+%28mean+values%2C+n+%3D+2%29%3B+http%3A%2F%2Fwww.cerep.fr%2FCerep%2FUsers%2Findex.asp+%28accessed+December+30%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit43"><span>The p<i>K</i><sub>a</sub> of the conjugate acid of the piperidine was calculated using Advanced Chemistry Development (ACD/Labs) Software v12.0; <a href="http://www.acdlabs.com" class="extLink">http://www.acdlabs.com</a> (accessed September 10,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+pKa+of+the+conjugate+acid+of+the+piperidine+was+calculated+using+Advanced+Chemistry+Development+%28ACD%2FLabs%29+Software+v12.0%3B+http%3A%2F%2Fwww.acdlabs.com+%28accessed+September+10%2C+2010%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit44a"><span><span class="NLM_contrib-group">Peters, J.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattei, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span> </span><span class="NLM_article-title">Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=680-686&author=J.-U.+Petersauthor=P.+Schniderauthor=P.+Matteiauthor=M.+Kansy&title=Pharmacological+promiscuity%3A+Dependence+on+compound+properties+and+target+specificity+in+a+set+of+recent+Roche+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26aulast%3DSchnider%26aufirst%3DP.%26aulast%3DMattei%26aufirst%3DP.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DPharmacological%2520promiscuity%253A%2520Dependence%2520on%2520compound%2520properties%2520and%2520target%2520specificity%2520in%2520a%2520set%2520of%2520recent%2520Roche%2520compounds%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D680%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit44b"><span><span class="NLM_contrib-group">Azzaoui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitebread, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacoby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span> </span><span class="NLM_article-title">Modeling promiscuity based on in vitro safety pharmacology profiling data</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+J.+Jenkinsauthor=L.+Urban&title=Modeling+promiscuity+based+on+in+vitro+safety+pharmacology+profiling+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44bR"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0liLngPDzU58AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BJ.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520promiscuity%2520based%2520on%2520in%2520vitro%2520safety%2520pharmacology%2520profiling%2520data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit44c"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit44d"><span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eren, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span> </span><span class="NLM_article-title">Charting the chemical space of target sites: Insights into the binding modes of amine and amidine groups</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci800414v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44d&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlegtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=900-912&author=A.+Macchiaruloauthor=R.+Nutiauthor=G.+Erenauthor=R.+Pellicciari&title=Charting+the+chemical+space+of+target+sites%3A+Insights+into+the+binding+modes+of+amine+and+amidine+groups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44dR"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Charting the Chemical Space of Target Sites: Insights into the Binding Modes of Amine and Amidine Groups</span></div><div class="casAuthors">Macchiarulo, Antonio; Nuti, Roberto; Eren, Gokcen; Pellicciari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">900-912</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nowadays there is growing awareness that the translation of the increasing no. of lead compds. into clin. candidates is still a slow and often inefficient process.  In order to facilitate the lead optimization procedure, due consideration must be given to the use of the correct bioisosteric replacements.  Very recently, it was reported that exploring a chem. space of binding sites is a more effective strategy for studying the bioisosteric relationships existing among functional groups.  As a continuation of the work in this field, the authors report herein the construction of a chem. space covered by binding sites of small mols. contg. diverse amine and amidine groups.  The anal. of the differences in some properties of the binding sites of these functional groups allow for gaining insights into the binding modes of pos. charged groups.  In addn., this study pinpoints that different types of interactions and bioisosteric relationships exist among primary, secondary, tertiary, quaternary amine, and amidine moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFrjE_jvqRMLVg90H21EOLACvtfcHk0lidBq6YUU3Ozw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlegtbs%253D&md5=69a36dd8ca3908dad887954b510249ac</span></div><a href="/servlet/linkout?suffix=cit44d&amp;dbid=16384&amp;doi=10.1021%2Fci800414v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800414v%26sid%3Dliteratum%253Aachs%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DNuti%26aufirst%3DR.%26aulast%3DEren%26aufirst%3DG.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DCharting%2520the%2520chemical%2520space%2520of%2520target%2520sites%253A%2520Insights%2520into%2520the%2520binding%2520modes%2520of%2520amine%2520and%2520amidine%2520groups%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D900%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_contrib-group">Starmer, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lastra, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, A. O.</span><span> </span><span class="NLM_article-title">Cardiac instability amplified by use-dependent sodium channel blockade</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">262</span><span class="NLM_x">, </span> <span class="NLM_fpage">H1305</span><span class="NLM_x">–</span> <span class="NLM_lpage">H1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1992&pages=H1305-H1310&author=C.+F.+Starmerauthor=A.+R.+Lancasterauthor=A.+A.+Lastraauthor=A.+O.+Grant&title=Cardiac+instability+amplified+by+use-dependent+sodium+channel+blockade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStarmer%26aufirst%3DC.%2BF.%26aulast%3DLancaster%26aufirst%3DA.%2BR.%26aulast%3DLastra%26aufirst%3DA.%2BA.%26aulast%3DGrant%26aufirst%3DA.%2BO.%26atitle%3DCardiac%2520instability%2520amplified%2520by%2520use-dependent%2520sodium%2520channel%2520blockade%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1992%26volume%3D262%26spage%3DH1305%26epage%3DH1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_contrib-group">Hiroaka, M.</span> In  <span class="citation_source-book">Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention</span>; <span class="NLM_contrib-group">Gussak, I.; Antzelevitch, C.; Wilde, A. A. M.; Friedman, P. A.; Ackerman, M. J.; Shen, W.-K.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1007%2F978-1-84628-854-8_49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=691-704&author=M.+Hiroakaauthor=I.+Gussak&author=C.+Antzelevitch&author=A.+A.+M.+Wilde&author=P.+A.+Friedman&author=M.+J.+Ackerman&author=W.-K.+Shen&title=Electrical+Diseases+of+the+Heart%3A+Genetics%2C+Mechanisms%2C+Treatment%2C+Prevention"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1007%2F978-1-84628-854-8_49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-84628-854-8_49%26sid%3Dliteratum%253Aachs%26aulast%3DHiroaka%26aufirst%3DM.%26btitle%3DElectrical%2520Diseases%2520of%2520the%2520Heart%253A%2520Genetics%252C%2520Mechanisms%252C%2520Treatment%252C%2520Prevention%26aulast%3DGussak%26aufirst%3DI.%26pub%3DSpringer%26date%3D2008%26spage%3D691%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_contrib-group">Clusin, W. T.</span><span> </span><span class="NLM_article-title">Calcium and cardiac arrhythmias: DADs, EADs, and alternans</span> <span class="citation_source-journal">Crit. Rev. Clin. Lab. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1080%2F713609356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12892319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVWhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2003&pages=337-375&author=W.+T.+Clusin&title=Calcium+and+cardiac+arrhythmias%3A+DADs%2C+EADs%2C+and+alternans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46aR"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium and cardiac arrhythmias: DADs, EADs, and alternans</span></div><div class="casAuthors">Clusin, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-375</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">CRC Press LLC</span>)
        </div><div class="casAbstract">A review.  Rapid progress has been made in understanding the mol. mechanisms by which calcium ions mediate certain cardiac arrhythmias.  Principal advances include imaging of cytosolic calcium in isolated cells and in intact tissues, use of fluorescent indicators and monophasic action potentials to record membrane potentials in isolated tissue, and sequencing of the genes that encode crit. ion channel proteins.  In this review, five types of arrhythmias are discussed where calcium ion currents, or currents controlled by calcium, appear to be responsible for arrythmogenesis.  These include: (1) the delayed afterpotential that occurs in conditions of intracellular calcium overload such as digitalis toxicity; (2) the early afterdepolarization that occurs when action potential duration is prolonged; (3) the slowly conducted calcium-dependent action potential (the slow response) in the SA and AV nodes; (4) the phenomenon of calcium transient alternans during ischemia, which is related to action potential duration alternans and t-wave alternans; (5) catecholamine-induced cardiac arrhythmias in families with mutations of the sarcoplasmic reticulum calcium-release channel.  For each type of arrhythmia, the clin. implications of emerging knowledge are discussed.  An esp. important issue is whether ventricular fibrillation during acute coronary artery occlusion is due to calcium transient alternans.  Ventricular fibrillation due to acute ischemia is an important subset of the 400,000 sudden cardiac deaths that occur annually in the U.S.  Certain drugs, including beta blockers, fish oils, verapamil, and diltiazem, seem to specifically prevent ventricular fibrillation in this setting, and in most cases an effect of the drug on cytosolic calcium appears to be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlOfaKoLDBnLVg90H21EOLACvtfcHk0lgHrlsaJI38iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVWhs7k%253D&md5=7c0eec58458a3e4102b97ebb3f2ca22a</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1080%2F713609356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F713609356%26sid%3Dliteratum%253Aachs%26aulast%3DClusin%26aufirst%3DW.%2BT.%26atitle%3DCalcium%2520and%2520cardiac%2520arrhythmias%253A%2520DADs%252C%2520EADs%252C%2520and%2520alternans%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2003%26volume%3D40%26spage%3D337%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_contrib-group">Salhanick, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, M. W.</span><span> </span><span class="NLM_article-title">Management of calcium channel antagonist overdose</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2165%2F00002018-200326020-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12534324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1yqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=65-79&author=S.+D.+Salhanickauthor=M.+W.+Shannon&title=Management+of+calcium+channel+antagonist+overdose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46bR"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Management of calcium channel antagonist overdose</span></div><div class="casAuthors">Salhanick, Steven D.; Shannon, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">65-79</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Calcium channel antagonists are used primarily for the treatment of hypertension and tachyarrhythmias.  Overdose of calcium channel antagonists can be lethal.  Calcium channel antagonists act at the L-type calcium channels primarily in cardiac and vascular smooth muscle preventing calcium influx into cells with resultant decreases in vascular tone and cardiac inotropy and chronotropy.  The L-type calcium channel is a complex structure and is thus affected by a large no. of structurally diverse antagonists.  In the setting of overdose, patients may experience vasodilatation and bradycardia leading to a shock state.  Patients may also be hyperglycemic and acidotic due to the blockade of L-type calcium channels in the pancreatic islet cells that affect insulin secretion.  Aggressive therapy is warranted in the setting of toxicity.  Gut decontamination with charcoal, or whole bowel irrigation or multiple-dose charcoal in the setting of extended-release products is indicated.  Specific antidotes include calcium salts, glucagon and insulin.  Calcium salts may be given in bolus doses or may be employed as a continuous infusion.  Care should be exercised to avoid the administration of calcium in the setting of concomitant digoxin toxicity.  Insulin administration has been used effectively to increase cardiac inotropy and survival.  The likely mechanism involves a shift to carbohydrate metab. in the setting of decreased availability of carbohydrates due to decreased insulin secretion secondary to blockade of calcium channels in pancreatic islet cells.  Glucose should be administered as well to maintain euglycemia.  Supportive care including the use of phosphodiesterase inhibitors, adrenergic agents, cardiac pacing, balloon pump or extracorporeal bypass is frequently indicated if antidotal therapy is not effective.  Careful evaluation of asymptomatic patients, including and ECG and a period of observation, is indicated.  Patients ingesting a nonsustained-release product should be obsd. in a monitored setting for 12 h, while those who ingest a sustained-release prepn. should be obsd. for no less than 24 h.  Charcoal should be given to the asymptomatic patient with a history of calcium channel antagonist overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqOfWkIunbLVg90H21EOLACvtfcHk0lhCmCaY0PM4zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1yqsL0%253D&md5=41407c8fbe641f8bc2da397848718a74</span></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=10.2165%2F00002018-200326020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200326020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DSalhanick%26aufirst%3DS.%2BD.%26aulast%3DShannon%26aufirst%3DM.%2BW.%26atitle%3DManagement%2520of%2520calcium%2520channel%2520antagonist%2520overdose%26jtitle%3DDrug%2520Saf.%26date%3D2003%26volume%3D26%26spage%3D65%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit46c"><span><span class="NLM_contrib-group">Packer, M.</span><span> </span><span class="NLM_article-title">Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">IV59</span><span class="NLM_x">–</span> <span class="NLM_lpage">IV67</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1989&pages=IV59-IV67&author=M.+Packer&title=Pathophysiological+mechanisms+underlying+the+adverse+effects+of+calcium+channel-blocking+drugs+in+patients+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DM.%26atitle%3DPathophysiological%2520mechanisms%2520underlying%2520the%2520adverse%2520effects%2520of%2520calcium%2520channel-blocking%2520drugs%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DCirculation%26date%3D1989%26volume%3D80%26spage%3DIV59%26epage%3DIV67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Wilson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illig, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballentine, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DesJarlais, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrounia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crysler, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikin, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthey, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Player, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczuk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegalla, S. K.</span><span> </span><span class="NLM_article-title">Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3925</span><span class="NLM_x">–</span> <span class="NLM_lpage">3929</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3925-3929&author=K.+J.+Wilsonauthor=C.+R.+Illigauthor=J.+Chenauthor=M.+J.+Wallauthor=S.+K.+Ballentineauthor=R.+L.+DesJarlaisauthor=Y.+Chenauthor=C.+Schubertauthor=R.+Donatelliauthor=I.+Petrouniaauthor=C.+S.+Cryslerauthor=C.+J.+Molloyauthor=M.+A.+Chaikinauthor=C.+L.+Mantheyauthor=M.+R.+Playerauthor=B.+E.+Tomczukauthor=S.+K.+Meegalla&title=Reducing+ion+channel+activity+in+a+series+of+4-heterocyclic+arylamide+FMS+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DIllig%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWall%26aufirst%3DM.%2BJ.%26aulast%3DBallentine%26aufirst%3DS.%2BK.%26aulast%3DDesJarlais%26aufirst%3DR.%2BL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSchubert%26aufirst%3DC.%26aulast%3DDonatelli%26aufirst%3DR.%26aulast%3DPetrounia%26aufirst%3DI.%26aulast%3DCrysler%26aufirst%3DC.%2BS.%26aulast%3DMolloy%26aufirst%3DC.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DTomczuk%26aufirst%3DB.%2BE.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26atitle%3DReducing%2520ion%2520channel%2520activity%2520in%2520a%2520series%2520of%25204-heterocyclic%2520arylamide%2520FMS%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3925%26epage%3D3929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davey, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emms, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragan, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broten, T.</span><span> </span><span class="NLM_article-title">3-(1-Piperazinyl)-4,5-dihydro-1<i>H</i>-benzo[<i>g</i>]indazoles: High affinity ligands for the human dopamine D<sub>4</sub> receptor with improved selectivity over ion channels</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">743</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1998&pages=743-753&author=I.+Collinsauthor=M.+Rowleyauthor=W.+B.+Daveyauthor=F.+Emmsauthor=R.+Marwoodauthor=S.+Patelauthor=S.+Patelauthor=A.+Fletcherauthor=I.+C.+Raganauthor=P.+D.+Leesonauthor=A.+L.+Scottauthor=T.+Broten&title=3-%281-Piperazinyl%29-4%2C5-dihydro-1H-benzo%5Bg%5Dindazoles%3A+High+affinity+ligands+for+the+human+dopamine+D4+receptor+with+improved+selectivity+over+ion+channels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DDavey%26aufirst%3DW.%2BB.%26aulast%3DEmms%26aufirst%3DF.%26aulast%3DMarwood%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DA.%26aulast%3DRagan%26aufirst%3DI.%2BC.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DScott%26aufirst%3DA.%2BL.%26aulast%3DBroten%26aufirst%3DT.%26atitle%3D3-%25281-Piperazinyl%2529-4%252C5-dihydro-1H-benzo%255Bg%255Dindazoles%253A%2520High%2520affinity%2520ligands%2520for%2520the%2520human%2520dopamine%2520D4%2520receptor%2520with%2520improved%2520selectivity%2520over%2520ion%2520channels%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1998%26volume%3D6%26spage%3D743%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_contrib-group">Ladduwahetty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boase, A. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchinson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span> </span><span class="NLM_article-title">A new class of selective, non-basic 5-HT2A receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3201</span><span class="NLM_x">–</span> <span class="NLM_lpage">3204</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3201-3204&author=T.+Ladduwahettyauthor=A.+L+Boaseauthor=A.+Mitchinsonauthor=C.+Quinauthor=S.+Patelauthor=K.+Chapmanauthor=A.+M.+MacLeod&title=A+new+class+of+selective%2C+non-basic+5-HT2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadduwahetty%26aufirst%3DT.%26aulast%3DBoase%26aufirst%3DA.%2BL%26aulast%3DMitchinson%26aufirst%3DA.%26aulast%3DQuin%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520class%2520of%2520selective%252C%2520non-basic%25205-HT2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3201%26epage%3D3204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rancovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49bR"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lhWR0CJAPdUfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRancovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Bertz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granneman, G. R.</span><span> </span><span class="NLM_article-title">Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2165%2F00003088-199732030-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=9084960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK2sXisV2ks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1997&pages=210-258&author=R.+J.+Bertzauthor=G.+R.+Granneman&title=Use+of+in+vitro+and+in+vivo+data+to+estimate+the+likelihood+of+metabolic+pharmacokinetic+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions</span></div><div class="casAuthors">Bertz, Richard J.; Granneman, G. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-258</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">This article reviews with 681 refs. the information available to assist pharmacokineticists in the prediction of metabolic drug interactions.  Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P 450 (CYP) isoform(s) metabolizing a particular drug as well as the ability of a drug to inhibit a specific CYP isoform.  The major isoforms involved in human drug metab. are CYP3A, CYP2D6, CYP2C, CYP1A2 and CYP2E1.  Often patients are taking multiple concurrent medications, and thus an assessment of potential drug-drug interactions is imperative.  A database contg. information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquant. prediction of the magnitude of potential interactions with drugs under development.  With knowledge of the in vitro inhibition const. of a drug (Ki) for a particular CYP isoform, it is theor. possible to assess the likelihood of interactions for a drug cleared through CYP-mediated metab.  For many agents, the CYP isoform involved in metab. has not been identified and there is substantial uncertainty given the current knowledge base.  The math. concepts for prediction based on competitive enzyme inhibition are reviewed in this article.  These relationships become more complex if the inhibition is of a mixed competitive/noncompetitive nature.  Sources of un.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtRdmXMijOLVg90H21EOLACvtfcHk0lhxtCSVV7WxNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisV2ks7s%253D&md5=6c2f7e6452c1493598cc9eecf8f03f21</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2165%2F00003088-199732030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199732030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DBertz%26aufirst%3DR.%2BJ.%26aulast%3DGranneman%26aufirst%3DG.%2BR.%26atitle%3DUse%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520data%2520to%2520estimate%2520the%2520likelihood%2520of%2520metabolic%2520pharmacokinetic%2520interactions%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1997%26volume%3D32%26spage%3D210%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.2174%2F1386207013331101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=11375740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkt1Crt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=245-263&author=C.+M.+Masimirembwaauthor=R.+Thompsonauthor=T.+B.+Andersson&title=In+vitro+high+throughput+screening+of+compounds+for+favorable+metabolic+properties+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery</span></div><div class="casAuthors">Masimirembwa, Collen M.; Thompson, Richard; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry and High Throughput Screening</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">245-263</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Drug metab. can have profound effects on the pharmacol. and toxicol. profile of therapeutic agents.  In the pharmaceutical industry, many in vitro techniques are in place or under development to screen and optimize compds. for favorable metabolic properties in the drug discovery phase.  These in vitro technologies are meant to address important issues such as: (1) is the compd. a potent inhibitor of drug metabolizing enzymes (DMEs) (2) does the compd. induce the expression of DMEs (3) how labile is the compd. to metabolic degrdn. (4) which specific enzyme(s) is responsible for the compd.'s biotransformation and (5) to which metabolites is the compd. metabolized.  Answers to these questions provide a basis for judging whether a compd. is likely to have acceptable pharmacokinetic properties in vivo.  To address these issues on the increasing no. of compds. inundating the drug discovery programs, high throughput assays are essential.  A combination of biochem. advances in the understanding of the function and regulation of DMEs (in particular, cytochromes P 450, CYPs) and automated anal. technologies are revolutionizing drug metab. research.  Automated LC-MS based metabolic stability, fluorescence, radiometric and LC-MS based CYP inhibition assays are now in routine use.  Automatable models for studying CYP induction based on enzyme activity, quant. RT-PCR and reporter gene systems are being developed.  We will review the utility and limitations of these HTS approaches and highlight on-going developments and emerging technologies to answer metab. questions at the different stages of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMkDhwueLF7Vg90H21EOLACvtfcHk0lg6hkgZeCul1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkt1Crt7w%253D&md5=17b5e9e3944e129ed1064682b37390c3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F1386207013331101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207013331101%26sid%3Dliteratum%253Aachs%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DIn%2520vitro%2520high%2520throughput%2520screening%2520of%2520compounds%2520for%2520favorable%2520metabolic%2520properties%2520in%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2001%26volume%3D4%26spage%3D245%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Morgenthaler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwiezer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann-Roder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeschke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&author=M.+Morgenthalerauthor=E.+Schwiezerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lg6hkgZeCul1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchwiezer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1100%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit53a"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53aR"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lhumaGpWcJnLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit53b"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitcheson, J. S.</span><span> </span><span class="NLM_article-title">Predicting drug-hERG channel interactions that cause acquired long QT syndrome</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=119-124&author=M.+C.+Sanguinettiauthor=J.+S.+Mitcheson&title=Predicting+drug-hERG+channel+interactions+that+cause+acquired+long+QT+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DMitcheson%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520drug-hERG%2520channel%2520interactions%2520that%2520cause%2520acquired%2520long%2520QT%2520syndrome%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2005%26volume%3D26%26spage%3D119%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit54a"><span><span class="NLM_contrib-group">Geissler, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housman, D. E.</span><span> </span><span class="NLM_article-title">The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1988&pages=185-192&author=E.+N.+Geisslerauthor=M.+A.+Ryanauthor=D.+E.+Housman&title=The+dominant-white+spotting+%28W%29+locus+of+the+mouse+encodes+the+c-kit+proto-oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeissler%26aufirst%3DE.%2BN.%26aulast%3DRyan%26aufirst%3DM.%2BA.%26aulast%3DHousman%26aufirst%3DD.%2BE.%26atitle%3DThe%2520dominant-white%2520spotting%2520%2528W%2529%2520locus%2520of%2520the%2520mouse%2520encodes%2520the%2520c-kit%2520proto-oncogene%26jtitle%3DCell%26date%3D1988%26volume%3D55%26spage%3D185%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit54b"><span><span class="NLM_contrib-group">Bijangi-Vishehsaraei, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadatzadeh, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson McKenzie, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichijo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haneline, L. S.</span><span> </span><span class="NLM_article-title">Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">4124</span><span class="NLM_x">–</span> <span class="NLM_lpage">4130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=4124-4130&author=K.+Bijangi-Vishehsaraeiauthor=M.+R.+Saadatzadehauthor=A.+Werneauthor=K.+A.+Wilson+McKenzieauthor=R.+Kapurauthor=H.+Ichijoauthor=L.+S.+Haneline&title=Enhanced+TNF-alpha-induced+apoptosis+in+Fanconi+anemia+type+C-deficient+cells+is+dependent+on+apoptosis+signal-regulating+kinase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBijangi-Vishehsaraei%26aufirst%3DK.%26aulast%3DSaadatzadeh%26aufirst%3DM.%2BR.%26aulast%3DWerne%26aufirst%3DA.%26aulast%3DWilson%2BMcKenzie%26aufirst%3DK.%2BA.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DIchijo%26aufirst%3DH.%26aulast%3DHaneline%26aufirst%3DL.%2BS.%26atitle%3DEnhanced%2520TNF-alpha-induced%2520apoptosis%2520in%2520Fanconi%2520anemia%2520type%2520C-deficient%2520cells%2520is%2520dependent%2520on%2520apoptosis%2520signal-regulating%2520kinase%25201%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D4124%26epage%3D4130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Trentham, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townes, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. H.</span><span> </span><span class="NLM_article-title">Autoimmunity to type II collagen: an experimental model of arthritis</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=857-868&author=D.+E.+Trenthamauthor=A.+S.+Townesauthor=A.+H.+Kang&title=Autoimmunity+to+type+II+collagen%3A+an+experimental+model+of+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrentham%26aufirst%3DD.%2BE.%26aulast%3DTownes%26aufirst%3DA.%2BS.%26aulast%3DKang%26aufirst%3DA.%2BH.%26atitle%3DAutoimmunity%2520to%2520type%2520II%2520collagen%253A%2520an%2520experimental%2520model%2520of%2520arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D857%26epage%3D868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Bendele, A. M.</span><span> </span><span class="NLM_article-title">Animal models of rheumatoid arthritis</span> <span class="citation_source-journal">J. Musculoskeletal Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=15758488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=377-385&author=A.+M.+Bendele&title=Animal+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of rheumatoid arthritis</span></div><div class="casAuthors">Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Musculoskeletal & Neuronal Interactions</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JMNIB3</span>;
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    
            (<span class="NLM_cas:orgname">Journal of Musculoskeletal and Neuronal Interactions</span>)
        </div><div class="casAbstract">A review.  Animal models of arthritis are used to study pathogenesis of disease and to evaluate potential anti-arthritic drugs for clin. use.  Therefore morphol. similarities to human disease and capacity of the model to predict efficacy in humans are important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability for efficacy in humans include: rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis and antigen-induced arthritis in several species.  Agents currently in clin. use (or trials) that are active in these models include: corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide interleukin-1 receptor antagonist (IL-1ra) and sol. TNF receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged dosing periods would preclude dosing in humans at levels that might provide disease modifying effects.  Data, conduct and features of the various models of these commonly utilized models of RA as well as some transgenic mouse models and less commonly utilized rodent models will be discussed with emphasis on their similarities to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhtLWBEJFcbVg90H21EOLACvtfcHk0lgYSxDFCfhmbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVOhu7o%253D&md5=21f16894bcfdad981a6b7d32773431cf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%2BM.%26atitle%3DAnimal%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Musculoskeletal%2520Interact.%26date%3D2001%26volume%3D1%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Joosten, L. A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helsen, M. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Loo, F. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Berg, W. B.</span><span> </span><span class="NLM_article-title">Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780390513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8639177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK28XjsValtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=797-809&author=L.+A.+B.+Joostenauthor=M.+M.+A.+Helsenauthor=F.+A.+J.+Van+de+Looauthor=W.+B.+Van+den+Berg&title=Anticytokine+treatment+of+established+type+II+collagen-induced+arthritis+in+DBA%2F1+mice%3A+A+comparative+study+using+anti-TNF%CE%B1%2C+anti-IL-1%CE%B1%2F%CE%B2%2C+and+IL-1Ra"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra</span></div><div class="casAuthors">Joosten, Leo A. B.; Helsen, Monique M. A.; Van De Loo, Fons A. J.; Van Den Berg, Wim B.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">797-809</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">The authors examd. the role of tumor necrosis factor α (TNF α), interleukin-1α (IL-1α), and IL-1β in collagen-induced arthritis (CIA), immediately after onset and during the phase of established arthritis.  Male DBA/1 mice with collagen-induced arthritis were treated with antibodies against murine TNF α and IL-1α/β at different time points of the disease.  IL-1 receptor antagonist (IL-1Ra) was administered using Alzet osmotic mini-pumps.  The effect of anti-cytokine treatment was monitored by visual scoring.  Histol. and cytokine reverse transcription polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period.  Anti-TNF α treatment showed efficacy shortly after onset of the disease, but had little effect on fully established CIA.  Histol. anal. after early treatment revealed that anti-TNF α significantly reduced joint pathol., as detd. by infiltration of inflammatory cells and cartilage damage.  Anti-IL-1α/β treatment ameliorated both early and full-blown CIA.  This clear suppression of established arthritis was confirmed by administration of high doses of IL-1Ra.  Dose-response expts. showed that a continuous supply of 1 mg/day was needed for optimal suppression.  Histol. anal. showed markedly reduced cartilage destruction both in the knee and the ankle joints.  Autoradiog. demonstrated full recovery of chondrocyte synthetic function of articular cartilage.  In addn., the authors found that the IL-1β isoform plays a dominant role in established CIA.  Profound suppression of CIA was obsd. with anti-IL-1β, although elimination of both IL-1α and IL-1β still gave better protection.  Anal. of mRNA with RT-PCR revealed that IL-1β was highly upregulated in synovium and cartilage at late stages of CIA, whereas anti-IL-1β treatment markedly reduced IL-1β message in the synovium.  The present study identified different TNFα/IL-1 dependencies in various stages of CIA and revealed that blocking of TNFα does not necessarily eliminate IL-1.  Continuous, high doses of IL-1Ra are needed to block CIA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPs5rv07Iyo7Vg90H21EOLACvtfcHk0lhlYUL42OHhlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsValtLc%253D&md5=cb86f131237c1b630e0d039215f52d72</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fart.1780390513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780390513%26sid%3Dliteratum%253Aachs%26aulast%3DJoosten%26aufirst%3DL.%2BA.%2BB.%26aulast%3DHelsen%26aufirst%3DM.%2BM.%2BA.%26aulast%3DVan%2Bde%2BLoo%26aufirst%3DF.%2BA.%2BJ.%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DW.%2BB.%26atitle%3DAnticytokine%2520treatment%2520of%2520established%2520type%2520II%2520collagen-induced%2520arthritis%2520in%2520DBA%252F1%2520mice%253A%2520A%2520comparative%2520study%2520using%2520anti-TNF%25CE%25B1%252C%2520anti-IL-1%25CE%25B1%252F%25CE%25B2%252C%2520and%2520IL-1Ra%26jtitle%3DArthritis%2520Rheum.%26date%3D1996%26volume%3D39%26spage%3D797%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">De Clerck, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Aubioul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Rossem, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Ammel, K.</span><span> </span><span class="NLM_article-title">In vivo measurement of QT prolongation, dispersion and arrythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity</span> <span class="citation_source-journal">Fundam. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1046%2Fj.1472-8206.2002.00081.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=12031065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFOrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=125-140&author=F.+De+Clerckauthor=A.+Van+de+Waterauthor=J.+D%E2%80%99Aubioulauthor=H.+R.+Luauthor=K.+van+Rossemauthor=A.+Hermansauthor=K.+Van+Ammel&title=In+vivo+measurement+of+QT+prolongation%2C+dispersion+and+arrythmogenesis%3A+Application+to+the+preclinical+cardiovascular+safety+pharmacology+of+a+new+chemical+entity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: Application to the preclinical cardiovascular safety pharmacology of a new chemical entity</span></div><div class="casAuthors">De Clerck, Fred; Van de Water, Andre; D'Aubioul, Jan; Lu, Hua Rong; van Rossem, Koen; Hermans, An; Van Ammel, Karel</div><div class="citationInfo"><span class="NLM_cas:title">Fundamental & Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-140</span>CODEN:
                <span class="NLM_cas:coden">FCPHEZ</span>;
        ISSN:<span class="NLM_cas:issn">0767-3981</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review.  In addn. to in silico and in vitro measurements, cardiac electrophysiol. in exptl. animals plays a decisive role in the selection of a potential "cardio-safe" new chem. entity (NCE).  The present synopsis critically reviews such in vivo techniques in exptl. animals.  In anesthetized guinea-pigs, surface eCG recordings readily identify the typical effects of Class I to IV anti-arrhythmic compds. and of If blockers such as zatebradine on eCG intervals and morphol., but also of non-cardiovascular NCEs affecting cardiac elec. activity via ion channels or neurogenic mechanisms.  QT/RR plots indicate that bradycardia is a dominant effect of IKr blockers (dual modulation by IKr of sinus node activity and ventricular repolarization).  Nevertheless, correction of QT with Bazett's formula usually distinguishes between drug-induced heart rate redn. and real prolongation of ventricular repolarization (QTc).  The anesthetized guinea-pig model thus is a useful tool for first line in vivo testing of an NCE for effects on cardiac electrophysiol., in particular when combined with measurements of drug levels in plasma and heart tissues.  In anesthetized dogs, advanced eCG analyses identify drug-induced effects on atrial and ventricular intervals, on temporal and transmural dispersion of ventricular repolarization and on incidences of early after-depolarizations.  This can be combined with complete hemodynamic, pulmonary and pharmacokinetic analyses in one prepn.  However, compd. doses/plasma levels needed for effects on ventricular repolarization in this model are substantially higher than those identified in guinea-pigs, at least for IKr blocking compds.  Therefore, the authors use this "information-rich" canine model as a second line approach.  In awake, trained and appropriately instrumented dogs, readings of surface eCG in combination with cardio-hemodynamic and behavioral assessments can be performed after the administration of an NCE via the expected therapeutic route, including oral medication.  However, at higher doses the compd. under scrutiny may induce overall behavioral side-effects, related to its primary pharmacol. action, such as gastrokinetic repercussions or CNS-mediated sedation or excitation.  Such primary pharmacol. effects are bound to compromise the evaluation of real drug-induced changes on cardiac electrophysiol., readily identified by resource-friendly setups in smaller animals.  Therefore, the authors use such paradigms as an imperative, final cardiovascular check-up, before a "First in Man" administration of the NCE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbEqHYy5WNvLVg90H21EOLACvtfcHk0lh7o6BWEC0hhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFOrurY%253D&md5=b12da3b167ed603fe3239b6285ce0122</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1046%2Fj.1472-8206.2002.00081.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1472-8206.2002.00081.x%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Aubioul%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DH.%2BR.%26aulast%3Dvan%2BRossem%26aufirst%3DK.%26aulast%3DHermans%26aufirst%3DA.%26aulast%3DVan%2BAmmel%26aufirst%3DK.%26atitle%3DIn%2520vivo%2520measurement%2520of%2520QT%2520prolongation%252C%2520dispersion%2520and%2520arrythmogenesis%253A%2520Application%2520to%2520the%2520preclinical%2520cardiovascular%2520safety%2520pharmacology%2520of%2520a%2520new%2520chemical%2520entity%26jtitle%3DFundam.%2520Clin.%2520Pharmacol.%26date%3D2002%26volume%3D16%26spage%3D125%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigenobu, K.</span><span> </span><span class="NLM_article-title">Positive inotropic and chronotropic effects of beraprost sodium, a stable analog of prostacyclin, in isolated guinea pig myocardium</span> <span class="citation_source-journal">Gen. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2F0306-3623%2895%2900095-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=8742503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK28XhsVKmtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=101-103&author=Y.+Uenoauthor=S.+Okazakiauthor=M.+Isogayaauthor=S.+Nishioauthor=H.+Tanakaauthor=Y.+Katoauthor=K.+Shigenobu&title=Positive+inotropic+and+chronotropic+effects+of+beraprost+sodium%2C+a+stable+analog+of+prostacyclin%2C+in+isolated+guinea+pig+myocardium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Positive inotropic and chronotropic effects of beraprost sodium, a stable analog of prostacyclin, in isolated guinea pig myocardium</span></div><div class="casAuthors">Ueno, Yuji; Okazaki, Seiji; Isogaya, Masafumi; Nishio, Shintaro; Tanaka, Hikaru; Kato, Yoshimitsu; Shigenobu, Koki</div><div class="citationInfo"><span class="NLM_cas:title">General Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-3</span>CODEN:
                <span class="NLM_cas:coden">GEPHDP</span>;
        ISSN:<span class="NLM_cas:issn">0306-3623</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inotropic and chronotropic effects of beraprost sodium, a chem. stable prostacyclin analog, were examd. in isolated myocardial prepns. of guinea pigs.  In the left atria, 10-9-10-7 M beraprost had no significant effect on the contractile force, but 10-6 and 10-5M produced a concn.-dependent pos. inotropic response.  This effect was antagonized by S-145, a potent and selective thromboxane A2 (TXA2) receptor antagonist, but not by propranolol.  Beraprost, from 10-9 to 10-5M, had no significant inotropic effect in the right ventricular papillary muscles.  In the right atria, 10-9 and 10-8 M beraprost had no significant effect, but 10-7-10-5 M caused an increase in beating rate; this effect was not affected by S-145.  The present study demonstrates that beraprost has pos. inotropic and chronotropic effects at high doses on isolated guinea pig atria.  The inotropic effect may be mediated by the TXA2 receptor, but some mechanism other than the TXA2 receptor is responsible for the chronotropic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetmYYbPqAJrVg90H21EOLACvtfcHk0lhk26IQB6KEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVKmtL4%253D&md5=c23cd007f38eb8d55b2c6355b1d246c4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0306-3623%2895%2900095-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0306-3623%252895%252900095-X%26sid%3Dliteratum%253Aachs%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DOkazaki%26aufirst%3DS.%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DNishio%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DShigenobu%26aufirst%3DK.%26atitle%3DPositive%2520inotropic%2520and%2520chronotropic%2520effects%2520of%2520beraprost%2520sodium%252C%2520a%2520stable%2520analog%2520of%2520prostacyclin%252C%2520in%2520isolated%2520guinea%2520pig%2520myocardium%26jtitle%3DGen.%2520Pharmacol.%26date%3D1996%26volume%3D27%26spage%3D101%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Pearson, C. M.</span><span> </span><span class="NLM_article-title">Development of arthritis, periarthritis and periostitis in rats given adjuvants</span> <span class="citation_source-journal">Proc. Soc. Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1956</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.3181%2F00379727-91-22179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=13297719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A280%3ADyaG28%252FltVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1956&pages=95-100&author=C.+M.+Pearson&title=Development+of+arthritis%2C+periarthritis+and+periostitis+in+rats+given+adjuvants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development of arthritis, periarthritis and periostitis in rats given adjuvants</span></div><div class="casAuthors">PEARSON C M</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSFGkgyxtxpckU0YCbOU3EfW6udTcc2eYqmrSQd-lo6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG28%252FltVSjtw%253D%253D&md5=a368faa14a24fea59b49350ed73e076a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3181%2F00379727-91-22179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-91-22179%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DC.%2BM.%26atitle%3DDevelopment%2520of%2520arthritis%252C%2520periarthritis%2520and%2520periostitis%2520in%2520rats%2520given%2520adjuvants%26jtitle%3DProc.%2520Soc.%2520Exp.%2520Biol.%2520Med.%26date%3D1956%26volume%3D91%26spage%3D95%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Carlson, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datko, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Neil-Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blazek, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delustro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beideman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, A. J.</span><span> </span><span class="NLM_article-title">Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred Wistar rats</span> <span class="citation_source-journal">Int. J. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1016%2F0192-0561%2885%2990043-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=4077344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaL28XkvFKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1985&pages=811-826&author=R.+P.+Carlsonauthor=L.+J.+Datkoauthor=L.+O%27Neil-Davisauthor=E.+M.+Blazekauthor=F.+Delustroauthor=R.+Beidemanauthor=A.+J.+Lewis&title=Comparison+of+inflammatory+changes+in+established+type+II+collagen+and+adjuvant+induced+arthritis+using+outbred+Wistar+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of inflammatory changes in established type II collagen- and adjuvant-induced arthritis using outbred Wistar rats</span></div><div class="casAuthors">Carlson, Richard P.; Datko, Louis J.; O'Neill-Davis, Lynn; Blazek, Eileen M.; DeLustro, Frank; Beideman, Robert; Lewis, Alan J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-26</span>CODEN:
                <span class="NLM_cas:coden">IJIMDS</span>;
        ISSN:<span class="NLM_cas:issn">0192-0561</span>.
    </div><div class="casAbstract">Type II collagen- and adjuvant-induced arthritis in outbred Wistar rats were compared using parameters that measured the inflammatory response, cellular and humoral immunity, blood protein changes, drug metab., and histopathol. and bony changes of the inflamed paws.  There was a lesser incidence and severity of arthritic disease in collagen-injected rats (40-70%) than in the adjuvant model (incidence ∼100%).  The use of muramyl dipeptide (MDP) increased the incidence and severity of collagen arthritis.  The acute phase protein response (plasma fibrinogen) was similar in both models during the peak of inflammatory response.  Drug metab. was inhibited in both type II collagen boosted with MDP or in adjuvant arthritic (Mycobacterium butyricum-sensitized) rats; however, arthritic rats sensitized with collagen alone produced no inhibition.  Only collagen arthritic rats produced type II collagen antibody and exhibited delayed hypersensitivity to type II collagen.  Bony changes as assessed by radiog. evaluation were more severe in adjuvant arthritic rats than in the collagen arthritic model; histopathol. findings from these animals confirmed this observation.  The primary lesions in both models were periosteal reaction of the bone and ankylosis.  Several classes of antiarthritic drugs were compared in both models using paw edema measurements and bony changes by radiog. evaluation.  Drugs with inhibitory activity in both models were indomethacin, methylprednisolone, D-penicillamine, and Au Na thiomalate.  Levamisole, chloroquine, and auranofin were inactive in both models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrya0z88A9WpLVg90H21EOLACvtfcHk0lizt9Jorg89qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XkvFKqsw%253D%253D&md5=8a7dadcbab41d96452fb0747660710bd</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2F0192-0561%2885%2990043-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0192-0561%252885%252990043-8%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DR.%2BP.%26aulast%3DDatko%26aufirst%3DL.%2BJ.%26aulast%3DO%2527Neil-Davis%26aufirst%3DL.%26aulast%3DBlazek%26aufirst%3DE.%2BM.%26aulast%3DDelustro%26aufirst%3DF.%26aulast%3DBeideman%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DA.%2BJ.%26atitle%3DComparison%2520of%2520inflammatory%2520changes%2520in%2520established%2520type%2520II%2520collagen%2520and%2520adjuvant%2520induced%2520arthritis%2520using%2520outbred%2520Wistar%2520rats%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D1985%26volume%3D7%26spage%3D811%26epage%3D826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Benslay, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A. M.</span><span> </span><span class="NLM_article-title">Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats</span> <span class="citation_source-journal">Agents Actions</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1007%2FBF01993296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=1793040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK3MXlvFOlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=254-256&author=D.+N.+Benslayauthor=A.+M.+Bendele&title=Development+of+a+rapid+screen+for+detecting+and+differentiating+immunomodulatory+vs.+anti-inflammatory+compounds+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a rapid screen for detecting and differentiating immunomodulatory vs. anti-inflammatory compounds in rats</span></div><div class="casAuthors">Benslay, D. N.; Bendele, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Agents and Actions</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">254-6</span>CODEN:
                <span class="NLM_cas:coden">AGACBH</span>;
        ISSN:<span class="NLM_cas:issn">0065-4299</span>.
    </div><div class="casAbstract">Polyarthritis can be induced in rats using a synthetic adjuvant, N,N-dioctyldecyl-N',N-bis(2-hydroxyethyl)propanediamine (LA) suspended in oil.  The disease is morphol. indistinguishable from the classic adjuvant arthritis induced by Freund's complete adjuvant (FCA).  LA injection (7.5 mg/animal) consistently induced paw swelling, splenomegaly and fibrinogen level increases at certain time points.  Studied evaluating various protocols and parameters detd. that a 15 day assay where agents administered from days 9 through 13, would differentiate immunomodulatory and anti-inflammatory compds.  Parameters utilized were body wt., paw vols., spleen wts., and fibrinogen levels.  Immunomodulatory agents reduce paw swelling, splenomegaly and in some cases fibrinogen levels.  NSAIDS reduce paw swelling, increase splenomegaly, and have no effect on fibrinogen levels.  These results indicate that compds. active in the traditional FCA assay can be detected and differentiated with respect to anti-inflammatory vs. immunomodulatory activity in a rapid screen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaOPxv0iZBLVg90H21EOLACvtfcHk0ljGKHr1VjCS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlvFOlsrs%253D&md5=52253efcd376b8765edb0c4f34a9f9fc</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2FBF01993296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01993296%26sid%3Dliteratum%253Aachs%26aulast%3DBenslay%26aufirst%3DD.%2BN.%26aulast%3DBendele%26aufirst%3DA.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520rapid%2520screen%2520for%2520detecting%2520and%2520differentiating%2520immunomodulatory%2520vs.%2520anti-inflammatory%2520compounds%2520in%2520rats%26jtitle%3DAgents%2520Actions%26date%3D1991%26volume%3D34%26spage%3D254%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Chang, Y.</span><span> </span><span class="NLM_article-title">Adjuvant polyarthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1002%2Fart.1780230111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm200900q&amp;key=7352945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaL3cXhsVCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=62-71&author=Y.+Chang&title=Adjuvant+polyarthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant polyarthritis.  IV.  Induction by a synthetic adjuvant:  immunologic, histopathologic, and other studies</span></div><div class="casAuthors">Chang, Yi-Han; Pearson, Carl M.; Abe, Chiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">A soln. of an apparently nonimmunogenic synthetic compd., N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)propanediamine (CP-20961), suspended in mineral oil or olive oil (50 mg/mL), induced an acute, as well as a chronic, polyarthritis when single intradermal injections were made in the tail or hind paw of Lewis rats.  The polyarthritis was morphol. almost indistinguishable from classic adjuvant arthritis induced by Freund's complete adjuvant.  CP-20961-induced arthritis was suppressed by an immunosuppressive agent (cyclophosphamide) or an antiinflammatory drug (phenylbutazone).  CP-20961 was a potent adjuvant.  These findings suggest that the immunogen responsible for the development of adjuvant arthritis is endogenous, e.g., a constituent of host tissue, a viral protein, or some complex of the two.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw9Tqkr0ix0bVg90H21EOLACvtfcHk0ljGKHr1VjCS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsVCntLs%253D&md5=5bfb607d29a2a4b94817a9f6b976a7de</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fart.1780230111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.1780230111%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%26atitle%3DAdjuvant%2520polyarthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D1980%26volume%3D23%26spage%3D62%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Cromartie, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderlie, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span> </span><span class="NLM_article-title">Arthritis in rats after systemic injection of streptococcal cells or cell walls</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=1977&pages=1585-1602&author=W.+J.+Cromartieauthor=J.+G.+Craddockauthor=J.+H.+Schwabauthor=S.+K.+Anderlieauthor=C.+Yang&title=Arthritis+in+rats+after+systemic+injection+of+streptococcal+cells+or+cell+walls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCromartie%26aufirst%3DW.%2BJ.%26aulast%3DCraddock%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DJ.%2BH.%26aulast%3DAnderlie%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DArthritis%2520in%2520rats%2520after%2520systemic%2520injection%2520of%2520streptococcal%2520cells%2520or%2520cell%2520walls%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1977%26volume%3D146%26spage%3D1585%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Richards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A. S.</span><span> </span><span class="NLM_article-title">Suppression of chronic streptococcal cell wall-induced arthritis in lewis rats by liposomal clodronate</span> <span class="citation_source-journal">Rheumatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">978</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=978-987&author=P.+J.+Richardsauthor=B.+D.+Williamsauthor=A.+S.+Williams&title=Suppression+of+chronic+streptococcal+cell+wall-induced+arthritis+in+lewis+rats+by+liposomal+clodronate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichards%26aufirst%3DP.%2BJ.%26aulast%3DWilliams%26aufirst%3DB.%2BD.%26aulast%3DWilliams%26aufirst%3DA.%2BS.%26atitle%3DSuppression%2520of%2520chronic%2520streptococcal%2520cell%2520wall-induced%2520arthritis%2520in%2520lewis%2520rats%2520by%2520liposomal%2520clodronate%26jtitle%3DRheumatology%26date%3D2001%26volume%3D40%26spage%3D978%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Wustrow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Coupling of arylboronic acids with a partially reduced pyridine derivative</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm200900q&amp;key=10.1055%2Fs-1991-26626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm200900q&amp;key=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&pages=993-995&author=D.+J.+Wustrowauthor=L.+D.+Wise&title=Coupling+of+arylboronic+acids+with+a+partially+reduced+pyridine+derivative"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of arylboronic acid with a partially reduced pyridine derivative</span></div><div class="casAuthors">Wustrow, David J.; Wise, Lawrence D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-5</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    </div><div class="casAbstract">1,2,3,6-Tetrahydro-4-[(trifluoromethyl)sulfonyloxy]pyridine-1-carboxylate I (R = tert-butoxycarbonyl, R1 = triflate) was prepd. and underwent palladium-catalyzed coupling reactions with a variety of substituted arylboronic acids to produce a series of tert-butyl-4-aryl-1,2,3,6-tetrahydropyridine-1-carboxylates I (R as above, R1 = substituted Ph, 1-naphthyl).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwI9XvXHB0iLVg90H21EOLACvtfcHk0liMlzR978oktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFWksg%253D%253D&md5=e585b1222bbd08f3a5afd0ffd64cc71f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1055%2Fs-1991-26626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1991-26626%26sid%3Dliteratum%253Aachs%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DCoupling%2520of%2520arylboronic%2520acids%2520with%2520a%2520partially%2520reduced%2520pyridine%2520derivative%26jtitle%3DSynthesis%26date%3D1991%26spage%3D993%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Maier, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugel, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golebiowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufersweiler, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanRens, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easwaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janusz, M. J.</span><span> </span><span class="NLM_article-title">Development of <i>N</i>-4,6-pyrimidine-<i>N</i>-alkyl-<i>N</i>′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3646</span><span class="NLM_x">–</span> <span class="NLM_lpage">3650</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3646-3650&author=J.+A.+Maierauthor=T.+A.+Brugelauthor=M.+Sabatauthor=A.+Golebiowskiauthor=M.+J.+Laufersweilerauthor=J.+C.+VanRensauthor=C.+R.+Hopkinsauthor=B.+Deauthor=L.+C.+Hsiehauthor=K.+K.+Brownauthor=V.+Easwaranauthor=M.+J.+Janusz&title=Development+of+N-4%2C6-pyrimidine-N-alkyl-N%E2%80%B2-phenyl+ureas+as+orally+active+inhibitors+of+lymphocyte+specific+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DJ.%2BA.%26aulast%3DBrugel%26aufirst%3DT.%2BA.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DGolebiowski%26aufirst%3DA.%26aulast%3DLaufersweiler%26aufirst%3DM.%2BJ.%26aulast%3DVanRens%26aufirst%3DJ.%2BC.%26aulast%3DHopkins%26aufirst%3DC.%2BR.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DHsieh%26aufirst%3DL.%2BC.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DEaswaran%26aufirst%3DV.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26atitle%3DDevelopment%2520of%2520N-4%252C6-pyrimidine-N-alkyl-N%25E2%2580%25B2-phenyl%2520ureas%2520as%2520orally%2520active%2520inhibitors%2520of%2520lymphocyte%2520specific%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3646%26epage%3D3650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRL','PDB','3KRL'); return false;">PDB: 3KRL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRJ','PDB','3KRJ'); return false;">PDB: 3KRJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2I0Y','PDB','2I0Y'); return false;">PDB: 2I0Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i80"><a href="/doi/suppl/10.1021/jm200900q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34645"></div></div></div></div></div><hr /></hr><p class="last">Supplementary data collection, refinement statistics, and crystallization/soaking conditions for cocrystal structures of FMS with compounds <b>8</b> and <b>49</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200900q/suppl_file/jm200900q_si_001.pdf">jm200900q_si_001.pdf (91.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm200900q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-22%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm200900q" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm200900q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c64fadb93cb2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
